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Venous thromboembolism (VTE) is a common and serious cardiovascular disease, though 
advancing knowledge about risk factors has not yet led to decreased incidence. Marine n-3 
PUFAs have several beneficial effects related to hemostasis, and our goal was to investigate 
the association between dietary intake of marine n-3 PUFAs and the risk of VTE in the 
general population. Only few studies have investigated this topic previously with conflicting 
results. However, there are several methodological challenges in epidemiological studies that 
could obscure the effect of marine n-3 PUFAs on VTE risk. Our main efforts to improve 
methods include a comprehensive and validated measure of marine n-3 PUFAs in the diet and 
the use of updated measurements through follow-up.  
 Paper I is a large prospective cohort study representing the general population in the 
municipality of Tromsø. There were 21 970 participants in Tromsø 4 and 6 that provided 
information of fish consumption and other n-3 PUFAs sources. The participants were 
followed in the period 1994-2016. Dietary n-3 PUFAs intake exceeding 4.7 grams per week 
was associated with a 22-26% lower risk of VTE. Higher intake did not add to the effect, and 
this apparent threshold effect was larger for provoked VTE (30-35% reduced risk) and PE 
(31-47% reduced risk).  
 Paper II is a prospective cohort study of 595 VTE patients recruited from the Tromsø 
Study. In this study, we investigated the overall association between dietary intake of marine 
n-3 PUFAs and risk or recurrent VTE and overall mortality. In analysis contrasting the higher 
and the lower tertile of n-3 PUFAs intake, we found a weak association between intake of n-3 
PUFAs and risk of recurrent VTE overall. However, we found a 55% reduced risk of 
recurrence in patients with unprovoked VTE, a 49% reduced risk in cancer-free patients, and 
a 51% reduced risk in deep vein thrombosis (DVT) patients, in subjects with high compared 
to low intake of n-3 PUFAs. The inverse associations were more evident when follow-up was 
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restricted to the period after discontinuation of anticoagulant therapy. We found no 
association between intake of n-3 PUFAs and mortality after incident VTE. 
Major surgeries are trigger events that cause a large proportion of all VTEs in the 
population. In Paper III, we conducted a case-crossover study and investigated whether the 
trigger effect of major surgery was modified with n-3 PUFAs intake. We recruited 445 
patients with VTE that occurred within the period between 1994 and December 31, 2012. We 
categorized the VTE patients according to tertiles of n-3 PUFAs. We found a significant 
lower odds ratio of having a major surgery as a trigging event in the VTE patients with a high 














NORSK SAMMENDRAG – NORWEGIAN SUMMARY 
Venøs tromboembolisme (VTE) er en vanlig og alvorlig karsykdom, men økende kunnskap 
om risikofaktorer har ennå ikke ført til redusert forekomst av VTE. Marine omega-3 fettsyrer 
(n-3 PUFAs) har flere gunstige effekter relatert til hemostase, og vårt mål var å undersøke 
sammenhengen mellom inntak av marine n-3 PUFAs i kosten og risikoen for VTE i 
befolkningen. Det har tidligere blitt gjennomført få studier om emnet og disse har vist til dels 
motstridende resultater. Dette kan delvis forklares av at tidligere studier har brukt ulike mål på 
fiskeinntak (total fiskeinntak, mager og fet fisk, og estimert inntak av n-3 PUFAs) og i ulik 
grad tatt hensyn til at fiskeinntaket varierer over tid. I våre studier har vi estimert inntaket av  
marine n-3 PUFAs i kostholdet og brukt repeterte målinger av inntaket av n-3 PUFAs 
gjennom oppfølgingstiden. 
Artikkel I er en stor prospektiv kohortstudie som representerer befolkningen generelt i 
Tromsø kommune. Det var 21 970 deltakere som hadde oppgitt komplette data om inntak av 
fisk til middag og andre kilder til n-3 PUFAs i dietten i Tromsø 4 og 6. Disse ble fulgt i 
perioden 1994-2016. Vi fant at n-3 PUFAs inntak på mer enn 4,7 gram per uke var assosiert 
med en 22-26% lavere risiko for VTE. Høyere inntak ga ikke økt effekt. Terskeleffekten var 
størst for provosert VTE (30-35% redusert risiko) og PE (31-47% redusert risiko). 
Artikkel II er en prospektiv kohortstudie av 595 VTE-pasienter rekruttert fra Tromsø-
studien. I denne studien undersøkte vi sammenhengen mellom inntaket av marine n-3 PUFAs 
i kostholdet og risiko for tilbakevendende VTE og generell dødelighet. I analyser som 
sammenliknet høyt og lavt inntak av n-3 PUFAs, fant vi en beskjeden, men gunstig effekt på 
sammenhengen mellom inntak av n-3 PUFAs og risikoen for tilbakevendende VTE totalt. I 
tilleggsanalyser fant vi imidlertid en 55% redusert risiko for tilbakefall hos pasienter med 
uprovosert VTE, en 49% redusert risiko hos kreftfrie pasienter, og en 51% redusert risiko 
etter dyp venetrombose (DVT) pasienter hos personer med høyt inntak av n-3 PUFAs. De 
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gunstige assosiasjonene ble forsterket når oppfølgingen ble begrenset til perioden etter 
seponering av antikoagulasjonsbehandling. Vi fant ingen sammenheng mellom inntak av n-3 
PUFAs og dødelighet etter VTE. 
Store kirurgiske inngrep er en utløsende faktorer for 15-22% av VTE tilfellene i 
befolkningen. I artikkel III gjennomførte vi en case-crossover-studie og undersøkte om 
triggereffekten av større kirurgi varierte ut fra n-3 PUFAs inntak i dietten. Vi kategoriserte 
VTE-pasienter i henhold til tertiler av n-3 PUFAs. Vi fant en betydelig lavere odds-ratio for å 
ha gjennomgått større kirurgiske inngrep som en utløsende faktor for VTE hos pasienter med 
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1.1 Epidemiology of venous thromboembolism  
Venous thromboembolism (VTE) is a collective term for deep vein thrombosis (DVT) and 
pulmonary embolism (PE). Approximately two thirds of VTE events present as DVTs in the 
lower extremities and one-third as PEs (1, 2). Less frequently, VTE occur in upper extremity 
veins (1-4%) or in other large veins in the abdomen like mesenteric veins and vena porta, or 
even cranially in dural venous sinuses (0.05-0.5%) (3-7). Altogether, VTE is the third most 
common cardiovascular disease after myocardial infarction (MI) and stroke, and afflicts 1-2 
per 1000 annually (8-10). Incidence rates (IRs) increase exponentially with age (11). VTE is 
rare in childhood with incidence rates less than 0.06 per 1000 annually (12). At the age 20-30, 
the rate is around 0.5, increasing to one per 1000 roughly around the age of 60. This rate 
doubles approximately around the age of 70, and at advanced age beyond 80 the rate may 
exceed 10 per 1000 annually (9, 13). In the Tromsø Survey, the mean age at first life-time 
VTE was 69 years (14). Large epidemiological studies on VTE are predominantly from 
Western societies that share characteristics in age composition, prevalence of lifestyle-related 
diseases and development of health care (1, 13, 15-19). These studies show annual incidence 
rates of VTE in the range between 0.63 and 1.83 per 1000 individuals in the adult population. 
Differences between estimates in different studies could arise from data selection, study 
designs, case definitions and availability of data. However, VTE incidence also vary by 
ethnicity. People with African ancestry have somewhat higher incidence of VTE than those 
with Western European ancestry, followed by Southern European origin, whereas the lowest 
rate is observed in people with East-Asian-Pacific ancestry. The latter group may have a 70-
80% lower incidence rate of VTE than Caucasians (1, 20, 21).  
Studies on VTE trends indicate stable or increasing incidence rates over the recent 
decades, with somewhat different figures for DVTs and PEs considered separately (8, 9, 13, 
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14, 22-27). Rates of PE seem to have increased after year 2000. In the Tromsø Study, the 
overall incidence rate of VTE increased from 1.6 per 1000 in 1996/97 to 2.0 in 2010/11. The 
increase in PE was also observed in the Tromsø Study, rising from 0.45 per 1000 in 1996/97 
to 1.1 in 2011/12, whereas incidence of DVT slightly decreased from 1.1 in 1996/97 to 0.9 in 
2011/12 (14). A proportion of the increase in PE is attributed to the introduction of highly 
sensitive multidetector row computed tomographic pulmonary angiography (CTPA). The use 
of CTPA in PE-diagnostics increased rapidly after year 2000. In a study addressing 
overdiagnosis (finding clinically unimportant emboli) by CTPA in the U.S., an 81% increase 
in the incidence of PE was observed comparing the period 1993-1998 (before CTPA) to 1998-
2006 (after the introduction of CTPA), while the corresponding rate of PE related deaths 
actually decreased by 8% (27). Although more frequent use of CTPA probably explain much 
of the increasing incidence of PE, the overall epidemiological trends seem paradoxical 
compared with the trends of MI and stroke. In these fields, the use of highly sensitive 
diagnostic methods have increased considerably too, while incidence- and mortality rates  
have decreased by 30-50% in many Western countries over the same time-span (28-30). An 
investigation from the Tromsø Study showed that the incidence rates (age- and sexadjusted) 
of total coronary heart diseases (primarily sudden deaths and ST-segment MI) decreased by 
an average of 3% each year between 1994 and 2010 (31). Interestingly, changes in modifiable 
coronary risk factors, such as smoking and hypercholesterolemia, accounted for 66% of the 
observed decrease in this study. 
Classical symptoms and signs of DVT include swelling, redness and pain in the 
afflicted limb, whereas symptoms of PE include shortness of breath, chest pain, hemoptysis 
and syncope. These symptoms and signs are somewhat unspecific and could overlap with 
other, less serious conditions. This, together with a generally lower awareness of VTE disease 
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in the population compared to stroke and heart attack, makes it challenging for patients to 
suspect VTE as the cause of the symptoms in an initial phase (32).  
 Long-term complications after VTE constitute a major health burden in the society 
(33). The most common long-term complication after DVT is termed post-thrombotic 
syndrome (PTS), and involves degrees of chronic symptoms and signs in the affected limb, 
including pain, edema, discoloration, varicose veins, sensation of heaviness, cramps and 
ulcers. PTS afflicts 20-50% of DVT patients, and is associated with reduced quality of life 
and up to a 50% increased risk of work-related disability (34, 35). The risk of PTS is highest 
after an ileo-femoral DVT (36, 37), and a 2-3 fold increased risk has been reported in patients 
with subtherapeutic anticoagulant treatment (38, 39). Catheter-directed thrombolysis vs. 
standard non-invasive treatment reduced the absolute risk of PTS with 14% after a 2 year 
follow-up in an open-label randomized trial (40). Other risk factors for PTS include ipsilateral 
recurrent DVT and obesity (41), while there are inconsistent findings for age and sex as risk 
factors (42).  
Long-term complications of PE include persisting shortness of breath, and in one 
study, 19% of PE patients had incomplete reperfusion after 2 years follow-up (43). The most 
severe long-term complication of PE involves fibrotic transformation of residual thrombi in 
the pulmonary arteries, which causes degrees of persistent obstruction of pulmonary arteries 
and elevated circulatory pressure in the right heart chambers, i.e., chronic thromboembolic 
pulmonary hypertension (CTEPH). Symptoms of CTEPH include hypoxemia and right-sided 
heart failure, and the condition is associated with elevated mortality risk (44). CTEPH afflicts 
1-4% of all PE cases (45, 46). The prevalence of CTEPH is somewhat difficult to determine 
as it is not subjected to routine diagnostics after PE, and develops gradually up to two years 
after an incident PE. Moreover, 25-42% of patients with chronic pulmonary hypertension 
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have no evidence of a previous PE (45, 47). Risk factors for CTEPH include previous PE, 
younger age, unprovoked PE and severe perfusion defects (46).  
Up to 30% of all VTE patients experience recurrence within 10 years (48). The risk of 
recurrence is highest during the first year and decreases over time (49). In the Tromsø Study, 
IRs (95% CIs) of recurrence per 100 person-years after 0-6 months, 6 months-1 year, 5-10 
years, and after 10 years were 9.2, 6.3, 3.5, 2.3 and 2.4 respectively (50). A recurrent PE is 
more likely to occur when the first event was a PE and a recurrent DVT is more likely to 
occur after a first DVT (51, 52). In the Tromsø Study this tendency applied to approximately 
70% of all recurring VTE events (50). Moreover, the risk of recurrence is 1.5 to 2.0-fold 
higher after a DVT compared with after a PE (51, 53, 54). In addition, men have a more than 
doubled risk of recurrence compared to women (55). Other risk factors for recurrent VTE 
include hereditary thrombophilia, active cancer, occult cancer, neurologic paresis and 
neurosurgery, high BMI and higher age (48, 56-59). Risk factors for incident VTE may not 
constitute equivalent risk factors for a recurrent event. This phenomenon is referred to as the 
paradox of recurrence (60). For instance, there is little difference between men and women in 
risk of a first VTE, and while age is the most important predictor for the first VTE, it is only a 
weak predictor for recurrence. The phenomenon is partly explained by the fact that a second 
VTE always arises from the highly selected group of those who have had a VTE in the first 
place, a group that differs from the general population (60). The recurrence paradox will be 
revisited in chapter 1.5. 
The risk of recurrence is also related to provoking factors for the first VTE. Therefore, 
the convention to categorize VTEs as either provoked or unprovoked, and whether or not 
these provoking factors were transient or persistent, has prognostic and treatment implications 
(61). Important transient provoking factors include acute medical conditions, surgery, trauma 
and plaster cast immobilization, whereas examples of persisting provoking factors are 
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malignant diseases and paresis. For instance, major surgery is a typical transient provoking 
factor, because the risk of VTE is high immediately after the procedure, and then drops 
rapidly within a few days or weeks (62). If no recognized provoking factor is documented, a 
VTE is considered as unprovoked. Guidelines on anticoagulant treatment aim to balance the 
benefits of terminating thrombi growth and prevent recurrence, to the risk of bleeding 
complications. The long-term risk of recurrence after a VTE provoked by a transient risk 
factor such as a surgery is low, and consequently, short-term treatment of 3-6 months is 
recommended (63). The highest risk of recurrence is observed when provoking factors are 
persistent. In such cases, long-term treatment until contraindicated or throughout life is 
recommended. Unprovoked VTEs have an intermediate risk of recurrence, which indicates 
that unknown risk factors exist and are likely to persist (60). In unprovoked VTE, American 
College of Chest Physicians (ACCP) guidelines recommend short-term treatment except for 
patients with unprovoked proximal DVT (the category with highest recurrence risk), given 
low or medium bleeding risk (63).       
VTE is associated with an increased risk of mortality. The one month cumulative 
mortality risk vary between 6-11%, increasing to 17-36% after one year (1, 9, 13, 36, 64), and 
30-52% after eight years (1, 13). Mortality rates (95% CI) after VTE were estimated in the 
Tromsø Study in the period 1994-2012, and were as follows (per 100 PY), 0-6 months: 9.2 
(6.3-13.9), 6 months-1 year: 6.3 (3.8-10.3), 1-5 years: 3.5 (2.6-4.6), 5-10 years: 2.3 (1.5-3.7), 
and finally, after 10 years: 2.4 (1.0-5.3) (50). The observation that 25% of PE cases present 
with sudden death (16) underlines the severity of PE. The one-month mortality rate for PE 
patients is 8-16% (first PE event) (1, 13). In general, the risk of sudden death after PE is 18-
fold higher than after a DVT event (16), and PE is considered as one of the most preventable 
lethal hospital acquired complications (65, 66). Most VTE-related all-cause mortality confine 
within the first year after the event, partly driven by concurrent malignancy, but even after 30 
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years of follow-up, a 1.5-fold increased risk of mortality after DVT, and a 2.7- fold increased 
risk after PE has been reported (67).  
VTE is treated with anticoagulant drugs (63). Acute treatment with low molecular 
weight heparin (LMWH) the first few days followed by continued treatment with vitamin K 
antagonist (VKA) monotherapy became widespread during the 1940’s, and was standard 
medication for several decades (65). In cancer patients, LMWH is favored over VKA for 
continued therapy due to less bleeding complications (68). Exceptional and comparatively 
rare treatments in the acute phase of severe or life-threatening VTE include use of systemic 
unfractionated heparin or alteplase, catheter-directed thrombolysis and thrombectomy. 
Nowadays, direct oral anticoagulants (DOACs) increasingly replace VKA therapy (61), 
mainly due to lower bleeding risk, and ease of administration that does not require regular 
monitoring, as is the case with VKA therapy (69).  
 
1.2 Pathophysiology of venous thromboembolism 
Until the 17th century, only anecdotal documentation of conditions that we now recognize as 
VTE are known, and the first descriptions of DVT as a clotting disorder began with 
pregnancy-related DVT (65). The modern understanding of the pathophysiology of VTE 
began in the mid-19th century with the German pathologist and physicist Rudolph Virchow. 
Virchow correctly inferred that thrombi developing in the deep veins of the legs (DVTs) 
could dislodge and cause the even more severe condition of PE. Moreover, Virchow 
postulated three broad risk categories involved in the pathogenesis of VTE; i) stasis of the 
blood flow, ii) endothelial injury or dysfunction, and iii) hypercoagulability (65, 70). 
Virchow’s triad (Figure 1) illustrates that one or more of the three categories must be present, 
or interplay to cause VTE, and captures the multifactorial nature of the disease. Known major 
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risk factors for VTE like paresis, surgery and inheritable thrombophilia represent well each of 
these three risk categories. 
 
Figure 1. Virchow’s triad consist of three main risk categories for venous thromboembolism, 
stasis, vessel wall injury and hypercoagulability.   
 
1.2.1 Hemostasis 
Hemostasis refer to prosesses that prevent and stop bleeding, and a healthy circulation is 
maintained by the regulations of procoagulant and anticoagulant systems (71). At the site of 
an injury, bleeding is stopped by the formation of a clot made up of circulating constituents. 
Excess clot formation is simultaneously restricted by the fibrinolytic system, that eventually 
dissolve the clot altogether and restore the vessel integrity. VTE and other thrombotic 
diseases can therefore be viewed as an inappropriate form of hemostasis at the wrong place 
(71).  
 
1.2.2 The mechanistic hypothesis for venous thrombosis 
Autopsy studies suggest that VTEs typically originate in the valvular sinuses in the lower 
extremities (72-74), and a positive correlation between number of valves (e.g. varying with 
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height) and risk of VTE has been reported (75). The valves’ function is to direct the blood 
flow, although they also create circulatory deadlocks in the valve pockets (Figure 2). Even 
though muscle work facilitates circulatory turnover (76), these microenvironments frequently 
become oxygen-deprived (77). 
 
Figure 2. The valve sinuses are vulnerable to low circulatory turnover and hypoxia. The 
endothelial layer and trapped cells such as monocytes, platelets and EVs in such an 
environment, could shift toward prothrombotic expressions. VTE is often initiated at these sites.  
 
Endothelial cells in the venous valves actually constitute phenotypes that tolerate more 
hypoxia than the endothelial cells elsewhere (78). However, under prolonged hypoxic stress, 
endothelial cells express P-selectin, E-selectin and vascular cell adhesion protein1 (VCAM1). 
These adhere to platelets and other blood elements like leukocytes, neutrophils, and 
leucocyte-derived extracellular vesicles (EVs) that express tissue factor (TF). The aggregated 
elements have the potential to initiate or positively feedback clot formation (79). Expression 
of plasminogen activator inhibitor-1 (PAI-1) and activated neutrophils that release 
extracellular traps (NETs) may also contribute to the hypercoagulable state in the valvular 
sinuses (80, 81). The proposed mechanism of these events is illustrated in Figure 3. 
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Remarkably, Virchow’s triad of endothelial dysfunction, stasis and hypercoagulability seems 
to apply at the cellular level in the modern understanding of VTE pathogenesis. 
 
Figure 3. A proposed mechanism for venous thrombosis. Venous thrombosis may be trigged through 
the intrinsic pathway by i), hypoxic stress causing endothelial cells to express adhesive proteins (P-
selectin, E-selectin and von Willebrand Factor (vWF)), ii) circulation leukocytes, platelets, TF and 
extracellular vesicles (EVs) binding to the activated endothelium, and iii), activation of bound leukocytes 
that express more TF. VTE occurs if the local activation of the coagulation cascade overwhelms the 
surrounding anticoagulant expression in the adjacent healthy vessel lumen. Adapted from Mackman 
2012 (73). 
 
1.3 The role of hemostatic factors in hemostasis 
1.3.1 The role of platelets in hemostasis 
Primary hemostasis is the first response to vessel damage. Primary hemostasis include 
vasoconstriction and the formation of a platelet plug that seal a vessel damage (82). Platelets 
are discoid cells 2.0-3.0 μm wide, which originate from the cytoplasm of polyploid 
megakaryocytes in the bone marrow. They have a typical life span of 5-9 days (83, 84). The 
platelets enter the bloodstream anucleated, though with granules and lysosomes ready to 
release at activation, causing reaction cascades (82, 84, 85). Platelet activation is mainly 
driven by increased intracellular Ca2+ level, that is regulated by cyclic adenosine 
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monophosphate (cAMP) in platelets (86). Signals transmitted through glycoproteins in the 
platelet membrane and certain contents of the granules are stimuli that induce increased Ca2+ 
levels and platelet activation (83). Activated platelets transform from discoid and circulating, 
to amoeboid-shaped and aggregating, a process that occurs in distinct steps (87, 88). The steps 
overlap and represent a simplification of platelet activation. The first step is adhesion and 
initiation, next excretion and propagation, and finally stabilization through cross-linked 
fibrin bonds (87). Figure 4 shows several of the involved mechanisms in platelet activation.   
 
Figure 4. Platelet activation mechanisms. Platelet activation can initiate when glycoprotein VI (GPVI) 
and integrin α2β1 adhere to collagen. The binding cause granule excretion of signalling molecules that 
bind to G-protein-coupled receptors (PAR, TP and P2), in an inside-out signalling pathway. 
Adherence to other platelets and additional bonding to collagen are mediated by the activation of 
integrin αIIbβ3, expression of GPIb-IX-V, von Willebrand factor (vWF) and fibrinogen bonds. The 
activated platelet facilitates coagulation by excreting factor V and factor XI, and by expressing 
phosphatidylserines (PS) that are binding sites for coagulation factor complexes. To the lower left 
corner, main endothelial expression of platelet inhibitors are shown (Modifyed after Storey 2008 




1.3.1.1 Activation by adhesion to collagen 
At a vessel injury, collagen is exposed to the bloodstream. Circulating platelets bind to 
collagen in glycoprotein VI (GPVI) that cause platelet activation and the release of dense- and 
α-granules, and activation of phospholipase A2 (Figure 4). Phospholipase A2 releases the 
omega-6 fatty acid arachidonic acid (ARA) from the platelet cell membrane (91). The 
released constituents take part in further platelet activation and propagation. When activated, 
the platelet express integrin αIIbβ3. Integrin αIIbβ3 is an abundant and unique platelet adhesive 
receptor (92) that form bridging bonds with the glycoprotein (GP) von Willebrand Factor 
(vWF) (93). vWF exists circulating, and in large polymers in endothelial cells, and has several 
binding sites. vWF and integrin αIIbβ3 form bridging bonds to collagen that resist high 
circulatory stress (83) (Figure 5).  
 
Figure 5. Bridging bonds with von Willebrand factor (vWF) in platelet adhesion. vWF has several 
binding sites that can bind between vWF and collagen, and between vWF and platelets (83).  
 
 
1.3.1.2 Excretion and propagation 
In platelets, cyclooxygenase 1 (COX1) cyclize free ARA to endoperoxides, which are 
catalyzed to thromboxane A2 (TxA2) by thromboxane syntetase (94). TxA2 diffuses through 
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the platelet cell membrane and binds to the TxA2-receptors (TPα and TPβ), causing activation 
of platelets and vasoconstriction in vessels (91). At activation, ADP, ATP and Ca2+ released 
from dense granules, enhance platelet activation through the P2X1, P2Y1 and P2Y12 receptors 
(84). This stimulates downregulation of cAMP that reduces Ca2+ efflux. At the same time, 
more Ca2+ ions are available outside the platelet due to the degranulation. An effect of these 
inside-out signaling pathways is the recruitment of nearby platelets. 
Platelet activation becomes irreversible at the point where integrin αIIbβ3 is activated. 
In addition to the role of integrin αIIbβ3 in attaching the platelet to collagen as described, it is 
involved in the formation of fibrinogen crosslink and aggregation with other platelets (87, 93), 
through bonds with fibrinogen, or through bonds with vWF and GP-1b-XI-V (Figure 4 and 5). 
Platelets also interact with, and adhere to, stimulated endothelial cells and monocytes 
(95). Activated platelets transmit inflammatory mediators, altering functions of endothelial 
cells to facilitate chemotaxis, adhesion and transmigration of monocytes to the site of the 
vessel damage (85). Activated platelets thus stimulate the endothelium in the vessel wall to 
shift from antithrombotic to pro-thrombotic phenotypes (96). Activated platelets can also 
recruit monocytes by releasing chemokines (97). Notably, under pathological stimuli, 
monocytes express TF, a primary initiator of the coagulation cascade (98).    
Activated platelets strongly stimulate coagulation activation (as described in the next 
paragraph) by the release of α- and dense granules that contain coagulation factor V, factor 
XI, and negatively charged phospholipids in the bloodstream. Activated platelets express 
phosphatidylserines (PS) on the outer cell membrane that facilitate the assembly and 
activation of coagulation factor complexes, i.e. the prothombinase complex, the FVIIa-TF 
complex and the FVIIIa-FIXa complex (99-101).  
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1.3.2 The role of coagulation in hemostasis 
The coagulation cascade is a catalytic pathway that culminates with fibrin deposition, which 
crosslink and stabilizes a developing blood clot. The cascade has an amplifying effect 
downstream the chain of reactions, in which coagulation factors (F), i.e. zymogens or serine 
proteases together with co-factors, are activated (a) and catalyze the next step. The 
coagulation factors’ roman numerics follow the sequence of their discovery and not the 
sequence of events. The coagulation cascade has two entry points, the intrinsic and extrinsic 
pathways. The extrinsic and intrinsic pathways coalescence in a common pathway at the point 
where FX is activated (FXa). Figure 6 shows a simplification of the coagulation cascade. 
 
Figure 6. An overview of the chain of reaction in the coagulation cascade. The extrinsic 
pathway is initiated by TF. The intrinsic pathway initiates through negatively charged 
surfaces. Both pathways coalescence in the common pathway and the formation of thrombin 
that cleaves fibrinogen into fibrin. Thrombin also causes upstream positive feedback in the 
cascade. The outburst of fibrin that stabilizes a growing blood clot is the functional endpoint 




The extrinsic pathway initiates with vessel damage and exposure of sub-endothelial 
cells that express tissue factor (TF). Monocytes and endothelial cells can also express TF 
under pathological conditions (102, 103). TF acts as a cofactor for FVII and the TF-FVIIa 
complex activates factors IX and X, entering the common pathway (90, 104).  
The intrinsic pathway is activated through negatively charged contact, including 
cellular RNA, polyphosphate from activated platelets or bacteria, and collagen (73). The 
intrinsic pathway initiates by the activation of FXII, causing a chain of coagulation factor 
activation following the sequence of FXIIa, FXIa, and FIXa. FXIa forms a complex with 
thrombin-activated FVIIIa as a co-factor. Next, the FVIIIa-FIXa complex activates FX that 
enters the common pathway (90).  
In the common pathway, FXa forms a complex with FV (90). The FXa-FVa 
prothombinase complex binds to negatively charged phospholipids on cell membranes, 
including PS on activated platelets (83, 101). The FXa-FVa complex (prothombinase) 
catalyzes prothrombin to thrombin that catalyzes fibrinogen to fibrin, which is the functional 
endpoint of the coagulation cascade. Fibrin eventually cross-links platelets and other blood 
cells that stabilize the growing platelet plug. Within the coagulation cascade, there are several 
amplifying interactions. For instance, FVIIa stimulates the activation of FIX (104). Thrombin 
facilitates the activation of FXI, VIII and FV upstream. Thrombin also activates FXIII that 
stabilizes the fibrin matrix with covalent bonds (90). In addition, thrombin act as a platelet 
activator through PAR1 and PAR4 receptors (101).  
It can be assumed that the intrinsic contact pathway is an important contributor to 
VTEs, e.g. under the pro-thrombotic microenvironments within deep veins (105). This is in 
contrast to a myocardial infarction, where endothelial rupture and release of accumulated 
atherosclerotic plaque with TF causes a rapid coagulation response through the extrinsic 
pathway (106, 107).  
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1.3.4 The role of the endothelium in hemostasis 
A healthy endothelial layer in vessels constitutes an antithrombotic surface (105). Endothelial 
cells repress platelet activation by the expression of prostacyclin I2 (PGI2), nitric oxide (NO) 
and the ligand entonucleoside triphosphate diphosphohydrolase-1 (CD39). ARA released in 
endothelial cells enters a slightly different enzymatic pathway compared to platelets. In 
endothelial cells, ARA-derived endpoeroxides are synthesized to PGI2 by prostacyclin 
syntetase. PGI2 act as a vasodilator, and upregulates cAMP levels in platelets that inhibit 
activation (108). NO upregulates platelets cyclic guanosine monophosphate (cGMP), which 
together with cAMP stimulate Ca2+ efflux in platelets (109). CD39 hydrolyses ATP and ADP 
and reduces the levels of these platelet activators (110).  
Healthy endothelial cell expressions also downregulate coagulation. Endothelial 
protein C receptors promote the activation of protein C in the presence of thrombomodulin, 
and activated protein C (APC) inhibits FVIIIa and FVa (111). Endothelial tissue factor 
pathway inhibitor (TFPI) reversibly inhibits FXa and the TFPI-FXa complex inhibits the 
FVIIa-TF complex (96). Endothelial expression of heparan sulfate enhances the binding of 
antihrombin to thrombin that inhibits factor Xa, and tissue plasminogen activator (TPA) 
catalyzes plasminogen to plasmin that breaks down fibrin (112). 
Interestingly, ARA, thrombin, FVa and VIIIa promote platelet activation and 
thrombosis formation at the site of endothelial damage, whereas they are elements in anti-
thrombotic expressions in a healthy endothelium. This situation dependent function assists to 






1.4 Risk factors of venous thromboembolism 
VTE is a multicausal disease with inherited or acquired risk factors, and often several factors 
need to occur simultaneously to cause thrombosis (113). A risk factor is associated with an 
increased probability of an adverse outcome, and is potentially, but not necessarily a causal 
factor (114). The thrombosis potential model is a theory that describe the risk of VTE as a 
function of inherited and acquired risk factors over time (Figure 7) (113). VTE develops when 
the thrombosis potential, due to the combination of inherited and acquired risk factors, 
exceeds a critical thrombosis threshold. In the thrombosis potential model, age is a universal 
risk factor that increases the risk over time. Transient risk factors such as surgery would add 
to the underlying risk temporarily, and may drive the potential risk over the thrombosis 
threshold. It follows that a transient risk factor for VTE tolerated at young age could cause 
VTE at older age. Inherited and persistent risk factors such as the Factor V Leiden Mutation 
(FVL) would add to the impact of age through life, and it follows that VTE could develop at 







Figure 7. The thrombosis potential model describes VTE risk as a dynamic and accumulative 
process. The thrombosis potential inevitably increases with age, and the outcome of any 
transient provoking factors during life such as surgery, depend on the combined impact of all 
risk factors at that time. An inheritable and persistent risk factor such as Factor V Leiden 
would add to the impact of age throughout life. Adapted from Rosendaal, Lancet. 1999 (113). 
 
1.4.1 Acquired risk factors 
Acquired risk factors for VTE include age, obesity, cancer, immobilization, major surgery, 
congestive heart failure, varicose veins, fractures, use of estrogen, trauma, pregnancy, birth 
and puerperium, myocardial infarction, stroke and infections (115). Age and obesity are 
examples of risk factors with high prevalence in the general population, whereas other risk 
factors such as surgery and cancer are less prevalent, but impose high relative risk. 
Age is a well established risk factor for VTE (116). Almost 90% of VTE patients have 
passed 40 years at the time of their first event (115). A report from the Tromsø Study showed 
an 11-fold higher risk of VTE for those above 70 compared to those below 50 years (117). 
Advanced age is associated with several characteristics that could influence the risk of VTE. 
Elderly have increased levels of fibrinogen, FVIII, FIX, and increased platelet activity (118). 
Degenerative changes in the vein walls and venous valves also come with age (119), as well 
elevated markers of C-reactive protein (CRP) and interleukin-6 that indicate an ongoing low-
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grade inflammation (118). Other risk factors, such as general immobilization and many 
comorbidities are also more common with advancing age. However, in a study of people ≥70 
years in the Tromsø population, there was no evidence that the higher risk of VTE in elderly 
could be attributed to malignancies (120).  
Obesity, defined as a body mass index (BMI) ≥30kg/m2 is associated with a 2-3-fold 
increased risk of VTE (121, 122). Results from the Tromsø Study have further shown that 
waist circumference identify more people at risk and display higher effect sizes for VTE than 
BMI (123), and that weight change per se, in particular weight gain in those already obese, 
increases the risk (124). Several mechanisms could be involved in this association. 
Abdominal obesity causes increased intra-abdominal pressure with subsequent iliofemoral 
venous pressure and stasis (125). Obesity is also associated with increased hepatic synthesis 
of fibrinogen, FVII, FVIII and TF, increased inflammation and reduced fibrinolysis (126-
128). Results from several recent Mendelian Randomization studies have suggested a causal 
relationship between obesity and risk of VTE (129-131). 
Height is a known risk factor for VTE, particularly in men (132). In men, a 34% 
increased risk per 10 cm increase in height was reported from the Tromsø Study (133). Height 
increases the vessel area at risk, hydrostatic pressure and sheer number of venous valves, 
which possibly explains stature as a risk factor for VTE (76).  
Cancer is a major risk factor for VTE and is associated with a 5-7 fold-increased risk 
(134-137). Among all VTEs, 18-22% are associated with active malignancy (9, 117). 
However, the risk varies with the cancer site, stage, histological type and time since cancer 
diagnosis (136, 138). VTE is reported to occur more frequently in pancreatic cancer, 
mesothelioma, in cancers with unknown primary site, lung cancer, brain cancer and cancer in 
the gastrointestinal tract, as reported from a large UK cohort (136). The relative risk may be 
highest with pancreatic cancer and brain cancer (137). Metastatic cancer and patient-related 
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comorbidities further increase the risk. There are several suggested mechanisms in cancer-
related VTE. Tumor growth can cause physical obstruction and stasis in vessels. Active 
cancer is associated with chronic pro-thrombotic changes including increased TF expression, 
activated platelets, release of EVs and an increased inflammatory state (139, 140). 
Chemotherapy has toxic and pro-thrombotic effects on vessel wall endothelial cells (141). 
Importantly, cancer types with high mortality introduce a bias that tend to overestimate the 
risk of VTE. Analysis taking competing risk of death into account specifies the risk of VTE 
more appropriately in cancers with high mortality (142).  
Major surgery in general anesthesia for more than 30 minutes is one of the most 
important hospital-related risk factors for VTE. Around 20% of VTEs occurring in the general 
population are trigged by major surgery, despite the routine use of thromboprophylaxis (9, 
22). About 8 out of 1000 patients undergoing surgery develop a post-operative VTE, and 
recent surgery in general confers a 4-22 fold increased risk of VTE (143). The risk depends on 
the type of surgery. The highest incidences are reported after total hip arthroplasty, major 
vascular surgery, and invasive neurosurgery (144). However, minor surgeries involving the 
larger vessels such as venous catheters and pacemaker insertion are associated with up to 10-
fold increased risk of VTE (135, 145).  
Trauma, depending on the extent, is a major risk factor for VTE. In a study of 349 
patients with multiple trauma 201 (58%) had an asymptomatic DVT, whereas 3 (<1%) had 
clinical symptoms and 3 (<1%) died from PE (146).  
VTE occurs in 1-2 per 1000 pregnancies, an incidence rate corresponding to a 4-5 
fold increased risk compared to non-pregnant women of reproductive age (147, 148). 
Delivery involves a significant risk of bleeding, and the organism has apparently adapted to 
the challenge by upregulating FI, FII, FV, FIII, FIX and FXII, and downregulating protein C  
(149). During the 6 first weeks after delivery, the puerperium, the risk of VTE even 
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increases up to 4-5 fold as compared with the risk during pregnancy, which might be caused 
by endothelial damage in pelvic vessels during delivery (148).  
Another risk factor for VTE restricted to women is the use of estrogen taken as 
contraceptives or medication to relieve menopausal symptoms. Estrogens cause increased 
levels of coagulation factors, and a 2-7 fold increased risk of VTE, dependent on estrogen 
type and indication (150, 151). The risk is transient and resolves after approximately a year of 
use. The risk of VTE by use of estrogen as contraceptives is defensible partly because the 
baseline risk of VTE in young women is low, and the pregnancy-related risk of VTE is higher 
than the risk related to estrogen use.  
A diversity of reasons for immobilization including lower extremity plaster-cast 
immobilization, neurological paresis, confinement to bed or wheelchair, bed-rest for more 
than three days and long-haul travels are associated with an approximately doubled risk of 
VTE (152, 153). The increased VTE risk with immobilization is likely due to venous stasis.  
Hospitalization per se is also a risk factor for VTE. Hospitalization is likely to 
involve several of the already described risk factors such as cancer, surgery and 
immobilization. Hence, hospitalization is associated with a 40-100 fold increased risk for 
VTE as compared to community residents (15, 154).  
Acute medical conditions include ischemic stroke, myocardial infarction and 
congestive heart failure, severe respiratory disease, severe infections and rheumatologic 
disorders. The risk of VTE associated with acute illness is typically transient. The VTE risk 
after ischemic stroke, myocardial infarction (MI) and acute infections was investigated in the 
Tromsø Study (155, 156). After ischemic stroke, IRs (per 1000 PY) after one, 3 and >3 
months were 82, 47 and 8, respectively (155). After MI, incidence rates were 18 within 6 
months and 7 within 6 months and 1 year. In a case-crossover study investigating acute 
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infection as trigger for VTE, an odds ratio (ORs) of 20 for acute infection as a trigger was 
reported (156). Moreover, a synergistic effect (OR: 141) of infection and immobilization was 
demonstrated. In the Tromsø Study 14% of VTE patients had an acute medical condition 
within 8 weeks before the event (14).    
 
1.4.2 Inherited risk factors 
Family and twin studies have shown that genetic factors probably account for 50-60% of the 
variation in VTE risk (157, 158), and a family history of VTE is an independent risk factor for 
VTE (157, 159-161). Genetic variants that inhibit or downregulate endogenous anticoagulants 
are referred to as loss-of-function mutations (162). Numerous mutations could cause loss of 
function in the same pathway, and more than 250 different gene variants are known to cause 
antithrombin deficiency, a condition that is present in 0.2% of the population (163). 
Antithrombin is a serine protease inhibitor produced in the liver that binds to and inhibits the 
function of thrombin and FXa. Glycosaminoglycans like heparin bind to and enhance the 
function of antithrombin, and heparins are widely used in medical anticoagulation (164). 
Antithrombin deficiency is associated with a 10-50 fold increased risk of VTE (165). Other 
loss-of-function mutations include protein C and protein S deficiency, which are present in 
0.03-0.2% of the population, and are associated with an approximately 10-fold increased risk 
of VTE in heterozygous carriers (166-168).  
Conversely, gain-of-function mutations upregulate normal proteins involved in 
hemostasis. Gain-of-function mutations include FV Leiden (FVL), Prothrombin gene 
mutation (PT20210A), variants increasing the levels of fibrinogen, FVIII, FIX, FX and FXI, 
and non-O blood groups (162). The prevalence of FVL mutation is high in Caucasians (5%) 
(169, 170), and is associated with a 2-5 fold increased risk of VTE in heterozygous carriers 
and a 10-80 fold increased risk in homozygous carriers (171). FVL affects the FV gene and 
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causes degrees of APC resistance. Prothrombin mutation G20210A, prevalent in 2% of the 
population, is associated with an approximate 3-fold increased risk of VTE. The mutation is 
associated with increased levels of prothrombin (172, 173). Non-O blood type is highly 
prevalent (60% of the world’s population) and is thereby a significant contributor to the 
overall incidence of VTE despite a modest 1.5-2.0 fold increased relative risk (172, 174). 
Levels of vWF and FVIII are higher in non-O blood groups (175).  
Modern genomics have allowed for hypothesis-free search for genetic variants 
associated with VTE. However, few of the recently discovered variants imposes >30% 
increased risk of VTE, and common variants may only account for 5-20% of VTE heritability 
(170, 176). This observation has implications for the prospects in this field. Genetic variants 
associated with a modestly increased risk of VTE are unlikely to be indicators for 
thromboprophylaxis due to the balancing of side effects. On the other hand, there is a 
potential to discover combinations of risk factors yielding a high risk that could exceed the 
threshold for prophylactic intervention.  
 
1.4.3 VTE triggers 
A trigger is a broad term that simply refers to an event that initiates another. In VTE etiology, 
triggers are considered as risk factors for VTE that are transient and discrete events limited to 
particular dates or periods (61). Typical triggers for VTE include several of the discussed risk 
factors including surgery, hospitalization, infections, temporal immobilization and acute 






1.5 Marine derived polyunsaturated fatty acids 
In 1956 H. M. Sinclear linked dietary fatty acid composition with “diseases of civilization”, a 
term that included thrombotic diseases. He noted as follows in the Lancet: “Eskimos have 
high dietary fat and little atherosclerotic plaque”, and “Norwegians and also Eskimos 
uncontaminated by so-called civilization fare well by taking marine foods” (177). Later, in 
1976, Bang and Dyerberg compared the diet of Danes with the Greenland Inuits and observed 
that even though the total intake of fat was similar, Inuits had relatively higher intakes of 
marine long-chained omega-3 polyunsaturated fatty acids (n-3 PUFAs) (178). Bang and 
Dyerberg reported that the relative high total fat intake appeared contradictory to a lower level 
of serum cholesterol and triglycerides measured in the Inuits, and suggested that marine long-
chained n-3 PUFAs have special metabolic effects. In a second study, Bang and Dyerberg 
found that plasma n-3 PUFAs levels were significantly higher and that bleeding-time was 
longer in Greenland Inuits than in Danes (179). In 1980, these associations were also reported 
from Japan, another population with low incidence of thrombotic disease, in a study 
comparing inhabitants in a fishing village to those in a farming village (180). Since then, 
marine fatty acids have been subjected to extensive research related to numerous diseases, and 
marine derived n-3 PUFAs are widely recommended as a component in a healthy diet (181-
183). 
 
1.5.2 Structure and properties 
Fatty acids are a diverse group of molecules characterized by repeating series of hydrophobic 
methylene groups (a carbon chain with hydrogen bonds) and an acyl compound that facilitate 
the composition of complex lipids (184, 185). The human diet contains a mixture of >20 
different types of fatty acids, mainly with a carbon chain length of 12-22 (186). Functions of 
fatty acids include energy supply, storage, insulation, and cell membrane structure, though 
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fatty acids also provide substances to physiological processes. Life would not sustain without 
them. The number of carbons, double bonds and their position are the main basis of 
nomenclature, and naturally occurring fatty acids generally share the characteristics of a cis-
isomer configuration and an even number of carbons (187).   
 
Figure 7. Structure of eicosapentaenoic acid (EPA). The omega-3 fatty acid family is named 
after the last double bound in the chain, which occur three carbons away from the terminal 
methyl group (n-3). The label C20:5n-3 specify the number of carbons and number of double 
bonds as well (Adapted from Wikimedia).  
 
Marine derived polyunsaturated fatty acids (n-3 PUFAs) have a chain length of 18, 20 
or 22 carbon atoms with 3-6 double bounds (n) (184). The last double bound in the carbon 
chain occurs three carbons away from the terminal methyl group, giving them the popularized 
name omega-3 (187, 188). The marine derived long-chained n-3 PUFAs include 
eicosapentaenoic acid (EPA, C20:5n-3), docosapentaenoic acid (DPA, C22:5n-3) and 
docosahexaenoic acid (DHA, C22:6n-3). These fatty acids mainly origin from marine algae 
that enter the human food chain through the marine fauna. In contrast to the long-chained n-3 
PUFAs, the shorter chained alpha linolenic acid (ALA, C18:3n-3) is also abundant in 
terrestrially derived plant oils. In 1929, it was discovered that mammals do not possess 
enzymes able to synthesize double bonds at the n-3 and n-6 position of the carbon chain. 
Therefore, n-3 PUFAs in humans depend on dietary sources, and are referred to as essential 
fatty acids (189, 190). Although ALA is 15-25 fold more abundant than EPA and DHA in the 
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typical Western diet, it only represents about 0.5% of total fatty acids concentration in plasma 
cells and tissue phospholipids, whereas concentrations of EPA and DHA usually are higher. 
(191). This indicates a significant affinity to take up the long chained n-3 PUFAs. However, 
in mammals ALA and linoleic acid (LA, C18:2n-6) can be extended to EPA and the omega-6 
arachidonic acid (ARA, C20:4n-6) respectively through elongation and desaturation (190). In 
a study where participants were given high doses of radioisotope labeled ALA and a 
background diet high in saturated fat, a 6% conversion from ALA to EPA was observed, a 
rate that was considerably slower under alternative background diets (192). Increased rates of 
ALA to EPA conversion has been reported in non-fish consumers, and the rate is generally 
higher in women in childbearing ages (193). Intake of LA also modifies the conversion rate 
because it is a competitive inhibitor of ALA for the Δ5 and Δ6 desaturase enzymes (194). 
Elongation from EPA to DHA may be <0.5% (193), or does not occur in humans (195), 
whereas reconversion of DHA to EPA readily occurs (192, 195). In all, the conversion of 
ALA to long-chained n-3 PUFAs is inefficient and unpredictable, while long-chained n-3 
PUFAs are readily taken up through dietary marine food or supplements (192, 196).  
 
1.5.3 Physiological effects of n-3 PUFAs on hemostasis and thrombosis 
Dietary n-3 PUFAs are incorporated into cellular membranes of all tissues, and the extent of 
incorporation depends on the intake (186). Increased intake of n-3 PUFAs is measurable in 
cellular membranes within days (197). n-3 PUFAs increases cell membrane fluidity which is 
considered to enhance trans-membrane functionality (186).   
Cell membrane polyunsaturated phospholipids constitute a pool of fatty acids used as 
components in the diverse eicosanoid lipid family of signaling molecules (198). The effect 
and type of eicosanoid that are produced differ between cell types (187). Eicosanoids have 
short half-lives and exert a local effect. Among the eicosanoids, prostaglandins and 
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prostacyclins have hemostatic regulatory functions in platelets and in endothelial cells (198). 
The prostaglandin thromboxane A2 (TxA2) is of particular interest because it causes platelet 
activation and vasoconstriction (83). Thromboxanes and other eicosanoids are formed in 
response to cell perturbation, and in the first step phospholipase releases ARA and EPA into 
the cytoplasm. In platelets, and also in monocytes, neutrophils and eosinophils, the COX-1 
enzyme cyclize ARA and EPA released from the cell membranes to endoperoxides, which 
next are metabolized to thromboxane by thromboxane syntethase. In platelets, ARA is a 
precursor of the 2-series of thromboxane (TxA2). However, EPA is a competitive inhibitor of 
ARA for the COX enzyme, and EPA is a precursor to the 3-series of thromboxanes (TxA3) 
(Figure 8). TxA3 ability to activate platelets may only be 1/10 of TxA2 (199, 200). In platelets, 
prostaglandin H3 (PGH3) is the immediate parent compound of TxA3, and a proportion of 
PGH3 rapidly degrades to PGD3 that increases platelet cAMP and Ca
2+ efflux that counteracts 
platelet activation (200).  
 
Figure 8. EPA is a competitive inhibitor of ARA for the COX enzyme, and EPA is a 
precursor of the considerably less potent 3-series of prostaglandins.   
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Several studies have shown that increased intake of EPA through fish oil increases the levels 
of the 3-series of eicosanoids at the expense of the ARA derived 2-series of eicosanoids (201-
205). A meta-analysis involving 52 publications with a majority of randomized controlled 
trials, concluded that fish oil supplements reduce platelet aggregation in healthy subjects 
(206). In medicine, inhibition of the COX-enzyme and thereby the metabolism of TxA2, is an 
efficient and well-established way to suppress platelet aggregation. This is achieved with 
acetylsalicylic acid (aspirin) that binds to, and irreversibly inhibits the COX enzyme. 
Although the role of platelets in VTE is not fully understood, accumulating evidence indicates 
that platelets contribute to thrombosis in animal models and in humans (207, 208). Two 
clinical trials (WARFSA and ASPIRE) indicated that a low dose of aspirin reduced recurrent 
VTE after the completion of anticoagulant treatment (209), and a meta-analysis estimated a 
42% risk reduction of recurrent VTE with aspirin therapy (210).  
The antithrombotic effects of n-3 PUFAs are not restricted to platelet reactivity. In The 
Atherosclerosis Risk in Communities (ARIC) Study, a cross sectional study of more than 
15 000 individuals, a high fish intake (>1 servings per day) was associated with lower levels 
of the coagulation proteins fibrinogen (-2.9mg/dL), FVIII (-3.3%), vWF (-2.7%), and a 
slightly increased level of protein C (211). High doses of n-3 PUFAs possibly attenuate 
procoagulant activity in endothelial cells. In an experiment with umbilical vein endothelial 
cell cultures, 43% lower TF activity was reported when exposed to serum from volunteers 
who had a daily intake of 25 ml cod liver oil for 8 weeks, as compared with the same persons 
before the high dose fish-oil intervention (212). The expression of TF in monocytes may also 
decrease with intake of n-3 PUFAs. In a controlled trial where 40 healthy volunteers had 25 
ml cod liver oil for 8 weeks, TF expression in monocytes decreased with 40% (213). Bleeding 
time is considered to reflect platelet-endothelial interactions, and the bleeding time is 
shortened in response to exercise (214). A randomized controlled trial in patients with 
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hypercholesterolemia showed that intake of fish oil completely inhibited the reduction in 
bleeding time after a standardized exercise, indicating an inhibition of the platelet-endothelial 
interaction (215).     
 
1.5.3 Dietary marine polyunsaturated fatty acids and risk of venous thromboembolism 
A possible link between marine food intake and incidence of surgery related VTE can be 
inferred from historic data in Norway during World War II. An observational study from 
1940-1948 in two hospitals in Oslo, showed a temporal decline in incidence of VTE after 
surgery (216). Compared with the stable or slightly increasing trends of incident VTEs as 
described in several studies over the recent decades, the observed U-shaped curve in surgery 
related VTE during the war years appeared exceptional. The study adequately accounted for 
important confounders like type of surgery and immobilization that varied in the period. The 
reason for the transient decline is not known, but it occurred in parallel with dietary changes 
during the war period, including higher intake of fish and cod-liver oil, and lower intake of 
red meat and dairy products (217). 
The effects of n-3 PUFAs intake on key pathways involved in hemostasis have 
motivated five large prospective cohort studies to investigate the association between fish 
intake and risk of VTE. In the ARIC study (2007), a prospective study following 14 962 
participants over 12 years, the risk of VTE was estimated over quintiles (Qnt) of fish servings 
(218). The lower Qnt reference corresponded to less than one fish serving per week and Qnt2-
5 corresponded to having more than one and up to more than three servings per week. A 30-
45% lower risk of VTE was reported in Qnt2-5, suggesting a threshold effect. In analysis over 
quintiles of total n-3 PUFAs intake in the diet, a similarly reduced risk of 30-46% was 
reported. Conflicting result were reported in the Iowa Women’s Health Study (IWHS, 2009) 
where 37 393 women aged 55-69 years at inclusion were followed for 19 years. This study 
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found that ≥2.5 as compared to <0.5 servings of fish per week was associated with a 22% 
increased risk of VTE (219). The study also reported no association between total intake of 
omega-3 fatty acids and the risk of VTE. The Nurses’ Health Study and Health Professionals 
Follow-up Study (NHS, 2012) included 129 430 individuals who were followed from 1984 to 
2008 (220). Food frequency questionnaires were answered every 2-4 years and the most 
recent one was used as basis for analysis. The study reported negligible effects when 
contrasting high versus low intake of fish or n-3 PUFAs. A non-significant 5% reduced risk 
for women and a 4% reduced risk for men were found. In analysis of total n-3 PUFAs intake, 
a corresponding and still non-significant risk reduction of 6 and 8% were reported. In The 
Danish Diet, Cancer and Health Study (DCH, 2014), 57 054 participants aged 50-64 were 
followed between 1993 and 2006, and fat fish and total fish intake was assessed at baseline 
(221). In analysis of quintiles of total fish intake, and using the lower Qnt as reference, no 
association with VTE risk was found. However, fat fish intake in Qnt2-5 compared to Qnt1 
was associated with a non-significant 18-38% risk reduction in men, and 29-44% reduced risk 
in women for unprovoked VTE. The models were adjusted for use or no use of fish oil. Our 
group has previously conducted a cohort study on this topic. Using a single baseline 
measurement in Tromsø 4, 23 621 participants aged 25-97 were followed from 1994/95 to 
2012. The weekly frequency of lean and fat fish for dinner combined with use or no use of 
fish oil was collected. A 48% lower risk for VTE was observed for those who reported fish 
for dinner ≥3 times per week and additionally used fish oil supplements, compared with 1-2 






Table 2. An overview of existing prospective cohort studies investigating fish intake and risk 





n Main finding 
(High vs. low intake) 
Fat fish/ All omega 3 




Focus of fish intake 
as exposure 
 
Focus on omega-3 intake 
as exposure 
Steffen et al. 2007 
(ARIC) 
45-64 years 14,962 30% reduced risk 
 
30% reduced risk 
Lutsey et al. 2009 
(IWHS) 
Women 55-69 37,393 22% increased risk 
 
Na 
Varraso et al. 2012 
(NHS) 
30-75 years 129,430 No association 
 
No association 
Severinsen et al. 2014 
(DCH) 
50-64 years 57,054 No association 
 
20-40% reduced risk 
Hansen-Krone 2014 
(TROMSØ) 
25-97 years 23,621 22% reduced risk 
 
48% reduced risk 
 
 Two small Japanese studies have investigated serum EPA/ARA ratios and the risk of 
VTE. The first study was a cross sectional study of 144 out-patients of which 12 had PE. The 
PE patients had a lower EPA/ARA ratio than the non-PE patients (223). The second study 
was a case-control study that included 45 patients with acute VTE who were compared to age-
, gender-, and BMI matched healthy individuals. Serum levels of ARA where higher whereas 
levels of EPA was lower among the VTE patients, a tendency that was stronger among the 
younger half of the participants (<58 years old) (224).  
To our knowledge, only the SWITCO65+ study of elderly patients have previously 
investigated the association between n-3 PUFAs and the risk of recurrent VTE, and VTE 
related mortality (225). Levels of n-3 PUFAs in erythrocytes were measured at the time of the 
first VTE. Low levels were compared to medium and high levels of n-3 PUFAs based on the 
25th and 75th percentile. After 6 months, medium and high levels were associated with a 61-
83% reduced risk of recurrent VTE. No association was observed after 3 years of follow-up. 
All-cause mortality risk was 66-71% reduced after 6 months and 33-45% reduced after 3 
years. A methodological advantage in this study was the use of an objective measurement of 
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the n-3 PUFAs status. However, the study did not separate marine derived n-3 PUFAs from 
terrestrial plant derived n-3 PUFA (ALA) that has different properties than the marine long 
chained n-3 PUFAs. For instance, ALA do not inhibit platelet activation.  
A beneficial effect of marine long-chained n-3 PUFAs on pathways involved in VTE 
formation is supported theoretically, and in several experimental and observational studies. 
However, the results are conflicting in epidemiological prospective cohort studies that aim to 
assess dietary marine food intake at a population level and the risk of VTE. This could have 
several explanations as the investigated populations differ in age composition and in average 
fish intake. For instance, a 6-fold difference between the lowest and the highest intakes was 
shown from a study comparing fish intake in 10 European countries (226). Importantly, the 
exposure variable definition also varies across the studies. The content of n-3 PUFAs varies 
substantially between lean fish, fat fish, fish as bread spread and in fish oil supplements. 
Therefore, the n-3 PUFAs intake could vary considerably with the same dietary intake of fish. 
In the available prospective cohort studies, the exposure variable was mostly expressed as fish 





2. AIMS OF THE THESIS 
 
The aims of the thesis were: 
 
1) To investigate the association between intake of marine n-3 PUFAs and the risk of 
incident VTE in a cohort recruited from the general population using repeated 
measurements (Paper I). 
2) To investigate the association between intake of marine n-3 PUFAs and the risk of 
VTE recurrence and mortality in patients with incident VTE (Paper II). 
3) To investigate whether dietary intake of marine n-3 PUFAs intake modifies the trigger 







3. STUDY POPULATION AND METHODS 
 
3.1 The Tromsø Study 
The first survey of the Tromsø Study was conducted in 1974 to investigate the causes of the 
high rate of cardiovascular diseases among men in the north of Norway, and thereby to find 
strategies to prevent heart attack and stroke in the population (227). Both sexes were included 
in the second survey (1979/80), and to date, seven surveys have been conducted representing 
the broader population, and survey goals and measurements have diversified along the way. 
Today, the Tromsø Study represents a single-center, population based cohort with prospective 
data relevant for a wide range of disease outcomes. We used data from the 4th and 6th surveys. 
The 4th survey, conducted in 1994/95, was the broadest initiative to date, inviting all 
inhabitants in the municipality of Tromsø above the age of 25, and 27 158 (77%) participated. 
In the 6th survey, conducted in 2007/08, a selection of the population aged between 30 and 87 
years were invited and 12 984 attended (66%). 
 
3.1.1 Study design 
In Paper I, we conducted a prospective cohort study with repeated measurements. We 
followed participants from the date of enrollment in Tromsø 4 and in Tromsø 6 respectively, 
until the date of a VTE, migration, death, or until end of follow-up at December 31, 2016 
(whichever occurred first). Out of 29 540 unique individuals, 21 970 had complete 
information on n-3 PUFAs intake and were included. Among these, 5 892 participated in both 
surveys. The participants who took part in two surveys were given two observational periods 
with updated exposure data for the second period, unless they had VTE or were censored in 
the first period between Tromsø 4 and 6. During follow-up, 541 of the included had a first 
lifetime VTE. We used Cox proportional hazard regression models with age as time scale and 
calculated hazard ratios (HRs) with 95% confidence intervals (CIs) for VTE across quartiles 
(Qrt) of total fish and n-3 PUFAs intake.   
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 In Paper II, we recruited patients with a first lifetime VTE from the 4th and the 6th 
surveys of the Tromsø Study in order to investigate the association between intake of marine 
n-3 PUFAs and risk of recurrent VTE and mortality. Out of 896 who had a first lifetime VTE, 
595 had complete information on n-3 PUFAs intake and were included. During follow-up, 98 
had recurrent VTE and 227 died. We used Cox regression models and calculated HRs for 
VTE and mortality across tertiles (T) of n-3 PUFAs intake. End of follow up was 31 
December, 2016.  
In Paper III, we conducted a case-crossover study involving cases with incident VTE 
(n=445), all recruited from Tromsø 4 and followed until December 31, 2012. The aim of this 
study was to assess the trigger effect of major surgery across categories of n-3 PUFAs intake. 
The patients’ medical record was searched for major surgery and hospitalization in a 90 days 
hazard period before the VTE event, and in four control periods. The four 90-days periods 
within the 6-18 months period before the VTE were defined as control-periods (Figure 9). A 
90-days washout period was included to avoid carry-over effects. We used conditional logistic 
regression to calculate regression coefficients and corresponding odds ratios (ORs) for the 
presence of major surgery in the 90-days hazard period according to tertiles of n-3 PUFAs 
intake. 
 
Figure 9. An overview of the case-crossover design. Triggers for VTE are registered within 3 months 
preceding the event, i.e. the hazard period. For comparison, occurrence of risk factors are also registered 
in four preceding 3-month control periods. Between the hazard period and the control-periods, a 3-
month wash-out period was included to avoid carry-over effects.   
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3.2 Baseline measurements 
At the survey visits, data were collected by physical examination, blood sampling and self-
administered questionnaires. Blood pressure measurements were taken three times with 2-
minutes intervals with a Dinamap Vital Signs Monitor, and the mean of the last two 
measurements was recorded. Height and weight were measured with light clothing and 
without shoes, and BMI was calculated as weight divided by the square in height (kg/m2). 
Non-fasting blood samples were drawn from an antecubital vein, and serum was prepared by 
centrifugation after one hour respite at room temperature. Analyzes were undertaken at the 
Department of Clinical Chemistry, University Hospital of North Norway (UNN). GPO-PAP 
kits (Boering Mannheim) were used to analyze serum total triglycerides. In Tromsø 4, serum 
concentration of EPA, DPA and DHA in the cholesterol ester fraction was analyzed in a 
subset of 1167 participants. In this analysis, 200 μl serum was extracted according to the 
method of Folch et al. (228). The separation of cholesterol-esters was achieved with a solvent 
system consisting of petroleum ether/diethyl ether/acetic acid. Next, individual phospholipid 
classes were separated by liquid chromatography (Agilent Technologies model 1100 series), 
and then quantified by capillary gas chromatography (Agilent Technologies model 6890). 
Lipomics Technologies, Inc. (West Sacramento, CA) performed the latter analysis according 
to the method of Watkins et al. (229). Information on diet, smoking habits, education, history 
of CVD, stroke and diabetes was obtained from self-administered questionnaires.  
 
3.2.1 Assessment of n-3 PUFAs intake 
In Tromsø 4 and 6, participants were asked how frequently they had fat or lean fish for dinner, 
fish as spread on bread and how many months a year they used fish oil supplements. In 
Tromsø 4, the questionnaire for those ≥70 years was simplified and had fewer items that 
included the predefined maximum option range. For participants aged ≥70 years in Tromsø 4, 
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the highest frequency option was ≥2/week which was recoded to 2.5/week. In the Tromsø  4 
questionnaire, it was possible for those aged < 70 to report fish for dinner daily. This option 
was rarely chosen (<2%) and possibly unrealistic, and it was therefore recoded to 2.5/week, 
corresponding to the maximum option for those aged > 70. In addition, the answer options 
were slightly different in Tromsø 4 and in Tromsø 6 (Tromsø 4, < 70 years: never, < 1/month, 
1/week, 2-3/week, 4-5/week or daily. Tromsø 4, >70 years old: never, < 1/month, 1/week or 
≥2/week. Tromsø 6: 0-1/month, 1-3/week or 4-6/week). We recoded the option 4-6/week in 
Tromsø 6 to 2.5/week to adapt to the maximum option with the Tromsø 4 questionnaires. 
Frequencies reported as ranges (e.g, 1-3/week) were recoded to the mean value (e.g, 
1.5/week).  
We calculated an average n-3 PUFAs content in the different items as given in 
Institute of Marine Research, Seafood data (NIFES) and in the Norwegian Food Safety 
Authority (Matportalen) (230, 231). Accordingly, 100 grams of fat and lean fish contains 3.1 
and 0.4 grams of n-3 PUFAs, respectively, fish as spread contains 0.9 grams per 25 grams, 
whereas 15 ml of fish oil supplements contains 3.6 grams of n-3 PUFAs. The total weekly 
intake of n-3 PUFAs was calculated as the sum of frequency multiplied by serving size. 
According to the Norwegian Directorate of Health, a standard serving unit of fish for dinner 
was defined as 200 grams, spread on bread as 25 grams and a spoon of fish oil as 15 ml. An 
overview of marine n-3 PUFAs in different dietary items is shown in Table 3.  
 
Table 3 Dietary marine n-3 PUFAs in different food items 
 n-3 PUFAs/100 g Serving unit n-3 PUFAs/serving unit 
Lean fish for dinner 0.4 200 g 0.8 
Fat fish for dinner 3.0 200 g 6.1 
Fat fish as spread 3.7 25 g 0.9 
Fish-oil supplement 0.24/ml 15 ml 3.6 
Based on information from https://www.nifes.no and http://matportalen.no/ 
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3.2.2 Assessment of major surgery as a VTE trigger in the case-crossover study 
Trained personnel thoroughly reviewed the patients’ medical records, and information on 
VTE triggers such as major surgery in the hazard and control periods was extracted using a 
standardized form. Major surgery was defined as procedures involving organs within the 
chest, abdomen, pelvic cavity, the cranium, and for knee and hip surgeries, or surgery with 
general anesthesia >30 minutes (232).  
 
3.3 Outcome assessment 
3.3.1 Venous thromboembolism 
VTE events within the Tromsø Study cohort during follow-up were identified and recorded. 
The University Hospital in North Norway (UNN) is the only hospital serving the Tromsø 
municipality, and exclusively provides diagnostics, hospitalization and outpatient consultation 
for VTE patients. The following discharge codes were used to identify the VTE cases: For the 
period 1994-1998 relevant International Classification of Diseases (ICD) 9th codes for VTE 
diagnosis were 325, 415.1, 451, 452, 453, 671.3, 671.4, 671.9, and for the period 1999-2016, 
the ICD 10th revision codes I26, I80, I82, I67.6, O22.3, O22.5, O878.1 and O87.3. The 
computerized registry of autopsy diagnosis was also searched, and cases were registered if 
VTE was the cause of death (part one of the death certificate) or a significant condition (part 
two of the death certificate). In addition, the radiology procedure registry was searched to 
identify any cases accidently not given the relevant medical diagnosis code, but yet had an 
objectively confirmed VTE.  
 The medical record of all potential VTE cases was reviewed and validated by trained 
personnel with no knowledge of the baseline variables. The following four criteria were 
mandatory to register a VTE: i) A VTE had to be objectively confirmed by radiology 
procedures, i.e. compression ultrasonography, venography spiral computed tomography, 
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perfusion-ventilation scan or autopsy. ii) A diagnosis of VTE was indicated by a physician in 
the medical record. iii) Signs and symptoms consistent with the VTE diagnosis were present. 
iv) The VTE diagnosis had to require anticoagulant treatment (heparin, warfarin, 
thrombolysis) or vascular surgery, and if no treatment was given, contraindications had to be 
specified in the patient’s medical record. For cases indicated by autopsy diagnosis, the VTE 
had to have caused, or significantly contributed to the death of the patient. All VTEs were 
classified as either PEs or DVTs. Only a minority of cases with PE are examined for a 
simultaneous DVT, because the additional diagnostics have none or minimal treatment 
consequences. Hence, isolated PEs could not be categorized separately. VTE cases were 
further classified as provoked or unprovoked based on the presence of provoking factors 
within 8 weeks ahead of the event. Provoking factors encompassed major surgery or trauma, 
acute medical conditions (acute MI, ischemic stroke or major infectious disease), active 
cancer and a high grade of immobilization (bed-rest for more than 3 days, wheelchair use or 
long distance travel over 4 hours within two weeks ahead of the VTE). Recurrent VTEs were 
identified and validated according to the same criteria in cases who had a previous VTE.  
 
3.3.3 Date of cancer and death 
Date of cancer diagnosis were obtained from the Cancer Registry of Norway, whereas date of 





4. MAIN RESULTS 
4.1 Paper 1 
DIETARY INTAKE OF MARINE n-3 POLYUNSATURATED FATTY ACIDS AND 
FUTURE RISK OF VENOUS THROMBOEMBOLISM.  
Polyunsaturated fatty acids (n-3 PUFAs) have beneficial effects on key pathways in the 
pathogenesis of thrombosis. Previous studies on the relationship between dietary intake of 
fish- or n-3 PUFAs and the risk of venous thromboembolism (VTE) have shown inconsistent 
results, potentially due to challenges in assessing the total n-3 PUFAs intake and taking into 
account changes in the diet during follow-up. Our aim was to investigate the association 
between intake of n-3 PUFAs of marine origin and the risk of incident VTE in a population-
based cohort. We included 21 970 individuals aged 25-97 years from the fourth (1994-95) and 
sixth (2007-08) surveys of the Tromsø study, and incident VTE events were recorded to 
December 31, 2016. Weekly intake of n-3 PUFAs was calculated from self-reported fish for 
dinner, fish oil supplements and from fat fish as bread spread. For participants attending both 
surveys, data were updated and they contributed with two observation periods. Total weekly 
intake of n-3 PUFAs in grams was divided in quartiles (Qrt1:<4.7, Qrt2:4.7-13.4, Qrt3:13.4-
29.1, Qrt4:>29.1).  
 There were 451 incident VTE events during a median follow-up time of 11.6 years. 
Compared to Qrt1, subjects in Qrt2-4 had 22-26% lower risk of VTE after adjustment for age, 
sex and BMI (HR Qrt2 0.74, 95% CI 0.57-0.96; HR Qrt3 0.77, 95% CI 0.59-0.99; HR Qrt4 
0.78, 95% CI 0.61-1.00). The association was more pronounced for provoked VTE, and  
provoked pulmonary embolism (PE), and the HRs for provoked PE were 0.42 (95% CI 0.25-
0.72), 0.40 (95% CI 0.23-0.68) and 0.61 (95% CI 0.38-0.96) for Qrt2-4, respectively. 
In conclusion, dietary intake of marine n-3 PUFAs exceeding 4.7 g/week was 
associated with a lower risk of VTE, particularly of provoked PE. The results suggest a 
threshold protective effect of n-3 PUFAs intake.  
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4.2 Paper 2 
DIETARY INTAKE OF MARINE POLYUNSATURATED N-3 FATTY ACIDS AND 
RISK OF RECURRENT VENOUS THROMBOEMBOLISM 
Venous thromboembolism (VTE) is associated with a significant risk of recurrence, 
particularly following an unprovoked or a cancer-related index event. However, the impact of 
marine n-3 PUFAs intake on the risk of recurrent VTE remains virtually unexplored. Our aim 
was to investigate the association between dietary intake of n-3 PUFAs and the risk of 
recurrence and all-cause mortality in VTE-patients derived from the general population. A 
total of 595 patients with incident VTE and complete data on dietary intake of n-3 PUFAs 
were derived from the 4th (1994-95) and the 6th (2007-08) surveys of the Tromsø Study, and 
categorized according to tertiles (T) of weekly intake in grams (T1: <8.2, T2: 8.2-29.1, T3: 
>29.1). Participants entered the study on the date of the incident event and were followed 
until recurrence, death, migration or the end of the study period (December 31, 2016).  
During a median follow-up of 3.6 years, there were 98 recurrent VTEs. We found no 
overall association between intake of n-3 PUFAs and risk of recurrent VTE. However, high 
intake was associated with inverse associations after unprovoked VTEs (HR 0.45, 95% CI 
0.20-1.01), and after DVT (HR 0.49, 95% CI: 0.24-0.97). The risk reduction was more 
pronounced in cancer free patients (HR 0.51, 95% CI: 0.27-0.95). There were 227 deaths 
during a median follow-up of 4.5 years. No association was observed between intake of n-3 
PUFAs and the risk mortality after incident VTE. 
In conclusion, we found that a high dietary intake of n-3 PUFAs was associated with 
lower risk of recurrent VTE following an unprovoked first event, DVT and in cancer-free 





4.3 Paper 3 
IMPACT OF DIETARY MARINE n-3 POLYUNSATURATED FATTY ACIDS ON 
SURGERY AS A TRIGGER FOR VENOUS THROMBOEMBOLISM – RESULTS 
FROM A CASE-CROSSOVER STUDY 
Surgery is an important trigger of venous thromboembolism (VTE) and previous 
observational studies suggest that dietary intake of n-3 polyunsaturated fatty acids (n-3 
PUFAs) lower the risk of incident VTE. However, it is unknown whether n-3 PUFAs intake 
influences the effect of surgery as a trigger for VTE, and the aim of the study was to 
investigate whether intake of n-3 PUFAs modifies the trigger effect of surgery. 
We conducted a case-crossover study with 445 VTE patients recruited from the 
Tromsø Study, a population-based cohort. Self-reported intake of n-3 PUFAs was collected at 
baseline, and information on surgery and hospitalization was registered during the 90-day 
period prior to the VTE event (hazard period) and in four preceding 90-day control periods. 
Conditional logistic regression was used to estimate odd ratios (ORs) with 95% confidence 
intervals (CIs) of surgery as a VTE trigger, and these were compared across tertiles of n-3 
PUFAs intake. 
The overall OR of surgery was 7.6 (95% CI 5.2-11.1), and a higher intake of n-3 
PUFAs mitigated the association. The ORs across tertiles of n-3 PUFAs intake were 11.8 
(95% CI 6.1-22.6), 8.1 (95% CI 4.2-15.7) and 4.1 (95% CI 2.1-8.2). The effect was strongest 
for pulmonary embolism (PE), with ORs of 14.7 (95% CI 5.5-39.6), 7.0 (95% CI 2.1-23.5) 
and 2.8 (95% CI 1.1-7.4), respectively. In conclusion, a high intake of n-3 PUFAs strongly 




5. GENERAL DISCUSSION 
5.1 Methodological consideration 
5.1.1 Study design  
Paper I and II have a prospective cohort study design, whereas Paper III is a case-crossover 
study, and all papers are based on data from the Tromsø Study, a large population-based 
cohort. Our results should be interpreted in the light of strengths and limitations of the study 
designs and the risk of bias. 
In a cohort study, a population of interest is first defined. In Paper I, the study 
population represents the general population of Tromsø, Norway, whereas the study 
population in Paper II consists of VTE cases. A cohort study usually starts with a baseline 
visit where study variables are measured. Participants are then followed until a defined 
outcome occurs, or up to a defined end date of the study. Follow-up is censored, i.e. ends, 
when continuation becomes impractical or impossible, as with migration, withdrawal from the 
study or death. In general, the cohort design is well suited to estimate the incidence rate or 
absolute risk of a disease in the population, and relative risks (e.g., HRs) according to 
exposure status can readily be estimated (233). Cohort studies are considered well suited to 
investigate common diseases, such as VTE. Cohort studies are expensive to conduct because 
they typically enroll a large number of participants who are followed over a long time (234). 
A methodological strength of cohort studies is that the exposure is measured before the 
outcome of interest occurs, and a clear temporal sequence is a criterion for causal inference. 
Causal relationships has previously been established in cohort studies, and merits include the 
first recognitions of now well-known cardiovascular risk factors such as diet, exercise and 
hypertension (235) and the verification of a causal link between cigarette smoking and lung-
cancer (236). Yet, causal inference is one of the main challenges in cohort studies, as further 
explained in section 5.4.1.  
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A case-crossover study design have similarities with a case-control study. A 
comparison between these two approaches is useful to explain the case-crossover design used 
in Paper III. In a case-control study, the level of a risk factor in cases is compared with that of 
healthy controls, and the relative risk of the outcome is usually expressed as an odds ratio 
(OR). A case-control design is cost-efficient and suited to study rare outcomes, because cases 
could be scarce even in large cohort studies leading to low statistical power. Even though 
controls typically are age- and sex -matched, a disadvantage in case-control studies is that 
cases and controls could still differ systematically and cause a bias (e.g. selection bias, as 
explained in the next section). Whereas the case-control design basically address the question 
“why me?”, the case-crossover design rather addresses the question “why now?”. Triggers 
such as hospitalization and surgery are transient exposures and the effect is confined to 
limited periods (hazard periods) (61). Such time windows can be used as control periods in 
the same individual, and this is utilized in the case-crossover study design. Since cases serve 
as their own controls, all persisting characteristics such as age, sex, genetic predispositions 
and socioeconomic status, are in theory controlled for through the design. The case-crossover 
design is well suited to study the effect of transient triggers (237). In the case-crossover study 
in Paper III, we recruited VTE cases derived from the Tromsø study, and investigated the 
effect of n-3 PUFAs intake on major surgery as a trigger for VTE. It is challenging to define 
the proper duration of the hazard period. Increased risk of VTE after major surgery tend to 
resolve within 3 months [61]. However, 3 months is an approximation of the hazard period 
and the effect of certain surgeries tend to resolve within 2 months. Our definition of a 90 days 
hazard period was probably long enough to account for most of the effect of major surgery. 
An inappropriate lengthy hazard period would tend to include triggers that had no true effect 
at the time of the VTE, which would cause underestimated risk estimates. A too short hazard 
period would fail to take into account all relevant trigger events. We included a 90 days 
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washout period, which presumably would prevent carry-over effects of trigger events from the 
control-periods to the hazard period. A drawback of the case-crossover design is that it does 
not yield absolute risks or incidence rates.  
 
5.1.2 Errors and bias 
Errors are inevitable in studies. Random errors, or sampling errors, could affect study results 
in any direction. Improved measurement accuracy and increasing sample sizes will minimize 
the effect of random errors and increase the precision of estimates (114). In contrast, bias 
refers to systematic errors causing study results to be different from true results in a specific 
direction (238). Selection bias refers to an unequal chance of being recruited into the study 
based on either the exposure or the outcome of interest. As a consequence, the study results 
may not by representative for the target population. In cohort studies, selection bias on the 
basis of outcomes is unlikely as participants are recruited to the study before the outcome 
occurs. However, cohort studies are vulnerable to non-response bias, referring to the fact that 
non-responders to study invitations tend to differ in some respects from those enrolled. In the 
Tromsø study, relatively more non-responders were males, or belonged to the oldest or 
youngest group. These characteristics of non-responders are reported from other large cohort 
studies as well, together with lower socio-economic status (239). It is likely to assume that 
those with the highest burdens of disease also are less likely to participate than those who are 
healthy or suffer from milder burdens. It follows that non-responders could differ in levels of 
exposure and risk of outcomes. Within our study, we measured different intakes of n-3 
PUFAs across age groups, and since younger and elder had lower participation rates, a degree 
of non-response bias must be expected. Non-responder bias reduces how well a study 
represent the general population, and our study may be less representative for the youngest 
and oldest segments of the general population.  
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Information bias denotes the tendency to place study participants in an incorrect 
exposure or outcome category, which will lead to misclassification. Differential 
misclassification refers to an erroneous categorization of study participants that relates to the 
outcome. One example is recall bias, referring to differences in cases and controls due to a 
strong motivation in cases to search their mind thoroughly for any exposures that could have 
caused their diagnosis, a motivation not present in healthy controls (240). Another example is 
reversed causation, which implies that the outcome is a causal factor of the exposure, and 
not vice-versa. Differential misclassification causes biased study results in one or the other 
direction (238). Prospective cohort studies are principally less vulnerable to differential 
misclassification as the exposure is measured before the outcome occurs. For instance, in our 
studies it would be unlikely that those who got VTE during follow-up were more prone to 
over- or underestimate their marine food intakes at baseline. Cohort studies can influence 
outcome assessment if a baseline measurement causes increased surveillance for the outcome. 
The marine food intake as measured in the Tromsø surveys were unlikely to influence the 
likelihood of VTE diagnostics and cause surveillance bias, and in addition, those who 
registered the outcome were blinded to the exposure. Non-differential misclassification 
describes the situation where the probability to be erroneously categorized is unrelated to the 
outcome status. Non-differential misclassification generally leads to an underestimation of the 
association under investigation (238). Self-administered questionnaires can have an inherent 
degree of non-differential misclassification. In dietary questionnaires in general and in the 
Tromsø surveys, participants are often asked to approximate their typical food intakes per 
week during the last year within fixed ranges (e.g. 1-3 times per week, etc), because it cannot 
be expected that people are aware of their accurate intake of marine food over long time-
spans. Moreover, there were slight differences in the questionnaires used the fourth and the 
sixth survey of the Tromsø Study, possibly causing non-differential misclassification. Still, 
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our assessment of marine food intake was comprehensive as fish oil supplements and fat fish 
as bread spread was included in both questionnaires. Self-reported intake of marine food is the 
strongest predictor of n-3 PUFAs levels (241-243), and in a subgroup of 1167 individuals, we 
demonstrated a significant dose-dependent increase of marine long chained n-3 PUFAs in the 
serum cholesterol ester fraction with higher self-reported intake of n-3 PUFAs (p < 0.001) 
(244). In addition, baseline triglyceride levels decreased with increasing self-reported n-3 
PUFAs intake. It is therefore likely to assume that the calculated quartiles of n-3 PUFAs 
intake fairly well classified four distinct levels of exposures of marine n-3 PUFAs. However, 
the variance in EPA+DHA levels explained by self-reported intake is generally low, and in a 
Spanish cross-sectional study of 198 subjects at high CVD risk, 12% of the variance in 
EPA+DHA content in erythrocytes was explained by self-reported intake (241). Other 
contributing biological factors on EPA+DHA levels include BMI, smoking, heritability, and 
an inverse relationship with high intake of saturated fatty acids is also demonstrated (241, 
245).  
In Paper III we focused on surgery as a trigger for VTE. Triggers in general could also 
be subjected to degrees of non-differential misclassifications. Certain hospital-related triggers 
such as immobilization and major infections can build up gradually and are challenging to 
classify consistently in time and extent. In addition, we had no access on information about 
infections and immobilization outside the hospital setting. In contrast, hospitalizations and 
surgeries are well-defined in time with presumably few unregistered instances. In this respect, 
surgery was well suited to use in the case-crossover study design. Hospitalization is a major 
trigger for VTE that increases the risk of VTE up to a 100-fold (15, 154, 246). However, 
hospitalizations are heterogeneous and can involve serious disease with multiple interventions 
associated with high risk of VTE, or little intervention and risk. The effect of n-3 PUFAs 
would probably vary with different trigger situations. A low effect of n-3 PUFAs on a given 
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hospital related trigger would tend to weaken an association between n-3 PUFAs intake and 
hospitalization as a trigger, whereas a higher effect of n-3 PUFAs would tend to strengthen 
the association. Although our focus on major surgery represent a narrowly defined trigger that 
consistently causes damaged vessel walls, stasis and hypercoagulability, different surgeries 
are still associated with varying risk of postoperative VTEs. For instance, VTE occurs three 
times as often after orthopedic surgeries (1.2%) as compared to gastrointestinal surgeries 
(0.4%) (247).  
Competing risk refer to another type of selection bias. An assumption of the Cox 
regression model is that censoring events and loss of follow-up are non-informative to the 
outcome, i.e., individuals who remain in the study should have the same risk of developing 
the outcome as those who are no longer under follow-up. Censoring due to high mortality of a 
disease is a competing event that could alter the probability that the other event occur. For 
instance, recurrent VTE is more common in cancer patients than in VTE patients without 
cancer. High mortality rates could cause substantial censoring and loss of follow-up time in 
cancer patients.  A general effect of competing risk of death is a tendency to overestimate the 
risk of the disease of interest, e.g. as confirmed in VTE risk in patients with pancreatic cancer 
(142). In Paper II, we calculated relative risk of recurrent VTE taking competing risk of death 
into account, as there could be a different n-3 PUFAs intake among the censored. However, 
we observed no effect of competing risk by death on our results. 
 Analyzing recurring events (Paper II), introduces a form of selection bias called index 
event bias. Since patients are selected based on the occurrence of an index event (i.e. first 
VTE), multiple risk factors for the disease tend to accrue within this narrow study population. 
For instance, in studies of first VTE the estimated increased risk in a person with a 
prothrombotic genotype is compared with the general population without the genotype, and 
where the majority have a low burden of other VTE risk factors. This balance changes when 
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risk factors are compared within individuals who have suffered from a first VTE. When the 
risk of recurrence for the individual with a prothrombotic genotype is compared with other 
patients with a first VTE, this selected population carry a higher burden of VTE risk factors 
than the general population and the impact of the genotype is less apparent (248). The 
accruement of individuals with risk factors causes a conflict with the Cox regression model 
assumption that individuals and events are independent. Recurrence studies are in general at 
risk of introducing dependency between risk factors, causing recognized risk factor for the 
first event to appear neutral or even reversed for the second event. Index event bias is a likely 
explanation of the observation that FVL mutation imposes up to a 5-fold increased risk for a 
first VTE, and only a 1.2-fold increased risk for recurrence (60). In Paper II, we found a 
moderate negative association between high n-3 PUFAs intake and risk of recurrence after 
unprovoked VTE and in cancer free patients, and no association for all VTEs. However, HRs 
could be underestimated due to index event bias. 
 
 
5.1.3 Modifiable risk factors and regression dilution bias 
Modifiable risk factors represent another source of non-differential misclassification in cohort 
studies. This may introduce regression dilution bias with underestimation of the true 
association between the exposure and the outcome (249, 250). Intake of n-3 PUFAs could 
change over time and this was only partly taken into account in two of the previous cohort 
studies that applied an accumulated average of repeated measurements (218, 220). Possible 
regression dilution bias is a limitation of all cohort studies with single baseline measurements 
of modifiable exposures (250). For instance, it has been shown that the use of single baseline 
measurements of risk factors for cardiovascular disease significantly underestimated the true 
association (251). In Paper I, we used updated measurements rather than an accumulated 
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average of n-3 PUFAs intake in the analysis in an effort to minimize regression dilution bias. 
However, only 5892 out of the study population of 21970 participated in two surveys, and our 
efforts to minimize the effect of dietary changes were therefore suboptimal. Therefore, we 
also performed a sensitivity analysis where we restricted follow-up time to 5 years after 
baseline. The results of the sensitivity analysis showed stronger associations between intake 
of n-3 PUFAs and risk of VTE, indicating an underestimated effect of n-3 PUFAs in the main 
analysis due to regression dilution. In relevance to Paper II, the experience of having a first 
VTE event could have a modifying effect on n-3 PUFAs intake after baseline, because fish 
intake and n-3 PUFAs intake have been widely recommended for vascular health (182). This 
would add to the potential regression dilution bias in the study of n-3 PUFAs intake and VTE 
recurrence in Paper II, and our risk estimates may be underestimated. 
 
5.1.4 Confounding 
A weakness of cohort studies is that confounders cannot be ruled out through the 
study design. Confounders are variables that influence both the outcome and the exposure of 
interest, but are not in the causal path between the exposure and the outcome (233). Basically, 
confounding mixes up causal and non-causal relationships. Confounders result in either 
strengthening or weakening of an association. There are several methods to address 
confounders. In the Cox model, confounders can be adjusted for (i.e., included as covariates) 
in order to subtract their contribution to the association under investigation. Such 
multivariable adjustment models have the advantage of conserving statistical power. 
Confounders can also be controlled for by stratification, for instance by conducting separate 
analysis for the sexes or across age groups. However, stratification always imply loss of 
statistical power and multivariate models are therefore often preferred. Stratification is still an 
appropriate strategy to account for statistical interaction, for instance in models where a 
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covariate has a multiplicative effect on a second covariate (238). The consequence of 
interaction is that the risk estimate will vary across strata of this particular covariate. In such 
cases, stratified analysis according to the effect modifier would be appropriate.  
In our main analysis in Paper I, the risk estimates were adjusted for age, sex and BMI. 
Age was probably the strongest confounder in the analysis because elderly eat more fish, and 
the risk of VTE is strongly dependent with age. We used age as time-scale to control for age 
as a confounder (252). The effect of age-adjustment was large, flipping n-3 PUFAs intake 
from seemingly to be a risk factor to being a protective factor (This was observed by running 
an analysis with calendar time and no age adjustment). Sex and BMI were also possible 
confounders in our analyses. Males may have relatively higher risk of VTE than women at 
higher age (117), and we observed slight differences between the sexes in n-3 PUFAs intake. 
Risk of VTE and intake of n-3 PUFAs also vary with BMI, but additional adjustment for sex 
and BMI had negligible effects. Age is not a strong predictor for recurrence, and in Paper II 
we included age as a covariate in the Cox model with time on study as the time-scale. In the 
analysis of mortality after VTE, we included systolic blood pressure and smoking as 
covariates by using a stepwise backward elimination method (Starting with all candidate 
variables and eliminate statistically non-significant variables stepwise each time the model is 
run). In the analysis of VTE recurrence and mortality, the effect of age and other possible 
confounders in the multivariate models were modest. Although multivariate Cox models can 
strengthen causal inference by adjusting for confounders, unknown or unaccounted 
confounding variables could still cause the observed association. Such residual confounding 
represent a crucial weakness in the inference of causality in cohort studies. If possible, 
supporting evidence should be provided to strengthen assumptions of causality in cohort 
studies. Bradford Hills 9 criteria for establishing epidemiologic evidence of causality is a 
practical tool for this purpose (253). Briefly, Hill postulated that the more a study can 
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demonstrate strength (effect-size), consistency (reproducibility), specificity, temporality (the 
cause must precede the effect), a dose-response relationship, plausibility (a plausible theory of 
the causation should be present), coherence (agreement between the cohort study and 
experiments), experimental validations and analogy to other circumstances, the more likely 
there is a true causal link.  
Randomized controlled trials (RCT) and Mendelian randomization studies represent 
superior study designs to infer causality. In RCTs, individuals are randomly assigned to the 
exposure of interest, which thereby brake any underlying links to confounders (Section 5.1.4), 
even if they are unknown. However, RCTs have some practical limitations. Inclusion criteria 
in RCTs are often narrow and tend to result in a selection of relatively healthy individuals 
(233). The results in RCTs may therefore not represent the general population. Moreover, 
some interventions could cause unintended harmful effects, and ethical regulations are 
therefore strict compared to cohort studies (233, 254). Theoretically, it would be possible to 
conduct a RCT on n-3 PUFAs intake and risk of VTE. However, such a study would be 
practically demanding because a large number of individuals would need to be enrolled and to 
be followed for a long time to achieve sufficient statistical power.  
Mendelian randomization studies are novel approaches that can control for 
confounders and thereby reveal causal pathways. Mendelian randomization studies exploit 
allele allocation in meiosis as a natural randomization procedure (238). The design is possible 
if a gene variant inflicts the exposure of interest, for instance increasing the likelihood for 
obesity (129). A possibility in the field of n-3 PUFAs could be genes that control the 
transformation of fatty acids, for instance the conversion of ALA to EPA (255). Meiotic 
allocation to an exposure is unbiased similar to the randomization in an RCT, though there are 
known exceptions to consider. Mendelian Randomization is not appropriate for low risk 
variants and in ethnic heterogeneous populations where the effect of the risk allele could vary 
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between groups. In meiosis, some alleles are inherited in linkage with other genetic variants, 
which could introduce a confounding effect (256).  
 
5.1.5 Generalizability 
The generalizability, or external validity of the study, refers to what degree results from a 
study applies to other populations (257). Internal validity refers to which extent the study 
measured the effect it intended to measure (258). The generalizability in cohort studies relies 
on the definition of inclusion and exclusion criteria, the participation rate and loss to follow-
up. The participation rate in the Tromsø Study has been high, and was 77% and 66% in the 4th 
and 6th surveys respectively. Men and women aged 25-97 years old were enrolled, and the 
distribution of risk factors in the Tromsø Study is comparable with other western populations 
(9, 10). This indicates that the Tromsø cohort represents the general population well. 
However, participation rates were lower among the younger (<40 years) and the older (>80 
years), and in both surveys, the participation rate was lower among men than women (227). 
These traits are typical for cohort studies and reduces the generalizability in the groups with 
lower attendance (239). An advantage of cohort studies is that participants are selected before 
the outcome occurs. Therefore, errors would affect individuals with high or low intake of n-3 
PUFAs equally and probably have a low influence on the generalizability of the study results. 
  
5.1.6 Missing data 
Missing data are expected in large epidemiological studies (259). Missing data can be 
particularly common in self-administered questionnaires as unassisted respondents frequently 
leave some items unanswered (260). This was evident in our studies as well. In Paper I, 34% 
had one or more missing item in the questionnaires on marine food, and the total intake of n-3 
PUFAs could not be calculated. In contrast, a baseline visit examination such as systolic 
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blood pressure in Tromsø 4 and 6 was missing in <0.003% of the participants. Reasons for 
high rates of missing data in self-administered questionnaires could be diverse. For instance, 
unclear language and difficult questionnaire designs, or lack of motivation to answer the full 
questionnaire could contribute. Missing data causes loss of statistical power, and can cause 
biased estimates similar to non-response bias. There are several types of missing data. Data 
missed completely at random (MCAR) are unrelated to the study variables. In such cases, 
analyses based on complete cases would be unbiased. Data missing at random (MAR) 
signifies that the missing data mechanism is unrelated to the missing variables but may be 
related to other observed values. Data are missed not at random (MNAR) when the missing 
data mechanism is related to the missing values (260). The most common and simplest 
method to deal with missing data is to do a complete case analysis, in which all individuals 
with missing data are excluded. Computational techniques such as multiple imputation can be 
applied to assign probable values to replace missing data, and have been shown to represent 
actual data well, which thus improves statistical power and risk estimate precision. However, 
use of imputation depends on the missing mechanism and are not guaranteed to adjust for the 
presumed bias (259). Imputation can be considered in MAR and MCAR situations. In our 
study population, the participants with missing n-3 PUFAs data were older (mean age was 53 
years vs. 46 years), more likely to be current smokers (37.3% vs. 32.9%) having a history of 
CVD (11.6% vs. 5.45%) and cancer (5% vs. 2.7%). More people had higher education in the 
group with complete data (36.4% vs. 19.9%). In all, the group with missing n-3 PUFAs data 
were somewhat older and had more comorbidities, which most likely explains a higher 
incidence rate of VTE (2.9 vs. 1.6 per 1000 per year). The missing data mechanism was not 
completely unrelated to the study variables, though in complex relationship to other variables. 
In addition, our data on total n-3 PUFAs intake represented the sum of several variables with 
widely different contributions of n-3 PUFAs from lean fish, fat fish, fat fish as spread and fish 
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oil supplement. Imputation based on an assumption of MAR in our study would be 
ambiguous, and we chose to conduct complete-case analysis. Consequences are similar as in 
non-response bias, which can influence the generalizability of the study results. Our study 
population was probably more homogenous than the source population due to missing data. 
Still, the study’s internal validity addresses the principal association between intake of n-3 
PUFAs and the risk of VTE. Actually, homogeneity in the study population is often preferred 
in RCTs and in animal experiments to reduce random sampling errors and confounders, 















5.2 Discussion of the main results 
5.2.1 Dietary intake of n-3 PUFAs and risk of incident VTE 
In Paper I, we found an inverse association between self-reported intake of marine n-3 PUFAs 
and the risk of incident VTE in a large population-based cohort using repeated measurement 
and a time varying Cox model. Our results suggested that n-3 PUFAs intake exceeding the 
lowest quartile (4.7 grams per week) was associated with 22-26% lower risk of VTE, and 
there was no further reduced risk with a higher intake. The association was mainly driven by 
provoked events, and particularly PEs. We also investigated the effect of fish intake 
irrespective of n-3 PUFAs content, and found no association with overall risk of VTE. 
Results from previous studies have shown conflicting results (218-222, 262, 263). In 
the ARIC study, a 30-45% lower VTE risk was observed for n-3 PUFAs intake exceeding 0.7 
g/week, and a similar effect was observed for fish intake exceeding one serving per week 
(218). In the DCH Study, intake of fatty fish at baseline exceeding 35 g/week in women and 
49 g/week in men was associated with a non- significant 20-40% lower risk of unprovoked 
VTE (221). The NHS reported no association between the intake of fish or n-3 PUFAs and 
VTE risk (220). Finally, the IWHS study reported that ≥2.5 servings of fish per week at 
baseline was associated with a 22% increased risk of VTE compared to <0.5 serving per week 
(219). Factors that could explain some of the variations in the reported results include 
different definitions of the exposure variable and handling of potential changes in diet during 
follow-up. Intake of n-3 PUFAs or fish intake was assessed at baseline only (219, 221, 222), 
or the cumulative average of two or more measurements were used (218, 220). Dietary 
behavior could change during the course of follow-up causing non-differential 
misclassification, and the reported relative risks could therefore be underestimated due to 
regression dilution (264, 265). In Paper I, we addressed changes in dietary habits by updating 
the self-reported intake for those participating in both surveys. The time-varying model was 
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somewhat suboptimal as only 27% participated in two surveys. However, we also conducted 
analyzes with follow-up time restricted to maximum 5 years, which reduced the average time 
between n-3 PUFAs measurement and VTE event. These analysis yielded stronger effect sizes 
and suggests that the HRs in the main analysis were underestimated due to regression dilution 
bias.  
An intuitive alternative explanation of our results is that high intake of fish merely 
substitutes otherwise unhealthy meals, which in turn could cause the observed reduced risk of 
VTE according to n-3 PUFAs intake. In our study population, consumption of lean fish was 
more common than fat fish (>70% reported to have lean fish for dinner once or more per 
week), and lean fish have low concentrations of n-3 PUFAs compared to fat fish (230, 231, 
266). The n-3 PUFAs intake could therefore vary substantially with the same amount of 
dietary intake of fish. Our analysis of total fish intake irrespective of n-3 PUFAs 
concentration (fish oil supplements were not included in this analysis) therefore largely 
represented lean fish intake. Accordingly, we found no association between total fish intake 
and risk of VTE. This observation is in accordance with the previous cohort studies that 
reported separate analyses for intake of lean and fatty fish (i.e. low and high n- 3 PUFAs 
content). Generally, they found largest effect sizes between intake of fatty fish and fish oil 
supplements and risk of VTE, and lower effect sizes in analyses on lean fish intake (221, 
222). This suggests that the total content of n-3 PUFAs in the diet, rather than fish intake were 
key components that modulated the risk of VTE.  
The inverse association between intake of n-3 PUFAs and VTE was stronger in 
relation to provoked events and PEs. This propensity corresponds with the observation of a 
temporal decline in postsurgical VTEs during World War II, a period characterized with high 
intake of marine food and low intake of saturated fat (216, 217). More recently, a Japanese 
study reported an inverse association between fresh fish consumption or n-3 PUFAs intake 
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and risk of fatal PE (DVTs were not studied) in a cohort of 90 791 individuals with a median 
follow-up time of 19.2 years (267). For fresh fish intake exceeding >1 time per month up to 
daily, a 64-83% reduced risk of fatal PE was reported. Moreover, total n-3 PUFAs intake 
(including plant derived ALA) exceeding the lower 10th percentile (<0.8 grams per day) was 
associated with 64-74% reduced risk. As in our study, no association was observed when a 
variable of fish low in n-3 PUFAs content was used as exposure variable.  
The larger effect of n-3 PUFAs intake on PEs was not shown before we conducted our 
study. It could be speculated that n-3 PUFAs have an effect on the clot structure that reduces 
the risk of embolization of clots in the deep veins. Recently, platelet expression of cell 
adhesion molecules (E-cadherins) was shown to strongly influence platelet aggregation, clot 
stability and clot retraction in a murine model (268). As n-3 PUFAs have a downregulating 
effect on platelet activation, an effect on clot stability may also be possible. Most PEs 
probably originate in the lower extremities, however, de novo formation in the lungs or 
embolus of cardiac origins may possibly account for a substantial proportion of cases (269). It 
is therefore another possibility that the effect of n-3 PUFAs on provoked VTE, particularly 
PE, could be explained by a lower prevalence of VTE-related disease (e.g. atrial fibrillation) 
in those with a high intake (270, 271). 
Our observation of a modest protective effect of dietary intake of marine n-3 PUFAs 
on the risk of incident VTE is consistent with findings in other cohort studies (218, 221, 222). 
The measurement of dietary n-3 PUFAs intake was likely subjected to some degree of non-
differential misclassification at baseline and through dietary changes over the course of 
follow-up, which are likely to cause underestimated risk estimates. The observation that the 
risk was confined to provoked events and PEs was also in accordance with the scarce 
literature on the topic (216, 217, 267). The results should be interpreted with caution as 
residual confounders cannot be ruled out in a prospective cohort study design (114). In 
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conflict with our findings, a recent large Mendelian randomization study reported a 13% 
increased risk of VTE for genetically increased EPA levels. The study investigated single 
nucleotide polymorphisms (SNPs) in the gene that encodes Δ5-desaturase, an enzyme 
involved in the conversion of ALA to EPA (255). However, methodological limitations in this 
study included pleiotropic effects of the investigated SNPs, and that Δ5-desaturase 
functionality is also associated with the levels of other fatty acids. For instance, Δ5-desaturase 
also controls the conversion of LA to the pro-inflammatory arachidonic acid (ARA), and in a 
small Japanese case-control study, VTE patients were found to have higher ARA levels and 
lower EPA/ARA ratios than controls without VTE (224).  
We found that a low intake of dietary marine n-3 PUFAs was associated with 
increased risk of future provoked VTEs or PEs, which suggest a beneficial effect with a 
relatively modest increased intake. Future studies should focus on whether the observed 
association is causal, as there is an inherent risk of residual confounders in cohort studies. 
 
5.2.2 Dietary intake of n-3 PUFAs and risk of VTE recurrence 
In Paper II, we found that a high intake of n-3 PUFAs (upper tertile, >29.1 g/week) was 
associated with a lower risk of recurrent VTE compared with a low intake (lower tertile, <8.2 
g/week) in patients with unprovoked incident VTE events and in those with DVT. There was 
no association between n-3 PUFAs intake and risk of mortality after incident VTE. Prior to 
our report, there was limited data on the association between marine n-3 PUFAs intake and 
the risk of recurrence and mortality in patients with incident VTE. In a study of elderly 
(SWITCO65+), high levels of n-3 PUFAs in erythrocyte membranes was associated with a 61 
to 83% lower risk of recurrence and a 66 to 71% lower risk of mortality after 6 months of 
follow-up (225). After 3 years, a 45% lower risk of mortality was reported. The observed 
reduced risk of recurrence appeared to be transient, as no association was reported after 3 
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years. This contrast our findings where we observed the effect on recurrence only after 2 
years and no association with mortality. However, there were differences in the study 
populations and study design that could partly explain the differences in the study results.  
The n-3 PUFAs intake in our study population was high and was calculated only from 
marine foods, whereas the n-3 PUFAs erythrocyte level variable in the SWITCO65+ study 
was not restricted to marine origin. Thus, the influence of plant derived ALA (α-linolenic 
acid) in the SWITCO65+ study may have led to different findings in the two studies (272-
274). The patients included in SWITCO65+ were also older than those in our study (75 vs. 67 
years), and whereas 29% of the patients had a history of previous VTE in the SWITCO65+ 
study, our study population was limited to those with a first lifetime VTE. In our study, we 
only observed a beneficial association of n-3 PUFAs on recurrence risk in those with a high 
intake, which indicates only a moderate beneficial effect of n-3 PUFAs on the recurrence risk. 
A moderate effect is in accordance with the observation that the association was mainly 
confined to those with unprovoked index events. The risk for a recurrent VTE after an 
unprovoked event is moderate. In comparison, the risk of recurrence after a VTE provoked by 
a transient risk factor is low, whereas the risk of recurrence is high in patients with persistent 
risk factors (61, 113). Hence, a moderate effect of n-3 PUFAs could be difficult to detect in 
those at low risk, and conversely, a moderate effect could be overwhelmed in those at high 
risk. In a sensitivity analysis, we excluded patients with active cancer, who are at high risk of 
recurrence. In cancer free patients we observed a beneficial effect of high n-3 PUFAs intake, 
supporting the notion that the effects of n-3 PUFAs may have been overwhelmed in 
individuals with high recurrence risk.  
Apparently conflicting, we observed that high intake of n-3 PUFAs was associated 
with an increased risk of recurrence after a PE index event. PE typically recurs as a new PE 
which is a more serious condition than DVT (50). However, the current guidelines for 
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antithrombotic therapy recommend the same duration of anticoagulant treatment for PE and 
DVT under most circumstances (63). In our study, most patients with PE were under 
anticoagulant treatment for a longer time period than those with DVT. Specifically, in our 
data, representing treatment of VTE patients from 1994 to 2016, we found that 45% of 
patients with PE were scheduled with anticoagulant treatment for 1 year, which applied to 
only 13% of patients with DVT. This could partly explain the apparent lack of effect of n-3 
PUFAs on recurrence after PEs in our study. The risk of recurrent VTE is highest within the 
first year (48, 50), and in our study 53% of the recurrences occurred during the first year. It is 
therefore possible that patients with an index PE and under anticoagulant treatment the first 
year achieved no additional beneficial protective effect of n-3 PUFAs intake on top of the 
anticoagulant treatment. Conversely, DVT patients with shorter duration of the anticoagulant 
treatment seemingly had an effect of a high intake of n-3 PUFAs. In a separate analysis, we 
therefore restricted the follow-up time to the period after completion of anticoagulant 
treatment. The results consistently showed inverse associations between high n-3 PUFAs 
intake and recurrence after overall VTE and subtypes of VTE (unprovoked, provoked, DVT, 
and PE), indicating that anticoagulant treatment overwhelm any effect of n-3 PUFAs. 
In contrast to the results of the SWITCO 65+ study (225), we did not observe an 
association between n-3 PUFAs and risk of mortality in patients with VTE. Observational 
studies on the effects of fish- or n-3 PUFAs intake on mortality are conflicting (275-278). 
Possibly, the long chained marine n-3 PUFAs are associated with a lower risk of CVD related 
death, while ALA is associated with a lower risk of death from other causes (273, 279). Of 
relevance, the most frequently reported causes of death in VTE patients are cancer, PE, 
infections, and other cardiovascular or respiratory diseases (9, 280, 281). Consequently, a 
high proportion of deaths due to non-CVD causes in VTE patients could explain the lack of a 
beneficial association between marine n-3 PUFAs and all-cause mortality in our study. 
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Unfortunately, we did not have the possibility to assess distinct causes of death. However, the 
results did not change after exclusion of patients with active cancer.  
We observed a reduced risk of recurrent VTE with high intake of n-3 PUFAs mainly 
in cancer-free patients and in patients after discontinuation of anticoagulant treatment. As the 
risk of recurrence is relatively high, a protective effect of dietary marine n-3 PUFAs would be 
valuable knowledge for VTE patients, though future studies are necessary to confirm whether 
this relationship is causal.  
 
5.2.3 Modification of the effect of surgery as a trigger for VTE by intake of n-3 PUFAs 
In Paper III, we conducted a case-crossover study and the results indicated that a high intake 
of n-3 PUFAs strongly attenuated the effect of surgery as a trigger of VTE. The ORs for 
surgery across tertiles of higher n-3 PUFAs intake displayed an inverse relationship, where 
the ORs were 11.8 (95% CI 6.1-22.6) for tertile 1, 8.1 (95% CI 4.2-15.7) for tertile 2 and 4.1 
(95% CI 2.1-8.2) for tertile 3. Subgroup analyses further showed that this effect across n-3 
PUFAs intake was largest in PE, rather than DVT. For PE, the ORs according to surgery were 
14.7 (95% CI 5.5-39.6) for tertile 1, 7.0 (95% CI 2.1-23.5) for tertile 2 and 2.8 (95% CI 1.1-
7.4) for tertile 3.  
Previous investigations on surgery as a trigger for VTE and the relationship with n-3 
PUFAs intake are scarce. During World War II, data from two hospitals in Norway showed 
that the incidence rates of VTEs after surgery decreased from approximately 40 per 1000 
before the war, to <10 per 1000 during the war (216). Three years after the war, the incidence 
rate had risen to 20-30 per 1000. This U-shaped temporal decline correlated with a temporal 
increase in fish and fish oil intake during the war (217), and could indicate a beneficial effect 
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of marine n-3 PUFAs. Moreover, in Paper I, we observed an apparent stronger protective 
effect of n-3 PUFAs on the risk of provoked VTEs compared to unprovoked VTEs. 
 Prothrombotic trigging effects of major surgery include vessel wall injury, initiation of 
coagulation and altered hemodynamics, which basically affect all three categories in 
Vichow’s triad (endothelial injury, stasis of blood flow, hypercoagulability) (282). The risk of 
VTE after major surgery is transient and peaks within three weeks after the procedure (62). 
Measured pro-thrombotic responses after major surgery include increased inflammatory 
mediators (144), coagulation factors (FVII, FV, FVIII and fibrinogen) and monocyte 
activation (283), platelet activation (284) and NETs formation, which are all associated with 
an increased risk of VTE (80). Crucially, several of the factors that trigger VTE after surgery 
are both transient and modifiable, and a lowered VTE rate is therefore anticipated with 
lowered pro-thrombotic responses. According to the thrombosis potential model, VTE only 
develops if the thrombosis potential, due to combined impact from risk factors, exceeds the 
threshold for VTE (113). Interestingly, a beneficial effect of marine n-3 PUFAs on pro-
thrombotic factors that are associated with surgery, have been reported in ex vivo 
experiments. Specifically, TF expression in endothelial cells is downregulated with n-3 
PUFAs in vitro (212), and the potential to activate monocytes and platelets was reduced 
experimentally ex vivo (186, 213). Moreover, a 40% reduction of the synthesis of TF and a 
10-20% reduction in serum arachidonic acid levels was shown in a trial of participants who 
were given 25 ml cod liver oil per day for 8 weeks. In this study, the authors concluded that 
activation of extrinsic pathways of coagulation was suppressed by dietary enrichment of n-3 
PUFAs (213). No experimental studies have investigated the effect of n-3 PUFAs on the risk 
of surgery-related VTE. However, a placebo-controlled trial of 567 patients with newly 
created arteriovenous fistulas (AVF) investigated whether the AVF patency could improve 
with fish oil intake. Those randomized to fish oil (4 grams/d in three months) had reduced 
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intervention rates for acute thrombosis (285), whereas there were no beneficial effect on other 
endpoints such as AVF usability, or time to AVF patency loss (285, 286). Comparable results 
were reported in a RCT that involved synthetic arteriovenous grafts (287). However, these 
interventions may be questionable analogues for major surgeries in the general population, 
and the studies were also naturally limited to patients with severe renal failure.  
The risk reduction of surgery-related VTE by n-3 PUFAs was strongest for surgery-
related PE. In general PEs are considered to be a complication of DVT, and it may be 
speculated that a high n-3 PUFAs intake alters the clot structure with more stable clots that 
are less likely to embolize. Alternatively, many PEs could also have a cardiac origin or 
develop de novo in the lungs (269). Thus, a lower rate of PE-related post-surgical 
complications (e.g., atrial fibrillation) could be observed in those with a high n-3 PUFAs 
intake (270, 288). 
The case-crossover design is robust against confounding from persisting patient 
characteristics since cases serve as their own controls. However, the average age varied across 
the n-3 PUFAs tertiles, and the impact of surgery as a trigger potentially varies across age 
groups. Yet, the beneficial impact of high n-3 PUFAs intake on surgery as a VTE trigger 
remained present in sensitivity analyses where we used two different approaches to control for 
age as a potential confounder. Finally, confounding by factors that change over time within 
individuals remains possible. Although the n-3 PUFAs intake was assessed prospectively, the 
triggers for VTE were documented with a prior knowledge that a subsequent VTE would 
occur. This is a retrospective approach that could influence the decision to document certain 
triggers and introduce a bias. For instance, minor surgeries with negligible trigger effects 
could be included erroneously. Future interventional studies should investigate whether there 
is a true causal relationship between n-3 PUFAs intake and risk of post-surgical VTE, as 





1)  We found that weekly intake of marine n-3 PUFAs above 4.7 grams per week (a 
threshold effect) was associated with a 22-26% lower risk of VTE. We observed a 
stronger association for PE than DVT, and particularly for provoked PE (39-60% 
reduced risk).  
 
2)  Overall, we observed a moderate effect of dietary intake of n-3 PUFAs on the risk of 
recurrent VTE and no association with all-cause mortality. However, sub analysis 
showed a 55 % lower risk of recurrent VTE after unprovoked index events and a 49% 
reduced risk in cancer-free patients. These findings suggest that VTE patients under 
intermediate risk of recurrence may benefit from a high n-3 PUFAs intake. 
 
3) We observed a beneficial effect of n-3 PUFAs intake on major surgery as a trigger for 
VTE. Odds ratio for surgery decreased with high intake of n-3 PUFAs in the hazard 
compared to the control periods (OR 11.8 with low intake, 8.1 with medium intake, 
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VTE,	 particularly	 provoked	PE.	 The	 association	 displayed	 a	 threshold	 pattern	 and	
suggested	a	protective	effect	of	an	n-	3	PUFA	intake	≥4.7	g/week.
K E Y W O R D S
deep	vein	thrombosis,	diet,	omega-3	fatty	acids,	pulmonary	embolism,	risk	factors,	venous	
thromboembolism






Contemporary	 data	 have	 shown	 that	 the	 incidence	 of	 VTE	 has	 re-
mained	 stable	 or	 increased	 slightly	 over	 the	 past	 decades,6,7 which 





and	 is	 now	 implemented	 in	 dietary	 guidelines	 worldwide.12-14 The 
beneficial	effects	are	largely	attributed	to	the	essential	long-	chained	

















assessment	 and	 data	 handling.	 First,	 the	 content	 of	 n-	3	 PUFAs	 in	
fatty	fish	can	be	up	to	seven-	to	eightfold	higher	than	in	 lean	fish,	
and	dietary	 supplements	comprise	even	higher	n-	3	PUFA	concen-
trations.26,27	 It	 is	 therefore	possible	 to	have	a	high	 intake	of	 (lean)	






























has	 been	 published	 elsewhere.29	 Briefly,	 the	 entire	 (Tromsø	 4)	 or	
parts	(Tromsø	6)	of	the	adult	population	were	invited	to	participate,	
and	 the	 attendance	 rates	 ranged	 from	 66%	 in	 Tromsø	 6%-	77%	 in	
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(in	cm)	and	weight	(in	kg)	were	measured	with	participants	dressed	
in	 light	 clothes	with	 no	 shoes,	 and	 BMI	was	 calculated	 as	weight	
divided	by	 the	 square	of	height	 (in	m,	kg/m2).	Blood	pressure	and	
serum	lipid	concentrations	were	assessed	according	to	procedures	
described	 previously.30	 Information	 on	 fish	 intake,	 use	 of	 dietary	
supplements,	education,	current	smoking,	diabetes,	and	prior	CVD	
(comprising	myocardial	infarction,	angina	pectoris,	and	stroke)	were	
based	 on	 self-	administered	 questionnaires.	 Information	 on	 cancer	
history	was	obtained	from	the	Norwegian	Cancer	Registry.
2.3 | Assessment and validation of marine n- 3 
PUFA and fish intake
Information	on	dietary	intake	was	obtained	by	self-	administered	ques-
tionnaires.31	In	Tromsø	4,	participants	aged	<70	years	were	asked	to	
report	 how	 frequently	 they	 consumed	 lean	 and	 fat	 fish	 for	 dinner	
and	how	often	they	used	fish	as	spread	on	bread	(never,	<1,	1/week,	
2-	3/week,	4-	5/week,	or	daily).	Participants	 aged	≥70	years	 received	
a	 similar	 questionnaire,	 but	with	 fewer	 options	 (never,	 <1/week,	 1/
week	or	 ≥2/week).	 These	 assessments	were	 repeated	 in	 Tromsø	6,	
however,	 the	 frequency	 options	 differed	 slightly	 from	 those	 in	 the	
Tromsø	 4	 questionnaire	 (0-	1/month,	 2-	3/month,	 1-	3/week,	 4-	6/
week,	or	1-	2/day.	 In	both	 surveys,	 the	participants	were	also	asked	












of	 fat	 and	 lean	 fish,	 fish	 as	 bread	 spread	 and	 fish	 oil	 supplements.	








Q1 (n = 6970) Q2 (n = 7012) Q3 (n = 6967) Q4 (n = 6913)
Quartile	range,	g/wk <4.7 4.7-	13.4 >13.4-	29.1 >29.1
Age,	y 41	(12) 47	(14) 49	(14) 56	(14)
Sex,	male 47.1	(3282) 50.6	(3546) 40.8	(3539) 46.4	(3210)








1.45	(0.38) 1.48	(0.40) 1.50	(0.42) 1.56	(0.44)
Serum	triglycerides,	
mmol/L
1.54	(1.01) 1.55	(1.00) 1.52	(1.00) 1.46	(0.89)
Systolic	blood	
pressure,	mmHg
130	(17) 133	(20) 133	(20) 138	(23)
Diastolic blood 
pressure,	mmHg
76	(11) 77	(11) 77	(11) 78	(11)
Current	smoking 38.0	(2640) 31.6	(2210) 27.6	(1916) 22.4	(1541)
Diabetes 1.6	(108) 2.3	(158) 2.6	(181) 3.5	(241)
History	of	CVD 3.2	(221) 5.7	(398) 6.8	(471) 10.3	(700)
History	of	cancer 1.7	(116) 2.7	(192) 3.5	(243) 5.9	(410)
Higher	educationb 34.4	(2391) 36.0	(2511) 40.0	(2775) 38.0	(2615)
Values	are	mean	(±SD)	or	percentage	(count).
BMI,	body	mass	index;	CVD,	cardiovascular	disease	(angina	pectoris,	stroke,	myocardial	infarction);	
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and	DHA)	in	the	cholesterol-	ester	fraction	was	measured	in	a	sub-










if	 all	 of	 the	 following	 criteria	were	 present:	 signs	 and	 symptoms	













immobilization	 (bed	 rest	 ≥3	days,	 confinement	 to	wheelchair,	 long	
distance	travel	≥4	hours	within	the	last	14	days),	or	other	provoking	
factors	specified	 in	 the	medical	 record	 (eg,	 intravascular	catheter).	
The	remaining	cases	were	categorized	unprovoked.	The	events	were	












ity	 of	 Tromsø	 (n	=	3525)	 during	 follow-	up	were	 censored	 at	 these	
respective	time	points.
Statistical	 analyses	 were	 performed	 with	 STATA	 ver-
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TABLE  3  IRs	and	HRs	with	95%	CIs	for	VTE,	PE,	and	DVT,	overall	and	stratified	by	the	presence	of	provoking	factors,	across	quartiles	of	
weekly	intake	of	marine	n-	3	PUFAs	in	the	Tromsø	Studya
n- 3 PUFA intake (g/wk) Person- years VTE events
Crude IR  
(95% CI)b
HR model 1  
(95% CI)c P value
HR model 2  
(95% CI)d P value
Total	VTE
Q1	<	4.7 96 809 120 1.24	(1.04-	1.48) 1.00 0.12 1.00 0.13
Q2	4.7-	13.4 88 864 120 1.35	(1.13-	1.61) 0.75	(0.58-	0.96) 0.74	(0.57-	0.96)
Q3	>	13.4-	29.1 81 104 129 1.59	(1.34-	1.89) 0.77	(0.6-	1) 0.77	(0.59-	0.99)
Q4	>	29.1 71	711 172 2.40	(2.07-	2.79) 0.78	(0.61-	1) 0.78	(0.61-	1)
Unprovoked	VTE
Q1	<	4.7 96 809 46 0.48	(0.36-	0.63) 1.00 0.81 1.00 0.82
Q2	4.7-	13.4 88 864 49 0.55	(0.42-	0.73) 0.81	(0.54-	1.21) 0.81	(0.54-	1.21)
Q3	>	13.4-	29.1 81 104 59 0.73	(0.56-	0.94) 0.94	(0.64-	1.4) 0.94	(0.63-	1.40)
Q4	>	29.1 71	711 73 1.02	(0.81-	1.28) 0.89	(0.60-	1.31) 0.89	(0.6-	1.31)
Provoked	VTE
Q1	<	4.7 96 809 74 0.76	(0.6-	0.96) 1.00 0.07 1.00 0.07
Q2	4.7-	13.4 88 864 71 0.89	(0.63-	1.01) 0.71	(0.51-	0.99) 0.70	(0.51-	0.98)
Q3	>	13.4-	29.1 81 104 69 0.85	(0.67-	1.08) 0.66	(0.47-	0.93) 0.65	(0.47-	0.91)
Q4	>	29.1 71	711 99 1.38	(1.13-	1.68) 0.72	(0.52-	0.98) 0.72	(0.52-	0.98)
Total	DVT
Q1	<	4.7 96 809 60 0.62	(0.48-	0.8) 1.00 0.51 1.00 0.50
Q2	4.7-	13.4 88 864 74 0.83	(0.66-	1.05) 0.95	(0.68-	1.35) 0.95	(0.67-	1.34)
Q3	>	13.4-	29.1 81 104 81 1.01	(0.81-	1.26) 1.02	(0.72-	1.43) 1.01	(0.72-	1.42)
Q4	>	29.1 71	711 90 1.26	(1.26-	1.54) 0.88	(0.62-	1.24) 0.87	(0.62-	1.23)
Unprovoked	DVT
Q1	<	4.7 96 809 23 0.24	(0.16-	0.36) 1.00 0.87 1.00 0.87
Q2	4.7-	13.4 88 864 26 0.29	(0.20-	0.43) 0.88	(0.5-	1.55) 0.88	(0.50-	1.54)
Q3	>	13.4-	29.1 81 104 35 0.43	(0.31-	0.6) 1.15	(0.67-	1.97) 1.14	(0.67-	1.96)
Q4	>	29.1 71	711 38 0.53	(0.39-	0.73) 0.96	(0.56-	1.66) 0.96	(0.56-	1.66)
Provoked	DVT
Q1	<	4.7 96 809 37 0.38	(0.28-	0.53) 1.00 0.32 1.00 0.31
Q2	4.7-	13.4 88 864 48 0.54	(0.41-	0.72) 1.00	(0.65-	1.54) 1.00	(0.65-	1.54)
Q3	>	13.4-	29.1 81 104 46 0.57	(0.42-	0.76) 0.93	(0.6-	1.45) 0.93	(0.60-	1.44)
Q4	>	29.1 71	711 52 0.73	(0.55-	0.95) 0.82	(0.53-	1.28) 0.82	(0.53-	1.28)
Total	PE
Q1	<	4.7 96 809 60 0.62	(0.48-	0.8) 1.00 0.11 1.00 0.13
Q2	4.7-	13.4 88 864 46 0.52	(0.39-	0.69) 0.55	(0.37-	0.81) 0.54	(0.37-	0.8)
Q3	>	13.4-	29.1 81 104 47 0.58	(0.44-	0.77) 0.53	(0.36-	0.79) 0.53	(0.36-	0.78)
Q4	>	29.1 71	711 82 1.14	(0.92-	1.42) 0.68	(0.47-	0.96) 0.69	(0.48-	0.98)
Unprovoked	PE
Q1	<	4.7 96 809 23 0.24	(0.16-	0.36) 1.00 0.59 1.00 0.6
Q2	4.7-	13.4 88 864 23 0.26	(0.17-	0.39) 0.74	(0.41-	1.33) 0.74	(0.41-	1.33)
Q3	>	13.4-	29.1 81 104 24 0.30	(0.20.0.44) 0.75	(0.42-	1.34) 0.74	(0.42-	1.33)
Q4	>	29.1 71	711 35 0.49	(0.35-	0.68) 0.81	(0.46-	1.41) 0.81	(0.47-	1.42)
(Continues)
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(The	 R	 Foundation	 for	 Statistical	 Computing,	 Vienna,	 Austria).	
Demographics	and	clinical	characteristics	across	quartiles	of	n-	3	
PUFA	and	fish	intake	were	reported	as	means	with	SD.	Crude	in-
cidence	 rates	 (IRs)	 for	VTE	were	calculated	across	quartiles	and	
expressed	as	number	of	events	per	1000	person-	years.	Cox	pro-
portional	hazards	regression	models	with	age	as	time	scale	were	






In	 addition	 to	 analyzing	 across	 quartiles	 of	 n-	PUFA	 intake,	 Cox	
analyses	with	a	restricted	cubic	spline	with	four	knots	fitted	to	the	
n-	PUFA	intake	values	were	performed	and	plotted.
The	 proportional	 hazards	 assumption	 was	 evaluated	 and	 con-
firmed	based	on	Schoenfeld	residuals	using	a	global	test.	Statistical	




















































n- 3 PUFA intake (g/wk) Person- years VTE events
Crude IR  
(95% CI)b
HR model 1  
(95% CI)c P value
HR model 2  
(95% CI)d P value
Provoked	PE
Q1	<	4.7 96 809 37 0.38	(0.28-	0.53) 1.00 0.10 1.00 0.11
Q2	4.7-	13.4 88 864 23 0.26	(0.17-	0.39) 0.43	(0.25-	0.73) 0.42	(0.25-	0.72)
Q3	>	13.4-	29.1 81 104 23 0.28	(0.19-	0.43) 0.41	(0.24-	0.69) 0.40	(0.23-	0.68)















week.	Again,	 the	 largest	 effect	 sizes	were	 observed	 in	 relation	 to	









explored	 across	 quartiles	 of	 weekly	 fish	 intake,	 regardless	 of	 n-	3	
PUFA	content,	no	significant	associations	were	observed	(Table	S5).




those who were excluded.
4  | DISCUSSION
In	 the	 present	 study,	 we	 investigated	 the	 association	 between	
self-	reported	 intake	 of	marine	 n-	3	 PUFAs	 validated	 against	meas-









Previous	 reports	 on	 the	 association	 between	 n-	3	 PUFAs	 or	
fish	intake	and	the	risk	of	VTE	have	been	conflicting,	and	a	recent	
systematic	 review	 concluded	 that	 a	 risk	 modifying	 effect	 of	 fish	
consumption	has	meager	support	 in	 the	 literature.32	However,	 the	
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was	updated	 for	 those	participating	 in	both	surveys.	This	 resulted	
in	a	shorter	time	interval	between	assessment	of	exposure	and	out-
come	for	a	part	of	the	study	population	(27%).	Still,	sensitivity	anal-
yses	with	observation	 time	 further	 restricted	 to	maximum	5	years	








risk	 of	 VTE.	 Similarly,	 studies	 reporting	 separate	 analyses	 for	 in-
take	of	lean	and	fatty	fish	(ie,	low	and	high	n-	3	PUFA	content)	have	
generally	found	largest	effect	sizes	in	relation	to	fatty	fish	and	fish	
n- 3 PUFA intake Person- years VTE events Crude IR (95% CI)b HR (95% CI)c
Total	VTE
Q1d 96 809 120 1.24	(1.04-	1.48) 1
Q2-	Q4e 241	678 421 1.74	(1.58-	1.92) 0.76	(0.62-	0.94)
Unprovoked	VTE
Q1d 96 809 46 0.48	(0.36-	0.63) 1
Q2-	Q4e 241	678 181 0.75	(0.65-	0.87) 0.88	(0.63-	1.23)
Provoked	VTE
Q1d 96 809 74 0.76	(0.61-	0.96) 1
Q2-	4e 241	678 239 0.99	(0.87-	1.12) 0.69	(0.53-	0.91)
Total	DVT
Q1d 96 809 60 0.62	(0.48-	0.8) 1
Q2-	Q4e 241	678 245 1.02	(0.90-	1.15) 0.95	(0.71-	1.27)
Unprovoked	DVT
Q1d 96 809 23 0.24	(0.16-	0.36) 1
Q2-	Q4e 241	678 99 0.41	(0.34-	0.5) 0.99	(0.62-	1.59)
Provoked	DVT
Q1d 96 809 37 0.38	(0.28-	0.53) 1
Q2-	Q4e 241	678 146 0.60	(0.51-	0.71) 0.92	(0.63-	1.33)
Total	PE
Q1d 96 809 60 0.62	(0.48-	0.8) 1
Q2-	Q4e 241	678 175 0.72	(0.62-	0.84) 0.59	(0.43-	0.80)
Unprovoked	PE
Q1d 96 809 23 0.24	(0.16-	0.36) 1
Q2-	Q4e 241	678 82 0.34	(0.27-	0.42) 0.77	(0.47-	1.24)
Provoked	PE
Q1d 96 809 37 0.38	(0.28-	0.53) 1
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oil	supplements.21,24	This	suggests	that	a	high-	fish	diet	may	not	be	





















acteristics	 are	 equal,	 it	 follows	 that	 a	 given	provoking	 factor	more	
readily	exceeds	 the	 threshold	 for	 thrombus	 formation	under	 inad-














for	 changes	 in	 dietary	 habits	 during	 follow-	up	 with	 repeated	
assessments	 and	 including	 n-	3	 PUFA	 intake	 as	 a	 time-	varying	
variable	 in	our	analyses.	However,	 some	 limitations	of	 the	study	
merit consideration. There were substantial exclusions due to 
incomplete	 questionnaires,	 and	 the	 included	 participants	 were	
younger	and	healthier	compared	with	those	who	were	excluded.	
This	 influences	 the	 generalizability	 of	 the	 study	 population,	 but	
the	study	still	addresses	the	principal	association	between	intake	
of	n-	3	PUFAs	and	the	risk	of	VTE.	However,	several	factors	may	
influence	 the	precision	of	our	 risk	estimates.	The	 reproducibility	
of	self-	reported	fish	intake	in	the	Tromsø	study	has	been	reported	
to	 be	moderate	 (Spearman	 correlation	 coefficient =	0.41-	0.56),41 
and	 in	 general,	 dietary	 questionnaires	 may	 only	 reflect	 20%	 of	
n-	3	PUFAs	levels	measured	in	erythrocytes.42	However,	these	are	
misclassifications	unrelated	to	the	outcome,	which	would	lead	to	
underestimated	 risk	 estimates.	 Additionally,	 although	 we	 reas-
sessed	exposure	during	follow-	up,	the	median	duration	of	the	ob-
servation	periods	was	still	 relatively	 long	 in	our	study	 (12	years).	
As	 confirmed	 by	 the	 sensitivity	 analyses	with	maximum	 5	years	




models	were	 tested.	Finally,	 there	were	 slight	differences	 in	 the	
questionnaires	used	the	fourth	and	the	sixth	survey	of	the	Tromsø	
Study.	 However,	 serum	 triglyceride	 concentrations	 predicatively	
decreased	 with	 increasing	 n-	3	 PUFA	 intake,43 and there was a 


























Line H. Evensen  https://orcid.org/0000-0002-7169-9408 
REFERENCES
	 1.	 Huang	W,	Goldberg	RJ,	Anderson	FA,	Kiefe	CI,	Spencer	FA.	Secular	
trends	 in	 occurrence	 of	 acute	 venous	 thromboembolism:	 the	
Worcester	VTE	study	(1985-	2009).	Am	J	Med.	2014;127:829–839.e5.
68  |     ISAKSEN Et Al.
	 2.	 Næss	 IA,	 Christiansen	 SC,	 Romundstad	 P,	 Cannegieter	 SC,	
Rosendaal	 FR,	 Hammerstrøm	 J.	 Incidence	 and	 mortality	 of	 ve-







	 5.	 Silverstein	MD,	Heit	 JA,	Mohr	DN,	 Petterson	TM,	O’Fallon	WM,	





















	11.	 Kris-Etherton	 PM,	 Harris	 WS,	 Appel	 LJ.	 Fish	 consumption,	 fish	
oil,	 omega-	3	 fatty	 acids,	 and	 cardiovascular	 disease.	 Circulation.	
2002;106:2747–57.
	12.	 Rimm	 EB,	 Appel	 LJ,	 Chiuve	 SE,	 et	 al.	 Seafood	 long-	chain	 n-	3	
polyunsaturated	 fatty	 acids	 and	 cardiovascular	 disease:	 a	 sci-
ence	 advisory	 from	 the	American	Heart	 Association.	 Circulation.	
2018;138:e35–47.
	13.	 The	 Norwegian	 Directorate	 of	 Health.	 Kostråd om fisk og sjømat 
(Dietary advice on fish and seafood).	 [Accessed	 2018	 June	 22]	
Available	 from	 https://helsenorge.no/kosthold-og-ernaring/
kostrad/spis-fisk-oftere
	14.	 U.S.	 Department	 of	 Health	 and	 Human	 Services	 and	 U.S.	
Department	 of	 Agriculture.	 2015–2020	 Dietary Guidelines for 





platelet	 activation	 and	 tissue	 factor	 by	omega-	3	polyunsaturated	
fatty	acids	in	patients	with	advanced	chronic	heart	failure.	Thromb	
Haemost.	2011;106:457–65.
	17.	 Hansen	 JB,	 Olsen	 JO,	Wilsgård	 L,	 Østerud	 B.	 Effects	 of	 dietary	
supplementation	 with	 cod	 liver	 oil	 on	 monocyte	 thromboplas-
tin	 synthesis,	 coagulation	 and	 fibrinolysis.	 J	 Intern	 Med	 Suppl.	
1989;731:133–9.
	18.	 Hansen	 JB,	 Olsen	 JO,	 Wilsgard	 L,	 Lyngmo	 V,	 Svensson	 B.	
Comparative	 effects	 of	 prolonged	 intake	 of	 highly	 purified	 fish	
oils	as	ethyl	ester	or	triglyceride	on	lipids,	haemostasis	and	plate-
let	 function	 in	 normolipaemic	 men.	 Eur	 J	 Clin	 Nutr.	 1993;47: 
497–507.
	19.	 Hansen	 JB,	 Svensson	 B,	Wilsgard	 L,	 Osterud	 B.	 Serum	 enriched	
with	n-	3	polyunsaturated	fatty	acids	inhibits	procoagulant	activity	
in	endothelial	cells.	Blood	Coagul	Fibrinolysis.	1991;2:515–9.
	20.	 De	 Caterina	 R,	 Cybulsky	 MA,	 Clinton	 SK,	 Gimbrone	 MA	 Jr,	
Libby	 P.	 Omega-	3	 fatty	 acids	 and	 endothelial	 leukocyte	 ad-
hesion	 molecules.	 Prostaglandins	 Leukot	 Essent	 Fatty	 Acids.	
1995;52:191–5.
	21.	 Hansen-Krone	 IJ,	 Enga	 KF,	 Sudduth-Klinger	 JM,	 et	 al.	 High	
fish	 plus	 fish	 oil	 intake	 is	 associated	 with	 slightly	 reduced	






	23.	 Lutsey	 PL,	 Steffen	 LM,	 Virnig	 BA,	 Folsom	AR.	 Diet	 and	 incident	
venous	 thromboembolism:	 the	 Iowa	Women’s	 Health	 Study.	 Am	
Heart	J.	2009;157:1081–7.
	24.	 Severinsen	MT,	Overvad	K,	Andersen	VL,	Tjønneland	A,	Schmidt	
EB,	 Kristensen	 SR.	 Fish	 intake	 and	 venous	 thromboembolism:	 a	
Danish	follow-	up	study.	Thromb	Res.	2014;133:352–6.
	25.	 Varraso	 R,	 Kabrhel	 C,	 Goldhaber	 SZ,	 Rimm	 EB,	 Camargo	 CA	 Jr.	










I.	Cohort	profile:	 the	Tromso	Study.	 Int	 J	Epidemiol.	2012;41: 
961–7.
	30.	 Braekkan	 SK,	 Mathiesen	 EB,	 Njølstad	 I,	 Wilsgaard	 T,	 Størmer	 J,	
Hansen	JB.	Family	history	of	myocardial	 infarction	 is	an	 indepen-
dent	 risk	 factor	 for	 venous	 thromboembolism:	 the	Tromso	 study.	
J	Thromb	Haemost.	2008;6:1851–7.
	31.	 Jacobsen	BK,	Nilsen	H.	High	education	 is	associated	with	 low	fat	
and	high	 fibre,	beta-	carotene	and	vitamin	C.	Computation	of	nu-
trient	 intake	 based	 on	 a	 short	 food	 frequency	 questionnaire	 in	
17,256	 men	 and	 women	 in	 the	 Tromsø	 Study.	 Nor	 Epidemiol.	
2000;10:57–62.
	32.	 Mattiuzzi	C,	Cervellin	G,	Franchini	M,	Lippi	G.	Fish	intake	and	ve-
nous	 thromboembolism:	 a	 systematic	 literature	 review.	Clin	Appl	
Thromb Hemost. 2016;22:309–13.






	35.	 Jensen	 RA.	 Postoperative	 thrombosis-	emboli;	 their	 frequency	
in	 the	period	1940-	1948	at	 the	 III	department	of	Ulleval	Sykehus	




	37.	 Rosendaal	 FR.	Venous	 thrombosis:	 a	multicausal	 disease.	 Lancet.	
1999;353:1167–73.














	42.	 von	 Schacky	 C.	 Omega-	3	 fatty	 acids	 in	 cardiovascular	 dis-
ease—an	 uphill	 battle.	 Prostaglandins	 Leukot	 Essent	 Fatty	 Acids.	
2015;92:41–7.
	43.	 GISSI-Prevenzione	 Investigators	 (Gruppo	 Italiano	 per	 lo	 Studio	
della	Sopravvivenza	nell’Infarto	miocardico).	Dietary	supplementa-
tion	with	n-	3	polyunsaturated	fatty	acids	and	vitamin	E	after	myo-
cardial	 infarction:	 results	 of	 the	 GISSI-	Prevenzione	 trial.	 Lancet.	
1999;354:447–55.
SUPPORTING INFORMATION
Additional	 supporting	 information	 may	 be	 found	 online	 in	 the	
Supporting	Information	section	at	the	end	of	the	article.
How to cite this article:	Isaksen	T,	Evensen	LH,	Johnsen	SH,	
et	al.	Dietary	intake	of	marine	n-	3	polyunsaturated	fatty	
acids	and	future	risk	of	venous	thromboembolism.	Res Pract 
Thromb Haemost. 2019;3:59–69. https://doi.org/10.1002/
rth2.12168
Online Supporting Material (OSM) 
SUPPLEMENTAL MATERIAL  
 
Supplemental Table 1. Estimated weight and content of n-3 PUFAs in normal serving units of marine 
food items obtained from official web resources (1-3) 
Food item n-3 PUFAs Serving unit 
n-3 PUFAs 
per serving unit 
Lean fish 0.43 g/100 g 200 g 0.8 g 
Fat fish 3.03 g/100 g 200 g 6.1 g 
Fat fish spread 3.70 g/100 g 25 g 0.9 g 
Cod liver oil/ 
supplements 
0.24 g/ml 15 ml 3.6 g 
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Supplemental Table 2. Characteristics according to observational periods across quartiles of fish 









Quartile range, g/week ≤250 251-503 504-706 ≥707 
Age, years 41 (12) 46 (14) 51 (14) 56 (13) 
Sex, male 45.6 (3405) 47.4 (3133) 50.6 (3717) 51.7 (3322) 
BMI, kg/m2 25.2 (4.0) 25.3 (3.8) 25.8 (4.0) 26.5 (4.1) 
Serum total cholesterol, 
mmol/L 
5.60 (1.16) 5.80 (1.20) 5.97 (1.27) 5.86 (1.21) 
Serum HDL cholesterol, 
mmol/L 
1.46 (0.39) 1.50 (0.41) 1.52 (0.42) 1.52 (0.43) 
Serum triglycerides, mmol/L 1.52 (1.00) 1.50 (0.98) 1.52 (0.99) 1.53 (0.95) 
Systolic blood pressure, 
mmHg 
129 (17) 132 (19) 136 (21) 137 (23) 
Diastolic blood pressure, 
mmHg 
75 (11) 77 (11) 78 (12) 79 (12) 
Current smoking 34.3 (2554) 31.5 (2075) 28.2 (2065) 25.3 (1613) 
Diabetes 1.6 (119) 2.0 (134) 2.6 (190) 3.9 (245) 
History of CVD 3.1 (232) 5.1 (334) 7.8 (568) 10.3 (656) 
History of cancer 1.9 (142) 2.8 (186) 3.9 (290) 5.3 (343) 
Higher education† 39.5 (2948) 37.7 (2486) 33.2 (2424) 38.1 (2434) 
CVD cardiovascular disease (angina pectoris, stroke, myocardial infarction), Q quartile. 
*Based on 27862 observational periods from 21970 individuals in the period between 1994 and 2016. 
Values are mean (SD) or percentage (count). 
†≥15 years of education (corresponding to 3 years in university or academy). 
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Supplemental Table 3. Characteristics of VTE events in the Tromsø Study across quartiles of weekly 














Characteristics     
Age at incident VTE, years         60 (13) 67 (14) 68 (13) 71 (11) 
Male 54.2 (65) 52.7 (62) 49.6 (64) 51.2 (88) 
Clinical presentation     
   DVT 50.0 (60) 61.7 (74) 63.6 (82) 52.3 (90) 
   PE 50.0 (60) 38.3 (46) 36.4 (47) 47.7 (82) 
   Provoked VTE 61.7 (74) 59.2 (71) 53.9 (69) 57.6 (99) 
Clinical risk factors     
   Pregnancy/puerperium 0.8 (1) 0.8 (1) - 0.6 (1) 
   Heredity† 4.2 (5) 4.2 (5) 3.1 (4) 4.7 (8) 
   Other medical conditions‡ 15.5 (15) 17.4 (19) 24.5 (23) 20.0 (25) 
Provoking factors§     
   Surgery 22.5 (27) 19.2 (23) 13.3 (17) 11.6 (20) 
   Trauma 13.3 (16) 8.3 (10) 8.6 (11) 11.1 (19) 
   Acute medical conditions 10.8 (13) 15.8 (19) 7.8 (10) 11.1 (19) 
   Cancer¶ 23.3 (28) 21.7 (26) 21.1 (27) 29.7 (51) 
   Immobilization** 20.8 (25) 20.0 (/24) 12.4 (16) 15.1 (26) 
   Other†† 2.5 (3) 5.0 (6) 5.5 (7) 5.2 (9) 
DVT deep vein thrombosis, PE pulmonary embolism, Q quartile, VTE venous thromboembolism 
*n events = 541 in the period 1994-2016. Values are mean (±SD) or percentage (count). 
†VTE reported in a first-degree relative before the age of 60 years. 
‡Myocardial infarction, ischemic stroke, heart failure or chronic obstructive lung disease within the 
previous year. 
§One patient may have multiple provoking factors. 
¶Cancer disease present at the time of VTE diagnosis. 
**Bed rest ≥3 days, wheelchair user, plaster cast, air travel ≥4 h or long automobile travel < 14 days 
prior to VTE. 
††Other factors specified as provoking in the medical record (e.g., intravascular catheters).  
 
  
Online Supporting Material (OSM) 
Supplemental Table 4. IRs and HRs with 95% CIs for VTE, PE and DVT, overall and stratified by 
the presence of provoking factors, by weekly intake of marine n-3 PUFAs, with follow-up limited to 
maximum five years* 




 (95% CI) † 
HR 
(95% CI) ‡ 
Total VTE     
Q1§ 38176 35 0.92 (0.66-1.28) 1.00 
Q2-4¶ 144441 154 1.07 (0.91-1.25) 0.50 (0.34-0.73) 
Unprovoked VTE     
Q1§ 38176 10 0.26 (0.14-0.49) 1.00 
Q2-4¶  144441 59 0.41 (0.32-0.53) 0.74 (0.36-1.50) 
Provoked VTE     
Q1§ 38176 25 0.65 (0.44-0.97) 1.00 
Q2-4¶  144441 95 0.66 (0.54-0.80) 0.41 (0.26-0.65) 
Total DVT     
Q1§ 38176 20 0.52 (0.34-0.81) 1.00 
Q2-4¶  144441 84 0.58 (0.47-0.72) 0.50 (0.30-0.83) 
Unprovoked DVT     
Q1§ 38176 4 0.10 (0.04-0.28) 1.00 
Q2-4¶  144441 26 0.18 (0.12-0.26) 1.00 (0.33-3.06) 
Provoked DVT     
Q1§ 38176 16 0.42 (0.26-0.68) 1.00 
Q2-4¶  144441 58 0.40 (0.31-0.52) 0.39 (0.22-0.70) 
Total PE     
Q1§ 38176 15 0.39 (0.24-0.65) 1.00 
Q2-4¶  144441 70 0.48 (0.38-0.61) 0.50 (0.28-0.89) 
Unprovoked PE     
Q1§ 38176 6 0.16 (0.07-0.35) 1.00 
Q2-4¶  144441 33 0.23 (0.16-0.32) 0.59 (0.24-1.45) 
Provoked PE     
Q1§ 38176 9 0.24 (0.12-0.45) 1.00 
Q2-4¶  144441 37 0.26 (0.19-0.35) 0.44 (0.21-0.94) 
DVT deep vein thrombosis, IR incidence rate, PE pulmonary embolism, VTE venous 
thromboembolism 
*Based on data from the Tromsø Study in the period 1994-2016, analyzed by Cox proportional hazards 
regression models. 
†Per 1000 person-years. 
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Supplemental Table 5. IRs and HRs with 95% CIs for VTE, PE and DVT, overall and stratified by 
the presence of provoking factors, across quartiles of total weekly fish intake in the Tromsø Study* 







(95% CI) † 
HR  
model 1 




model 2  
(95% CI) § 
p for 
trend 
Total VTE        




Q 2  251-503 86255 111 1.29 (1.07-1.55) 0.93 (0.71-1.23) 0.93 (0.71-1.23) 
Q 3  >503-706 90127 173 1.92 (1.65-2.23) 1.00 (0.77-1.29) 0.98 (0.75-1.27) 
Q 4 >706 64602 161 2.49 (2.14-2.91) 1.03 (0.79-1.35) 0.99 (0.76-1.29) 
Unprovoked VTE        




Q 2  251-503 86255 50 0.58 (0.44-0.76) 0.99 (0.65-1.50) 0.99 (0.65-1.51) 
Q 3  >503-706 90127 74 0.82 (0.65-1.03) 1.00 (0.67-1.49) 0.99 (0.66-1.47) 
Q 4 >706 64602 62 0.96 (0.75-1.23) 0.94 (0.62-1.42) 0.90 (0.59-1.36) 
Provoked VTE        




Q 2  251-503 86255 61 0.71 (0.55-0.91) 0.89 (0.62-1.29) 0.89 (0.62-1.29) 
Q 3  >503-706 90127 99 1.10 (0.90-1.34) 1.00 (0.71-1.40) 0.97 (0.69-1.37) 
Q 4 >706 64602 98 1.52 (1.24-1.85) 1.10 (0.77-1.56) 1.05 (0.74-1.48) 
Total DVT        




Q 2  251-503 86255 60 0.70 (0.54-0.90) 0.92 (0.64-1.34) 0.93 (0.64-1.34) 
Q 3  >503-706 90127 105 1.17 (0.96-1.41) 1.14 (0.81-1.60) 1.12 (0.80-1.58) 
Q 4 >706 64602 87 1.35 (1.09-1.66)  1.06 (0.74-1.52) 1.04 (0.72-1.48) 
Unprovoked DVT        




Q 2  251-503 86255 20 0.23 (0.15-0.36) 0.66 (0.36-1.19) 0.66 (0.36-1.19) 
Q 3  >503-706 90127 44 0.49 (0.36-0.66) 1.00 (0.60-1.67) 0.98 (0.59-1.64) 
Q 4 >706 64602 33 0.51 (0.36-0.72) 0.84 (0.49-1.46) 0.81 (0.47-1.40) 
Provoked DVT        




Q 2  251-503 86255 40 0.46 (0.34-0.63) 1.16 (0.71-1.87) 1.16 (0.72-1.88) 
Q 3  >503-706 90127 61 0.68 (0.53-0.87) 1.25 (0.79-1.98) 1.25 (0.79-1.97) 
Q 4 >706 64602 53 0.82 (0.63-1.07) 1.24 (0.77-1.99) 1.22 (0.76-1.96) 
Total PE        




Q 2  251-503 86255 51 0.59 (0.45-0.78) 0.94 (0.62-1.42) 0.94 (0.62-1.42) 
Q 3  >503-706 90127 68 0.75 (0.59-0.96) 0.83 (0.56-1.24) 0.80 (0.54-1.20) 








Unprovoked PE        




Q 2  251-503 86255 30 0.35 (0.24-0.50) 1.49 (0.81-2.76) 1.50 (0.81-2.78) 
Q 3  >503-706 90127 30 0.33 (0.23-0.48) 1.01 (0.54-1.90) 1.00 (0.53-1.87) 
Q 4 >706 64602 29 0.45 (0.31-0.65) 1.08 (0.57-2.05) 1.04 (0.55-1.98) 
Provoked PE        




Q 2  251-503 86255 21 0.24 (0.16-0.37) 0.61 (0.34-1.09) 0.61 (0.34-1.08) 
Q 3  >503-706 90127 38 0.42 (0.31-0.58) 0.72(0.43-1.21) 0.69 (0.41-1.15) 
Q 4 >706 64602 45 0.70 (0.52-0.93) 0.93 (0.56-1.55) 0.85 (0.51-1.41) 
DVT deep vein thrombosis, IR incidence rate, PE pulmonary embolism, VTE venous 
thromboembolism. 
Online Supporting Material (OSM) 
*Based on data from the Tromsø Study in the period 1994-2016, analyzed by Cox proportional hazards 
regression models. 
†Per 1000 person-years. 
‡Adjusted for age (as timescale). 
§Model 1 + sex and BMI. 
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Supplemental Table 6. Baseline characteristics of included participants and those excluded due to 






Incidence rate of VTE  (n events) † 1.6 (541) 2.9 (324) 
Age, years 46 (14) 53 (17) 
Sex, male 48.6 (10865) 44.4 (3361) 
BMI, kg/m2 25.4 (3.9) 25.6 (4.2) 
Serum cholesterol, mmol/L 5.86 (1.25) 6.25 (1.37) 
Serum HDL, mmol/L 1.49 (0.41) 1.50 (0.42) 
Serum triglycerides, mmol/L 1.52 (1.00) 1.64 (1.12) 
Systolic blood pressure, mmHg 133 (20) 140 (24) 
Diastolic blood pressure, mmHg 77 (12) 80 (14) 
Current smoking 32.9 (7210) 37.3 (2810) 
Diabetes  2.04 (447) 3.24 (244) 
History of CVD  5.45 (1191) 11.6 (871) 
History of cancer 2.74 (601) 5.0 (381) 
Higher education‡ 36.4 (7977) 19.9 (1490) 
BMI body mass index, CVD cardiovascular disease (angina pectoris, stroke, myocardial infarction), 
HDL high-density lipoprotein, VTE venous thromboembolism 
*Based on data from the Tromsø Study in the period 1994-2016. Values are mean (±SD) or percentage 
(count) 
†per 1000 person-years 
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Background: Limited knowledge exists on the association between intake of long-chained n-3 
polyunsaturated fatty acids (n-3 PUFAs) and risk of recurrence and all-cause mortality in 
patients with venous thromboembolism (VTE). 
Objectives: To investigate whether intake of marine n-3 PUFAs was associated with risk of 
recurrence and mortality in patients with incident VTE. 
Methods: A total of 595 patients with incident VTE and available data on n-3 PUFA intake 
were derived from the Tromsø Study surveys 4 (1994-95) and 6 (2007-08). Weekly intake of 
n-3 PUFAs was categorized as low, medium and high based on tertiles. Recurrent VTEs and 
all-cause mortality were registered up to December 31, 2016. Hazard ratios (HRs) were 
calculated using Cox-regression models with the low intake-category as reference. 
Results: There were 98 recurrent VTEs and 227 deaths during follow-up. Overall, we found 
no association between intake of n-3 PUFAs and risk of recurrent VTE. However, inverse 
associations were found for high intakes in patients with unprovoked VTE (HR 0.45, 95% CI 
0.20-1.01), cancer-free patients (HR 0.51, 95% CI: 0.27-0.95), and DVT patients (HR 0.49, 
95% CI: 0.24-0.97). The inverse associations were more evident when follow-up was 
restricted to the time after discontinuation of anticoagulant therapy. No association was 
observed between intake of n-3 PUFAs and mortality after incident VTE. 
Conclusions: A high dietary intake of marine n-3 PUFAs was associated with lower risk of 
recurrent VTE after unprovoked index events, DVT and in cancer-free patients. 
 





Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary 
embolism (PE), is a common and burdensome disease associated with serious consequences 
(1, 2). The one- and eight-year mortality after VTE is 22-36% and 30-52%, respectively, with 
the highest rates observed after acute PE (3-6). Notably, patients with VTE have an elevated 
risk of mortality for up to three decades after the incident event when compared to the general 
population (7). Recurrent events are common, especially during the first year after the 
incident event, and the ten-year cumulative incidence of recurrence is 30-40% (4-6). The risk 
of recurrence is dependent on the etiology of the index event. The lowest risk is observed in 
patients with VTE provoked by a major transient risk factor (e.g., major surgery), an 
intermediate risk is observed in patients where a provoking factor cannot be identified, and 
the highest risk is recognized in presence of a major persistent risk factor (e.g., cancer) (8). 
Although anticoagulant therapy efficiently prevents VTE recurrence, such treatment is most 
often time-limited as the benefit must be balanced against the risk of bleeding (9, 10). In order 
to improve strategies for secondary prevention, there is a need to identify life-style factors that 
are inversely associated with adverse outcomes after VTE. 
 Fish and marine food products are advocated as important determinants of a healthy 
diet, and the long-chained n-3 polyunsaturated fatty acids (n-3 PUFAs; eicosapentaenoic acid 
(EPA), docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA)) are identified as key 
bioactive compounds (11-13). n-3 PUFAs are reported to be associated with downregulation 
of inflammation (14), platelet function (15), platelet endothelium-interactions (16, 17) and 
tissue factor expression (18), which are key pathways in the VTE pathogenesis. We and 
others have previously suggested a favorable association between dietary intake of fish and 
marine food products, particularly those high in n-3 PUFAs, and the risk of incident VTE (19-
22). Specifically, in our recent report based on the Tromsø Study, we found that moderate and 
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high intake of marine n-3 PUFA was associated with 22-26% lower risk of VTE (22). 
However, the role of n-3 PUFAs in relation to complications following VTE, such as 
recurrence and mortality, is largely unknown. 
 To our knowledge, only one study has investigated the association between n-3 
PUFAs and risk of recurrence and mortality after VTE. In the Swiss Cohort of Elderly 
Patients with Venous Thromboembolism (SWITCO65+), n-3 PUFA (marine- and plant-
based) levels in the erythrocyte membrane were measured in VTE patients aged ≥65 years, 
and the six-month and three-year risks of recurrence and mortality were investigated (23). 
They found that medium or high content of n-3 PUFAs in the erythrocyte membrane was 
associated with a lower six-month recurrence risk, and a lower risk of mortality at both time 
points. However, although, the fatty acid composition in the erythrocyte membrane reflects 
the fatty acid composition in the diet (24, 25), the association between dietary intake of n-3 
PUFAs and risk of recurrent VTE has not been studied. Further, whether the reported 
associations apply to VTE patients with a wider age-range and in a longer time-perspective, is 
not known. Finally, the plant-based and the marine-derived n-3 PUFAs may not be equally 
important in this context. Therefore, the aims of the present study was to investigate the 
association between dietary intake of marine n-3 PUFAs and the risk of recurrence and all-








The Tromsø Study is a population-based single-center cohort study with repeated health 
surveys of inhabitants of the Tromsø municipality in Norway (26). The study was approved 
by the Regional Committee for Medical and Health Research Ethics, and all participants 
provided written informed consent prior to inclusion. Patients with incident VTE were 
recruited among participants in the fourth (1994-95) and sixth (2007-08) surveys of the 
Tromsø study. The source population comprised of 29,538 unique individuals, of which 
10,304 took part in both surveys. The participants were followed from study inclusion to the 
end of the study period (December 31, 2016). All incident VTE events were identified and 
adjudicated by trained personnel searching the hospital discharge registry, the radiology 
procedure registry and the autopsy registry at the University Hospital of North Norway 
(UNN), as previously described in detail (27). UNN is the only hospital and the exclusive 
provider of relevant diagnostic radiology and hospital care in the study region, and manages 
essentially all in- and outpatients in Tromsø with a VTE diagnosis. Adjudication criteria for 
VTE were (i) signs and symptoms DVT or PE, (ii) objective confirmation by radiological 
procedures (compression ultrasonography, venography, spiral computed tomography, 
perfusion-ventilation scan or pulmonary angiography) or autopsy (only including cases where 
VTE was a significant contributor, or cause of death), (iii) a diagnosis of DVT or PE in the 
patient journal, and (iv) treatment initiation unless contraindications were specified. 
There were of 896 incident VTE events during follow-up, and these formed the basis 
of our study population. Participants (n=301) with incomplete information on n-3 PUFA 
intake were excluded, and 595 patients with incident VTE were included in the present study. 
A comparison of included VTE patients and those excluded due to incomplete data on fish 
intake and use of fish oil supplements is shown in Table S1.  
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 All VTE events were classified as provoked or unprovoked based on the presence of 
provoking factors at the time of diagnosis. Provoking factors were major surgery or trauma 
(within 8 weeks prior to the event), acute medical condition (acute myocardial infarction, 
acute ischemic stroke, major infectious disease), cancer, immobilization (bed rest ≥3 days or 
confinement to wheelchair, long distance travel ≥4 h. within the last 14 days) or a factor 
specifically described as provoking in the medical record, e.g. intravascular catheter. A VTE 




Information on anthropometry, dietary habits, physical activity and medical history was 
obtained from physical examinations and self-administered questionnaires at inclusion in 
Tromsø 4 or 6. Height, weight and blood pressure were measured by standardized procedures, 
as described elsewhere (27). Body mass index (BMI) was calculated as weight in kilograms 
divided by the square of height in meters (kg/m2). History of cardiovascular disease (CVD), 
diabetes, alcohol intake, physical activity, education level and smoking habits were reported 
via questionnaires. Information on cancer was obtained from the Cancer Registry of Norway. 
Active cancer was recorded when a cancer diagnosis was made in the time period from two 
years before to one year after the incident VTE event. Information on preplanned duration of 
anticoagulant treatment was obtained from the patients’ medical records. 
 
Assessment of marine n-3 PUFA intake  
The assessment of marine n-3 PUFA intake in the Tromsø Study has been described in detail 
previously (22, 28).  In brief, all participants in Tromsø 4 and 6 were asked to complete food 
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frequency questionnaires (FFQs), which included questions about how frequently they had fat 
fish and lean fish for dinner, how frequently they had fish as bread spread, and how often they 
used fish-oil supplements. In order to estimate the total intake of n-3 PUFAs, we first 
calculated the average content of n-3 PUFAs in different food items and supplements based 
on information obtained from official web resources (11, 29, 30), as previously described in 
detail (22). One serving unit of fish for dinner was defined as 200 g, and one serving unit of 
fish as bread spread was defined as 25 g. Total weekly intake of n-3 PUFAs was calculated by 
summarizing the amount of n-3 PUFAs derived from a person’s weekly intake of fat and lean 
fish, fish as bread spread and fish oil supplements. For participants with data on n-3 PUFAs 
intake in both Tromsø 4 and 6, the data with shortest proximity to the incident VTE event 
(before or after) was used, as it was assumed to be the most relevant intake. For the 
remaining, the available data, either from Tromsø 4 or 6, was used.  Eventually, there were 
342 and 253 participants with data form Tromsø 4 and 6, respectively. 
 
Outcome assessment  
All recurrent VTE events during follow-up were identified and adjudicated using the same 
procedure as described for the incident events. Data on mortality was obtained from the 
Norwegian Population Registry.  
 
Statistical analysis 
Person-years of follow were accrued from the date of the incident VTE to the date of 
recurrent VTE, death, migration or the end of the study period (December 31, 2016), 
whichever occurred first. Recurrent VTE was not included as a censoring event in the 
analyses on mortality. The study population was categorized into tertiles according to the 
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estimated intake of n-3 PUFAs. The ranges were <8.19, 8.19-29.1 and >29.1 g/week for low, 
medium and high intake, respectively. 
 Crude incidence rates of VTE recurrence (IRs) and mortality rates (MRs) according to 
n-3 PUFA intake were calculated and expressed as number of events per 100 person-years 
with 95% confidence intervals (CIs). Cox proportional hazards regression models were used 
to estimate hazard ratios (HRs) with 95% CIs for recurrence and mortality with the lowest 
tertile of n-3 PUFA intake as the reference. Calendar time was used as time scale for the 
recurrence analyses, and attained age was used as time scale in the mortality analyses. The 
analyses were performed in two models for VTE recurrence and two models for mortality. For 
recurrence, model 1 was unadjusted and model 2 was adjusted for age, sex and BMI. In 
addition, to account for death as a competing event to VTE recurrence, sub-distribution 
hazard ratios (SHR) were calculated according to the method by Fine and Gray (31). For 
mortality, model 1 included age (as time scale), while model 2 additionally included sex, 
BMI, systolic blood pressure and smoking. For both outcomes, sensitivity analyses excluding 
participants with active cancer at the time of incident VTE, were performed. Moreover, we 
performed sensitivity analysis where follow-up started at the time of discontinuation of 
anticoagulant treatment. IRs/MRs and HRs for recurrence and mortality according to n-3 
PUFA intake were calculated overall, and in subgroups stratified by characteristics of the 
incident event (unprovoked and provoked, DVT and PE). The proportional hazards 
assumption was evaluated and verified on the basis of Schoenfeld residuals. The cumulative 
incidence of VTE recurrence according to n-3 PUFA intake was visualized in 1-Kaplan-Meier 
plots. Statistical analyses were performed with STATA version 15.1 (Stata Corp, College 





RESULTS   
Characteristics of first and recurrent VTE according to categories of n-3 PUFAs intake are 
summarized in Table 1. Overall, the mean age at incident VTE was 67 (±13) years and 51% 
were men. Further, 38% of the incident VTE events were unprovoked and 58% presented as a 
DVT. The age at incident VTE increased with increasing intake of n-3 PUFAs. Likewise, the 
prevalence of CVD increased across tertiles, while the prevalence of cancer was lowest in the 
middle tertile. The mean age at recurrent VTE was 69 (±12) years, and 61% were men. 
 
Recurrence 
Among the 595 patients with incident VTE, there were 98 recurrences during a median 
follow-up of 3.6 years. HRs of recurrence according to n-3 PUFA intake are shown in Table 
2. Overall, there was no significant association between n-3 PUFA intake and risk of 
recurrence. Compared to the lowest tertile, the HR for tertile 2 was 1.09 (95% CI: 0.69-1.74) 
and the HR for tertile 3 was 0.77 (95% CI: 0.45-1.30) in the multivariable model (model 2). 
However, analyses stratified by characteristics of the incident event showed that a high n-3 
PUFA intake (i.e. tertile 3) was associated with a 55% lower recurrence risk after unprovoked 
VTE (HR model 2: 0.45, 95% CI 0.20-1.01), and a 51% lower risk after DVT (HR model 2: 
0.49, 95% CI 0.24-0.97). Further adjustment for alcohol consumption and physical activity 
did not affect our results (data not shown). 
The ten-year cumulative incidence of recurrence after VTE according to tertiles of n-3 
PUFA intake is shown in Fig. 1 and 2. The beneficial effect of a high n-3 PUFA intake on 
recurrence risk in patients with unprovoked VTE and DVT appeared to occur approximately 
two years after the incident event. 
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Sensitivity analyses excluding participants with active cancer (n=100) at the time of 
incident VTE are shown in Table 3. The results were comparable to the main analyses, but the 
inverse associations between n-3 PUFA intake and recurrence risk were stronger. Specifically, 
a high intake of n-3 PUFAs (tertile 3) was associated with a significant 49% lower risk of 
recurrence (HR model 2: 0.51, 95% CI: 0.27-0.95), which was most pronounced in those with 
unprovoked VTE (HR model 2: 0.41, 95% CI: 0.17-1.03) and DVT (HR model 2: 0.31, 95% 
CI: 0.13-0.71). However, in contrast to the main analyses, a high n-3 PUFA intake was also 
associated with a non-significant lower risk of recurrence after provoked VTE (HR: 0.66, 
95% CI: 0.27-1.57). We observed stronger inverse associations when start of follow-up was 
restricted to the period after discontinuation of anticoagulant treatment (Table S2). For high n-
3 PUFA intake we observed significantly reduced risk of recurrence after overall VTE (HR 
model 2: 0.42, 95% CI: 0.21-0.82), unprovoked VTE (HR model 2: 0.31, 95% CI: 0.12-0.83), 
and after DVT (HR model 2: 0.30, 95% CI: 0.13-0.73). Additionally, we observed a non-
significant reduced recurrence risk after provoked VTE and after PE in this analysis (HR 
model 2: 0.61, 95% CI: 0.24-1.55, and HR: 0.70, 95% CI: 0.24-2.04, respectively). In 
analyses taking competing risk by death into account, the SHRs were generally comparable to 
the HRs obtained from the Cox regression models (Tables 2 and 3). 
 
All-cause mortality 
There were 227 deaths during a median follow-up of 4.5 years. HRs of all-cause mortality 
according to n-3 PUFA intake are shown in Table 4. Overall, there was no association 
between intake of n-3 PUFAs and the risk of mortality after incident VTE in the multivariable 
model (HR tertile 2: 0.96, 95% CI: 0.69-1.35; HR tertile 3: 1.02, 95% CI: 0.73-1.43). 
Similarly, no association was observed between n-3 PUFA intake and mortality risk in 
analyses stratified by characteristics of the incident event. The results from the sensitivity 
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analyses restricted to participants without active cancer were generally comparable to the 
results from the main analyses (Table 5). However, a non-significant lower mortality risk was 




In the present study, we investigated the association between dietary intake of marine n-3 
PUFAs and the risk of VTE recurrence and all-cause mortality in patients with incident VTE 
recruited from a general population. We found that a high intake of n-3 PUFAs (upper tertile, 
>29.1 g/week) was associated with a lower recurrence risk compared to a low intake (lower 
tertile, <8.2 g/week) in patients with unprovoked incident events and in those with DVT. In 
contrast, there was no association between n-3 PUFAs intake and risk of mortality after 
incident VTE. The confidence intervals were wide, particularly in some subgroups, and our 
findings should therefore be interpreted with caution. 
We and others have previously reported on the association between fish or n-3 PUFA 
intake and the risk of incident VTE. Although findings have been inconsistent, the available 
data suggests that intake of n-3 PUFAs may lower the risk of incident VTE (19-21). In our 
previous report, we found an inverse association between intake of marine n-3 PUFAs and 
risk of VTE, while there was no association between total fish intake and VTE risk (22). 
Marine n-3 PUFAs have an impact on several molecular pathways and risk factors of 
relevance in the VTE pathogenesis. These include downregulation of inflammation (14), 
tissue-factor expression (18, 32), platelet function (15), platelet endothelium-interactions (16, 
17), and possibly hepatic excretion of coagulation factors (33). Moreover, n-3 PUFAs 




 To our knowledge, our study is among the first to explore the association between 
marine n-3 PUFAs and the risk of recurrence and mortality in patients with incident VTE. 
Reiner and colleagues investigated the association between levels n-3 PUFAs in the 
erythrocyte membrane, and the risk of recurrence and mortality in elderly VTE patients (23). 
Although there were few recurrent events (n=22), they found that a moderate or high level of 
n-3 PUFAs was associated with a 61-83% lower risk of recurrence and 66-71% lower risk of 
mortality at six months of follow-up. After three years, a moderate level was still associated 
with a 45% lower risk of mortality, while there was no association between n-3 PUFA levels 
and recurrence risk. As the fatty acid composition in the erythrocyte membrane reflects the 
diet (24, 25), these findings suggest that a medium or high dietary intake of n-3 PUFAs may 
be associated with a better prognosis after VTE, although the effect on recurrence risk 
appeared to be transient (23). Apparently conflicting, we found that a high dietary intake of n-
3 PUFAs was associated with 55% and 51% lower recurrence risk after unprovoked VTE and 
DVT, respectively, and that the effect occurred almost two years after the incident event. 
Although the different exposure assessments hamper a direct comparison of the studies, there 
are some plausible explanations for the diverging findings. First, the n-3 PUFA intake our 
study was high, and the upper tertile cut-off equals more than four grams per day, which is 
higher than the doses used in most clinical trials on prevention (34). Moreover, Reiner et al. 
(23) included PUFAs derived from both marine sources (i.e. EPA, DPA and DHA) and plants 
(i.e. alpha-linolenic acid, ALA) in their exposure variable. The impact of ALA in relation to 
health outcomes is less investigated and an effect is probably modest compared to marine-
derived n-3 PUFAs (35-37). Therefore, the association between n-3 PUFAs and recurrence 
risk may have been underestimated due to the inclusion of ALA in the study by Reiner et al. 
(23). Further, the patients included in SWITCO65+ were almost ten years older than those in 
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the present study (75 years vs. 67 years), and 29% of the patients had a history of previous 
VTE, while we exclusively included incident cases. 
The beneficial association of n-3 PUFAs on recurrence risk in our study was restricted 
to those with a high weekly intake, suggesting a mild protective effect of n-3 PUFA intake. 
Stratified analyses further revealed that the association was mainly driven by an effect in 
patients with unprovoked incident events. The risk of recurrence largely depends on the 
etiology of the incident event, which also reflects the underlying predisposition (baseline risk) 
for thrombosis (8, 38). Assuming a mild protective effect of n-3 PUFAs on VTE recurrence, it 
is plausible that the effect is most prominent in those with an intermediate recurrence risk, 
such as patients with unprovoked VTE. Conversely, a small effect may be difficult to observe 
in those with a low risk (e.g. VTE provoked by major surgery), and may be overwhelmed in 
those with a high risk (e.g. VTE provoked by active or progressive cancer). This is supported 
by our sensitivity analyses showing lowered risk estimates, even for provoked events, when 
patients with active cancer were excluded. 
We further observed a difference in the influence of n-3 PUFA intake on the risk of 
recurrence after DVT and PE. Apparently, a high intake was associated with a lower 
recurrence risk after DVT, and a higher risk of recurrence after PE. Although PE typically 
recur as a new PE and is regarded as a more severe form of VTE (39), the current guidelines 
for antithrombotic therapy do not distinguish between the two disease entities (9). However, 
in our data, which reflects clinical practice from 1994 to 2016, we found that 45% of patients 
with PE were scheduled anticoagulant treatment for ≥1 year, while this applied to only 13% 
of patients with DVT. The risk of recurrence is highest during the first year after incident 
VTE (4, 5), and 53% of the recurrences in the present study occurred during this period. 
Potentially, DVT patients receiving anticoagulant treatment for a shorter time-period may 
have benefitted more from a high intake of n-3 PUFAs, while an effect in patients with PE 
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may have been masked by long-term treatment. We addressed this point by restricting the 
follow-up time to the period after completion of anticoagulant treatment. Interestingly, this 
approach consistently showed inverse associations between high n-3 PUFA intake and 
recurrence after overall VTE and subtypes of VTE (unprovoked, provoked, DVT and PE).  
In contrast to the findings by Reiner and colleagues (23), we did not observe any 
association between n-3 PUFAs and the risk of mortality in patients with VTE. Although 
observational studies on the effect of n-3 PUFAs on cause-specific mortality in individuals 
without known CVD have shown somewhat diverging results  (40, 41), it may be suggested 
that marine-derived n-3 PUFAs are primarily associated with a lower risk of CVD-related 
death, while ALA is associated with a lower risk of death from non-CVD causes (36, 42). The 
most frequently reported causes of death in patients with VTE are cancer, PE, infections, and 
other cardiovascular or respiratory diseases (3, 43, 44). Potentially, a relatively higher 
proportion of deaths due to non-CVD causes in VTE-patients could explain the lack of a 
beneficial association between marine n-3 PUFAs and all-cause mortality in our study. 
Nevertheless, the results did not change after exclusion of patients with active cancer.  
The main strengths of our study include unselected VTE patients with a wide age 
distribution, a validated exposure variable, long follow-up and thoroughly validated 
outcomes. Limitations of the study include an observational design, which does not allow for 
random allocation to exposure groups, and residual confounding may be present. Further, a 
substantial proportion of participants were excluded due to incomplete information on n-3 
PUFA intake, and the included participants were younger and healthier compared to those 
excluded. This may influence the generalizability of our findings. Moreover, although we 
previously reported a significant trend between self-reported intake of marine n-3 PUFAs and 
serum concentrations (22), the correlation coefficients are generally reported to be low (45). 
Due to limited study power, the confidence intervals were wide, and our findings should 
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therefore be interpreted with caution. Finally, a long follow-up may introduce regression 
dilution as dietary habits may change over time. Such misclassification may influence the 
precision of our estimates, but is unlikely to be related the outcomes of the study, and would 
typically lead to an underestimation of the true association. 
In conclusion, a high intake of marine n-3 PUFAs was associated with a lower risk of 
VTE recurrence, which was most pronounced after unprovoked VTE and DVT, and in cancer-
free patients. In contrast, there was no association between n-3 PUFAs and the risk of all-
cause mortality in patients with incident VTE. 
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 TABLES AND FIGURES 
 
Table 1 Characteristics of patients with incident VTE (n=595) and recurrent events (n=98) according 
to tertiles of weekly intake of n-3 PUFAs. The Tromsø Study (1994-2016) 
n-3 PUFAs (g/week) All T1 (<8.19) T2 (8.19-29.1) T3 (>29.1) 
First VTE     
Number of patients 595 200 201 194 
   DVT 57.5 (342) 53.0 (106) 63.2 (127) 56.2 (109) 
   PE 42.5 (253) 47.0 (94) 36.8 (74) 43.8 (85) 
   Unprovoked 38.0 (226) 42.0 (84) 47.8 (96) 42.3 (82) 
Duration of anticoagulant treatment    
   < 3 months  20.0 (119) 31.9 (38)  37.0 (44) 31.1 (37) 
   3-6 months 42.5 (253) 30.4 (77) 35.2 (89) 34.4 (87) 
6-12 months 20.5 (122) 45.1 (55) 29.5 (36) 25.4 (31) 
   > 12 months 17.0 (101) 29.7 (30) 31.7 (32) 38.6 (39) 
Male sex 51.1 (304) 54.5 (109) 47.8 (96) 51.0 (99) 
Age at incident VTE 67 ± 13 63 ± 14 67 ± 13 71 ± 12 
BMI, kg/m2 27.4 ± 4.5 27.1 ± 4.3 27.4 ± 4.3 27.7 ± 4.4 
Diabetes 4.9 (29) 3.0 (6) 6.0 (12) 5.7 (11) 
History of CVD 13.1 (78) 7.5 (15) 14.4 (29) 17.5 (34) 
Cancer 16.8 (100) 18.0 (36) 13.9 (28) 18.6 (36) 
Current smoking 28.2 (168) 40.0 (80) 26.9 (54) 17.5 (34) 
Systolic BP, mmHg 142 ± 24 138 ± 23 142 ± 24 147 ± 25 
Second VTE (by index event):    
Number of patients  98 35 38 25 
   DVT 72.4 (71) 77.1 (27) 81.6 (31) 52.0 (13) 
   PE 27.6 (27) 22.9 (8) 18.4 (7) 48.0 (12) 
   Unprovoked 52.0 (51) 51.4 (18) 63.2 (24) 36.0 (9) 
Male sex 61.2 (60) 77.1 (27) 55.3 (21) 48.0 (12) 
Age at second VTE 69 ± 12 67 ± 13 69 ± 12 71 ± 12 
BMI, kg/m2 27.0 ± 4.5 27.1 ± 6.0 27.0 ± 3.3 26.8 ± 3.9 
Cancer 18.4 (18) 11.4 (4) 13.2 (5) 36.0 (9) 
Current smoking 20.4 (20) 31.4 (11) 23.7 (9) 20.0 (5) 
Systolic BP, mmHg 139 ± 20 135 ± 20 143 ± 20 139 ± 21 
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BMI body mass index, BP blood pressure, CVD cardiovascular disease (angina pectoris, stroke or myocardial 
infarction), DVT deep vein thrombosis, PE pulmonary embolism, PUFAs polyunsaturated fatty acids, T tertile, 
VTE venous thromboembolism. 





Table 2 Incidence rates (IRs) and hazard ratios (HRs) with 95% confidence intervals (CI) for recurrent 
venous thromboembolism (VTE) by tertiles of weekly intake of marine n-3 polyunsaturated fatty acids 
(PUFAs). The Tromsø Study 1994-2016. 









HR (95% CI)† 
Model 2 
HR (95% CI)‡ 
SHR 
(95% CI)§ 
VTE       
T1 <8.19 1111 35 3.1 (2.3-4.4) Ref. Ref. Ref. 
T2  8.19-29.1 1080 38 3.5 (2.6-4.8) 1.10 (0.69-1.74) 1.09 (0.69-1.74) 1.19 (0.76-1.87) 
T3 >29.1 916 25 2.7 (3.7-4.0) 0.86 (0.51-1.43) 0.77 (0.45-1.30) 0.83 (0.49-1.42) 
Unprovoked VTE       
T1 <8.19 537 18 3.4 (2.1-5.3) Ref. Ref. Ref. 
T2  8.19-29.1 591 24 4.1 (2.7-6.1) 1.20 (0.65-2.21) 1.13 (0.61-2.10) 1.12 (0.61-2.08) 
T3 >29.1 448 9 2.0 (1.0-3.9) 0.59 (0.26-1.31) 0.45 (0.20-1.01) 0.42 (0.18-1.00) 
Provoked VTE       
T1 <8.19 575 17 3.0 (1.8-4.8) Ref. Ref. Ref. 
T2  8.19-29.1 487 14 2.9 (1.7-4.9) 0.96 (0.47-1.96) 1.00 (0.49-2.04) 1.10 (0.56-2.19) 
T3 >29.1 468 16 3.4 (2.1-5.6) 1.21 (0.60-2.43) 1.25 (0.61-2.56) 1.35 (0.70-2.61) 
PE       
T1 <8.19 540 8 1.5 (0.7-3.0) Ref. Ref. Ref. 
T2  8.19-29.1 378 7 1.9 (0.9-3.9) 1.18 (0.43-3.27) 0.97 (0.35-2.71) 1.10 (0.41-2.95) 
T3 >29.1 405 12 3.0 (1.7-5.2) 1.93 (0.78-4.75) 1.55 (0.62-3.87) 1.64 (0.65-4.12) 
DVT       
T1 <8.19 571 27 4.7 (3.2-6.9) Ref. Ref. Ref. 
T2  8.19-29.1 703 31 4.4 (3.1-6.3) 0.94 (0.56-1.57) 1.00 (0.59-1.69) 1.12 (0.67-1.86) 
T3 >29.1 511 13 2.5 (1.5-4.4) 0.54 (0.28-1.06) 0.49 (0.24-0.97) 0.54 (0.27-1.08) 
CI confidence interval, DVT deep vein thrombosis, PE pulmonary embolism, SHR subdistribution hazard ratio,  
T tertile. 
*Per 100 person-years 
†Unadjusted 
‡Adjusted for age, sex and body mass index 




Table 3 Incidence rates (IRs) and hazard ratios (HRs) for recurrent venous thromboembolism (VTE) 
by tertiles of weekly intake of marine n-3 polyunsaturated fatty acids (n-3 PUFAs) after excluding 
individuals with active cancer. The Tromsø Study 1994-2016 









HR (95% CI)† 
Model 2 
HR (95% CI)‡ 
SHR 
(95% CI)§ 
VTE       
T1 <8.19 1026 31 3.0 (2.1-4.3) Ref. Ref. Ref. 
T2  8.19-29.1 1005 33 3.3 (2.3-4.6) 1.07 (0.65-1.74) 1.01 (0.61-1.66) 1.09 (0.67-1.77) 
T3 >29.1 826 16 1.9 (1.2-3.2) 0.64 (0.35-1.17) 0.51 (0.27-0.95) 0.56 (0.30-1.03) 
Unprovoked VTE       
T1 <8.19 524 16 3.1 (1.9-5.0) Ref. Ref. Ref. 
T2  8.19-29.1 570 21 3.7 (2.4-5.7) 1.20 (0.62-2.29) 1.13 (0.59-2.18) 1.15 (0.60-2.22) 
T3 >29.1 407 7 1.7 (0.8-3.6) 0.55 (0.23-1.34) 0.41 (0.17-1.03) 0.38 (0.15-1.00) 
Provoked VTE       
T1 <8.19 502 15 3.0 (1.8-5.0) Ref. Ref. Ref. 
T2  8.19-29.1 433 12 2.8 (1.6-4.9) 0.92 (0.43-1.96) 0.88 (0.40-1.90) 0.97 (0.47-2.04) 
T3 >29.1 419 9 2.1 (1.1-4.1) 0.76 (0.33-1.77) 0.66 (0.27-1.57) 0.79 (0.36-1.73) 
PE       
T1 <8.19 500 8 1.6 (0.8-3.2) Ref. Ref. Ref. 
T2  8.19-29.1 346 6 1.7 (0.8-3.9) 1.02 (0.35-2.96) 0.75 (0.26-2.18) 0.91 (0.33-2.52) 
T3 >29.1 354 8 2.3 (1.3-4.5) 1.35 (0.50-3.62) 0.99 (0.36-2.71) 1.07 (0.41-2.81) 
DVT       
T1 <8.19 526 23 4.4 (2.9-6-6) Ref. Ref. Ref. 
T2  8.19-29.1 660 27 4.1 (2.8-6.0) 0.93 (0.53-1.63) 0.98 (0.55-1.73) 1.04 (0.60-1.81) 
T3 >29.1 472 8 1.7 (0.8-3.4) 0.39 (0.17-0.88) 0.31 (0.13-0.71) 0.35 (0.15-0.81) 
CI confidence interval, DVT, deep vein thrombosis, PE pulmonary embolism, SHR subdistribution hazard ratio, 
T tertile. 
*Per 100 person-years 
†Unadjusted 
‡Adjusted for age, sex and body mass index 




Table 4 Mortality rates (MRs) and hazard ratios (HRs) for all-cause mortality across tertiles of weekly 
intake of marine n-3 polyunsaturated fatty acids (n-3 PUFAs). The Tromsø Study 1994-2016. 





Crude MR (95% 
CI)* 
Model 1 
HR (95% CI)† 
Model 2 
HR (95% CI)‡ 
VTE      
T1 <8.19 1302 72 5.5 (4.4-7.0) Ref. Ref. 
T2  8.19-29.1 1220 76 6.2 (5.0-7.8) 0.97 (0.70-1.34) 0.96 (0.69-1.35) 
T3 >29.1 1033 79 7.6 (6.1-9.5) 1.01 (0.72-1.40) 1.02 (0.73-1.43) 
Unprovoked VTE      
T1 <8.19 658 17 2.6 (1.6-4.2) Ref. Ref. 
T2  8.19-29.1 682 24 3.5 (2.4-5.3) 1.11 (0.59-2.08) 1.08 (0.56-2.10) 
T3 >29.1 510 26 5.1 (3.5-7.5) 1.26 (0.68-2.35) 1.26 (0.67-2.36) 
Provoked VTE      
T1 <8.19 644 55 8.5 (6.6-11.1) Ref. Ref. 
T2  8.19-29.1 537 51 9.5 (7.2-12.5) 0.98 (0.66-1.44) 1.02 (0.69-1.52) 
T3 >29.1 523 53 10.1 (7.7-13.3) 0.91 (0.61-1.35) 0.94 (0.62-1.42) 
PE      
T1 <8.19 586 29 4.9 (3.4-7.1) Ref. Ref. 
T2  8.19-29.1 403 23 5.7 (3.8-8.6) 0.95 (0.54-1.68) 0.95 (0.53-1.68) 
T3 >29.1 457 35 7.7 (5.5-10.7) 1.21 (0.73-2.02) 1.16 (0.69-1.96) 
DVT      
T1 <8.19 716 43 6.0 (4.5-8.1) Ref. Ref. 
T2  8.19-29.1 818 53 6.5 (5.0-8.5) 0.95 (0.63-1.44) 0.98 (0.64-1.49) 
T3 >29.1 575 44 7.6 (5.7-10.3) 0.87 (0.56-1.35) 0.94 (0.60-1.48) 
CI confidence interval, DVT deep vein thrombosis, PE pulmonary embolism, T tertile. 
*Per 100 person-years 
†Adjusted for age (as time-scale) 






Table 5 Mortality rates (MRs) and hazard ratios (HRs) for all-cause mortality by tertiles of weekly 
intake of marine n-3 polyunsaturated fatty acids (n-3 PUFAs) excluding individuals with active 
cancer. The Tromsø Study 1994-2016. 








HR (95% CI)† 
Model 2 
HR (95% CI)‡ 
VTE      
T1 <8.19 1203 43 3.6 (2.7-4.8) Ref. Ref. 
T2  8.19-29.1 1138 53 4.7 (3.6-6.1) 1.03 (0.68-1.55) 1.00 (0.66-1.51) 
T3 >29.1 921 51 5.5 (4.2-7.3) 0.96 (0.63-1.45) 0.91 (0.60-1.40) 
Unprovoked VTE      
T1 <8.19 631 14 2.2 (1.3-3.7) Ref. Ref. 
T2  8.19-29.1 653 17 2.6 (1.6-4.2) 0.95 (0.46-1.95) 0.92 (0.43-1.97) 
T3 >29.1 456 22 4.8 (3.2-7.3) 1.34 (0.68-2.64) 1.28 (0.64-2.57) 
Provoked VTE      
T1 <8.19 572 29 5.1 (3.5-7.3) Ref. Ref. 
T2  8.19-29.1 483 35 7.3 (5.2-10.1) 1.09 (0.66-1.80) 1.04 (0.62-1.74) 
T3 >29.1 465 29 6.2 (4.3-9.0) 0.75 (0.43-1.29) 0.68 (0.39-1.20) 
PE      
T1 <8.19 546 18 3.3 (2.1-5.2) Ref. Ref. 
T2  8.19-29.1 368 14 3.8 (2.3-6.4) 0.88 (0.42-1.83) 0.86 (0.41-1.80) 
T3 >29.1 401 23 5.7 (3.8-8.6) 1.33 (0.71-2.51) 1.21 (0.63-2.30) 
DVT      
T1 <8.19 657 25 3.8 (2.6-5.6) Ref. Ref. 
T2  8.19-29.1 770 39 5.1 (3.7-6.9) 1.05 (0.63-1.76) 1.11 (0.66-1.88) 
T3 >29.1 520 28 5.4 (3.7-7.8) 0.75 (0.43-1.31) 0.80 (0.45-1.41) 
CI confidence interval, DVT deep vein thrombosis, PE pulmonary embolism, T tertile. 
*Per 100 person-years 
†Adjusted for age (as time-scale) 




Figure 1 Ten-year cumulative incidence of recurrent venous thromboembolism (VTE) by tertiles of 
weekly intake of n-3 PUFAs for the total follow-up (Panel A) and follow-up restricted to the period 
after discontinuation of anticoagulant treatment (Panel B). Low intake: <8.19 g/week, medium intake: 












0 2 4 6 8 10














0 2 4 6 8 10







Figure 2 panel A-D. Cumulative incidence of recurrent venous thromboembolism (VTE) by tertiles of 
weekly intake of n-3 PUFAs according to the index event (A: unprovoked VTE, B: provoked VTE, C: 
Pulmonary embolism (PE), D: Deep vein thrombosis (DVT)). Low intake: <8.19 g/week, medium 
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Table S1 Comparison of included and excluded VTE-patients 
 Included (n=595) Excluded (n=304) 
  
Incident VTE    
     DVT 57 (342) 62 (187) 
     PE 43 (253) 38 (117) 
     Unprovoked 44 (262) 41 (124) 
Male sex 51 (304) 42 (129) 
Age at incident VTE 67 ± 13 71 ± 13 
Body mass index, kg/m2 27.4 ± 4.5 27.1 ± 4.5 
Diabetes 5 (29) 3 (10) 
History of CVD 13 (78) 18 (55) 
Cancer 17 (100) 16 (48) 
CVD cardiovascular disease (angina pectoris, stroke or myocardial infarction), DVT deep vein thrombosis, PE 
pulmonary embolism, VTE venous thromboembolism. 

















Table S2  
Incidence rates (IRs) and hazard ratios (HRs) with 95% confidence intervals (CI) for recurrent venous 
thromboembolism (VTE) by tertiles of weekly intake of marine n-3 polyunsaturated fatty acids 
(PUFAs) in sensitivity analyses with follow-up restricted to the period after discontinuation of 
anticoagulant therapy. The Tromsø Study 1994-2016. 









HR (95% CI)† 
Model 2 




T 1 935 31 3.3 (2.3-4.7) Ref. Ref. Ref. 
T 2 927 32 3.5 (2.4-4.9) 1.03 (0.63-1.69) 0.99 (0.60-1.63) 1.03 (0.62-1.68) 
T 3 747 13 1.7 (1.0-3.0) 0.53 (0.28-1.02) 0.42 (0.21-0.82) 0.48 (0.25-0.94) 
Unprovoked VTE 
T 1 425 15 3.5 (2.1-5.9) Ref. Ref. Ref. 
T 2 502 22 4.4 (2.9-6.7) 1.24 (0.64-2.40) 1.14 (0.58-2.23) 1.18 (0.61-2.30) 
T 3 361 6 1.7 (0.7-3.7) 0.48 (0.19-1.25) 0.31 (0.12-0.83) 0.33 (0.12-0.89) 
Provoked VTE 
T 1 511 16 3.1 (1.9-5.1) Ref. Ref. Ref. 
T 2 424 10 2.4 (1.3-4.4) 0.76 (0.34-1.68) 0.79 (0.35-1.77) 0.77 (0.35-1.69) 
T 3 386 7 1.8 (0.9-3.8) 0.63 (0.26-1.56) 0.61 (0.24-1.55) 0.69 (0.29-1.64) 
PE 
T 1 415 8 1.9 (1.0-3.9) Ref. Ref. Ref. 
T 2 294 6 2.0 (0.9-4.5) 1.02 (0.35-2.95) 0.67 (0.23-1.95) 0.74 (0.26-2.15) 
T 3 321 6 1.9 (0.8-4.2) 0.99 (0.34-2.87) 0.70 (0.24-2.04) 0.82 (0.29-2.32) 
DVT 
T 1 521 23 4.4 (2.9-6.6) Ref. Ref. Ref. 
T 2 634 26 4.1 (2.8-6.0) 0.92 (0.53-1.62) 0.99 (0.56-1.76) 1.11 (0.63-1.95) 
T 3 426 7 1.6 (0.8-3.4) 0.38 (0.16-0.88) 0.30 (0.13-0.73) 0.36 (0.15-0.86) 
CI confidence interval, DVT deep vein thrombosis, PE pulmonary embolism, SHR subdistribution hazard ratio,  
T tertile. 
*Per 100 person-years 
†Unadjusted 
‡Adjusted for age, sex and body mass index 
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Background: Surgery is an important trigger of venous thromboembolism (VTE) and 
previous observational studies suggest that dietary intake of n-3 polyunsaturated fatty acids 
(n-3 PUFAs) lowers the risk of incident VTE. However, it is unknown whether n-3 PUFAs 
intake influences the effect of surgery as a trigger for VTE. 
Objective: To investigate whether intake of n-3 PUFAs modifies the effect of surgery as a 
trigger of VTE. 
Methods: We conducted a case-crossover study with 445 VTE patients recruited from the 
population-based Tromsø Study. Self-reported intake of n-3 PUFAs was collected at study 
inclusion, and information on surgery was registered during the 90-day period prior to the 
VTE event (hazard period) and in four preceding 90-day control periods. Patients were 
stratified on tertiles (T) of n-3 PUFAs intake, and conditional logistic regression was used to 
estimate odds ratios (ORs) with 95% confidence intervals (CIs) of surgery as a VTE trigger. 
Results: The overall OR of surgery was 7.6 (95% CI 5.2-11.1). Higher intake of n-3 PUFAs 
mitigated the association, as the ORs of surgery were 11.8 (95% CI 6.1-22.6) in T1, 8.1 (95% 
CI 4.2-15.7) in T2 and 4.1 (95% CI 2.1-8.2) in T3 of n-3 PUFAs intake. The effect was 
strongest for pulmonary embolism (PE), with ORs of 14.7 (95% CI 5.5-39.6), 7.0 (95% CI 
2.1-23.5) and 2.8 (95% CI 1.1-7.4) in T1-3, respectively.  
Conclusions: A high intake of n-3 PUFAs strongly attenuated the effect of surgery as a 
trigger for VTE, and particularly for PE. 






Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary 
embolism (PE), is a common and potentially life-threatening condition. The incidence of VTE 
has remained stable or slightly increased over the past decades, and it is recognized as a 
significant contributor to the global burden of disease (1-3). Surgery is an important risk 
factor, and surgery-related VTE is estimated to account for 15-22% of all incident events in 
the population (1, 4, 5). Despite awareness of the great preventive potential to improve patient 
safety in hospitals, the proportion of VTEs in the population that can be attributed to surgery 
has increased slightly during the last decades (4). Whether lifestyle factors, such as diet, may 
modify the effect of VTE triggers, such as surgery, remains elusive. However, ecological data 
from Norway demonstrated a temporal decrease in the incidence of postoperative VTE during 
World War II, which coincided with substantially increased intake of fish in the population (6, 
7). 
 n-3 polyunsaturated long-chained fatty acids (n-3 PUFAs, i.e. eicosapentaenoic, 
docosapentaenoic and docosahexaenoic acid) are essential nutrients mainly found in foods of 
marine origin (8). The content of n-3 PUFAs varies and may be up to eightfold higher in fat 
fish than in lean fish, while dietary supplements have the highest concentrations (9, 10). n-3 
PUFAs have been found to influence key pathways in the VTE pathogenesis, including 
downregulation of inflammation (11), tissue-factor expression (12, 13), platelet function and 
platelet-endothelium interactions (14, 15). Observational studies on the association between 
fish intake and the risk of incident VTE have shown conflicting results (16). However, sub-
analyses according to the total content of n-3 PUFAs in the diet indicated that a higher n-3 




 The objective of the present study was to investigate whether intake of n-3 PUFAs 
modified the effect of surgery as a trigger for VTE. We used a case-crossover design to test 
the hypothesis that a higher n-3 PUFAs intake reduced the risk of surgery-related VTE. This 
design is well-suited for studying transient exposures and theoretically eliminates 





The source population included participants from the fourth survey (1994-95) of the Tromsø 
Study, a single center population-based cohort with repeated health surveys. All inhabitants 
living in the Tromsø municipality above 24 years were invited and 27 158 participated (77% 
of the eligible). Detailed methodology and description of the Tromsø Study can be found 
elsewhere (22). Incident VTE events during follow-up (1994-2012) were identified by 
searching the hospital discharge registry, the radiology procedure registry and the autopsy 
registry at the University Hospital of North Norway (UNN). The UNN exclusively provides 
VTE diagnostics and treatment in the study region. All potential cases were adjudicated 
according to the following four criteria: (i) signs and symptoms of PE or DVT, (ii) presence 
of a thrombus confirmed by radiology, (iii) a diagnosis of PE or DVT in the medical records, 
and (iv) initiation of treatment (unless contraindications were specified) (23). The study was 
approved by the Regional Committee for Medical and Health Research Ethics, and all 






There were 707 incident VTE events during follow-up, and these formed the basis of the case-
crossover study. We defined five exposure periods; the hazard period was the 90-days 
preceding the VTE and four 90-day control periods. A 90-day washout period was included 
between the hazard and control periods in order to avoid carryover effects (Figure 1). The 
duration of the hazard and control periods were defined based on the timeframe that major 
transient risk factors are generally considered to influence VTE risk (24).  
 
Assessment of n-3 PUFAs intake 
Total dietary intake of n-3 PUFAs in grams per week was estimated based on reported intake 
in either Tromsø 4 (1994-95) or Tromsø 6 (2007-08), depending on which surveys that was 
closest to the VTE event in time. Only those with dietary information on these items were 
included in the study (n=445). Briefly, participants were asked how frequently they had lean 
and fat fish for dinner, used fish as bread spread and took fish oil supplements. Information on 
the average n-3 PUFAs content in different marine food products was provided by official 
web resources (9, 10). On average, fat fish for dinner, lean fish for dinner and fish as spread 
was estimated to contain 3.0 grams, 0.4 grams and 3.7 grams of n-3 PUFAs per 100 grams, 
respectively. One serving size of fish oil supplements contained 3.6 grams of n-3 PUFAs. A 
dinner serving was defined as 200 grams and fish spread as 25 grams, according to 
recommendations by the Norwegian Directorate of Health (25). Further details on the 





Definition of major surgery 
Trained personnel reviewed the medical records for each VTE case and systematically 
collected information on surgical procedures and other relevant information occurring during 
the exposure periods. This included risk factors for VTE, diagnostic procedures and 
laboratory test, surgical and medical treatment, and diagnoses given during admissions, day 
care and outpatient visits. We did not have any information from healthcare visits outside the 
hospital setting. Surgery was recorded for procedures involving organs within the chest, 
abdomen, pelvic cavity, the cranium, knee and hip surgeries, or surgery with general 
anesthesia >30 minutes (26). Surgery was dichotomized according to presence or absence 
during the hazard and control periods. 
 
Statistical analysis 
Baseline characteristics are shown as means ± standard deviation (SD) or percentage (count), 
overall and by tertiles of n-3 PUFAs intake. Conditional logistic regression was used to 
estimate regression coefficients with standard error (SE) and corresponding odds ratios (ORs) 
with 95% confidence intervals (CIs) for the presence of surgery in hazard versus control 
periods. To evaluate the differences of the impact of surgery between tertiles of n-3 PUFAs 
intake, we obtained p-values based on the ratio (Z-score) of the regression coefficients and 
their SEs (27). The threshold for significance was set to 0.05. The n-3 PUFAs intake 
increased substantially with age. Since the effect of surgery as a VTE trigger also could vary 
with age, we performed two sensitivity analyses to control for age as a potential confounder 
for the observed differences in ORs between tertiles. In the first approach, we defined tertiles 
based on the residuals from a linear regression of n-3 PUFAs on age. This approach removes 
the age-dependency, and the exposure variable can be interpreted as the deviation from the 
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expected n-3 PUFAs intake in relation to a given persons age. In the second approach, we 
performed a matched analysis, in which individuals across the three tertiles were matched on 
age (±2 years), which ensures an approximately identical age distribution in all three tertiles. 
As the matching process produces slightly different matched sets in each draw, we ran the 
matching and logistic regressions 1000 times and presented the mean OR from these 1000 
iterations as the risk estimate of each tertile. Analysis were performed in STATA version 15.0 
(Stata Corporation, College Station, TX, USA) and R version 4.0.1 (The R Foundation for 
Statistical Computing 2018).  
 
Results 
Characteristics of the 445 patients included at the time of VTE are shown in Table 1. The 
overall mean age was 67 ± 14 years and 50.8% were women. There were 57.7% presenting 
with DVT and 42.2% with PE ± DVT. The mean age increased with increasing intake of n-3 
PUFAs, whereas the sex distribution was similar across tertiles.  
 The frequencies of surgery in the hazard and control periods according to n-3 PUFAs 
intake are shown in Table 2. Overall, surgery occurred more frequently in the hazard period 
(19%) than in the control periods (3%), and the OR for surgery in the hazard versus the 
control periods was 7.6 (95% CI 5.2-11.1) (Table 3). The ORs for surgery as a VTE trigger 
decreased across tertiles of higher n-3 PUFAs intake, and were 11.8 (95% CI 6.1-22.6) for 
tertile 1, 8.1 (95% CI 4.2-15.7) for tertile 2 and 4.1 (95% CI 2.1-8.2) for tertile 3, respectively 
(Table 3 and Fig. 2; p=0.03 for the comparison of tertile 1 and tertile 3). Subgroup analyses 
indicated that the OR gradient across n-3 PUFAs intake was driven by PE, rather than DVT. 
For PE, the ORs according to surgery were 14.7 (95% CI 5.5-39.6) for tertile 1, 7.0 (95% CI 
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2.1-23.5) for tertile 2 and 2.8 (95% CI 1.1-7.4) for tertile 3 (p=0.02 for the comparison of 
tertile 1 and tertile 3).  
 The mean age varied across the n-3 PUFAs categories, and the impact of surgery as a 
trigger could potentially vary across age groups. Therefore, we performed two sensitivity 
analysis to adjust for age as a potential confounder. In the first sensitivity analysis, the 
residual approach yielded tertiles with essentially similar age-distribution (supplementary 
Table 1). The ORs of surgery as a VTE trigger were 8.7 (95% CI 4.9-15.4) in tertile 1, 11.9 
(95% CI 5.4-26.3) in tertile 2, and 4.4 (95% CI 2.2-8.6) in tertile 3. In the second sensitivity 
analysis we used a matching approach, and the mean ORs for surgery as a VTE trigger were 
9.6 (95% CI 4.6-20.0) in tertile 1, 11.0 (95% CI 4.8-26.6) in tertile 2 and 4.1 (95% CI 1.8-
10.0) in tertile 3. The frequencies of surgery in the hazard and control periods according to n-
3 PUFAs intake in the residual approach are shown in supplementary Table 2. 
  
Discussion 
In this population-based case-crossover study of VTE patients, we found that the impact of 
surgery as a trigger for VTE was lower in those with a high intake of n-3 PUFAs. Our 
findings suggest that a high intake of n-3 PUFAs may attenuate the effect of surgery as a 
trigger for VTE, and indicates the need for future studies on the role of n-3 PUFAs in 
prevention of surgery-related VTE.  
 Several observational studies have investigated the association between intake of n-3 
PUFAs (or fat fish as a proxy for n-3 PUFAs intake) and the risk of incident VTE. In the 
Atherosclerosis Risk in Communities (ARIC) Study, a cohort of 14 962 adults, an n-3 PUFAs 
intake exceeding 0.7 grams/week was associated with 30-46% lower VTE risk (17). Further, 
among 57 054 adults in the Diet, Cancer and Health (DCH) Study, an intake of fat fish 
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exceeding 35 grams/week in women and 49 grams/week in men was associated with 20-40% 
lower VTE risk (18). In the Tromsø Study, an early report including 23 621 individuals found 
that fish for dinner ≥3 times/week in combination with fish oil supplements was associated 
with 48% lower risk of VTE (19). Recently, we found that a weekly n-3 PUFAs intake 
exceeding 4.7 grams was associated with 24% lower risk of VTE in the Tromsø Study, with 
strongest risk reduction for provoked events (31%) and PE (41%) (20).  
Historical data displayed a clear and transient reduction in surgery-related VTE 
occurring in parallel with dietary changes, including a high dietary intake of n-3 PUFAs, in 
Norway during the second World War (6, 7). These findings suggested that n-3 PUFAs could 
have a protective effect against surgery-related VTE. This notion is further supported by the 
present study demonstrating that a higher intake of n-3 PUFAs modifies the impact of surgery 
as a trigger of VTE. A large proportion (15-22%) of the VTE burden worldwide can be 
attributed to surgery (1, 4, 5). Despite awareness and improved preventive strategies (28, 29), 
this proportion has slightly increased during the last decades (4). In the present study, surgery 
was confirmed to be a strong trigger associated with an 8-fold higher risk of VTE, and the OR 
for VTE by surgery decreased in a dose-dependent manner across tertiles of increasing n-3 
PUFAs intake. 
As proposed by Virchow, thrombus formation occurs as a result from changes in the 
vessel wall, blood flow (stasis) and blood coagulation (30). Surgery is a discrete event 
accompanied by several prothrombotic processes. Within hours or the first few days after 
surgery, higher levels of inflammatory markers (31) and coagulation factors (FVII, FV, FVIII 
and fibrinogen) as well as activation of monocytes (32) and platelets (33) can be measured. 
Furthermore, immobilization with subsequent stasis is a strong trigger for VTE (34, 35), 
which frequently accompanies surgical procedures. According to the thrombosis potential 
model, VTE occurs when the accumulation of risk factors overwhelms the anticoagulant 
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mechanisms and exceeds the thrombosis threshold (36). Data from experimental studies 
suggest several pathways through which n-3 PUFAs may diminish the trigger-effect of 
surgery. Specifically, tissue factor expression in endothelial cells have been downregulated 
experimentally in vitro by n-3 PUFAs (14), and the potential to activate monocytes and 
platelets has been reduced experimentally in vivo (11, 13). Additionally, a 40% reduction of 
the synthesis of tissue factor and a 10-20% reduction in serum arachidonic acid levels were 
shown in a trial where participants were given 25 ml cod liver oil daily for 8 weeks (13). In 
the latter study, the authors concluded that activation of the extrinsic pathway of coagulation 
may be suppressed by dietary enrichment of n-3 PUFAs. Thus far, no experimental study has 
investigated the effect of n-3 PUFAs intake on the risk of surgery-related VTE. 
In the present study, the dose-dependent risk reduction of surgery-related VTE by n-3 
PUFAs was strongest for surgery-related PE. As PE frequently develops as a complication of 
DVT, it may be speculated that a high n-3 PUFAs intake facilitates a more stable clot 
structure that is less likely to embolize. However, PE may also have a cardiac origin or 
develop de novo in the lungs (37). Although confounding by established comorbidities are 
controlled for by the study design in the present study, an alternative explanation may be a 
lower rate of PE-related post-surgical complications (e.g., atrial fibrillation) in those with a 
high n-3 PUFAs intake (38, 39). 
Strengths of the present study include a large number of VTE cases recruited from a 
population-based cohort with high attendance rate and thorough adjudication of VTE events. 
Furthermore, the case-crossover design is well suited to study transient risk factors while 
controlling for time-invariant confounders, as participants act as their own controls. Some 
limitations also merit consideration. The information on triggers was collected retrospectively 
using medical records, and rely on thorough documentation by the treating health 
professionals. However, surgery is a procedure that is normally well-documented in medical 
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records and the likelihood of misclassification of surgery in hazard and control periods is low. 
Further, the case-crossover design is susceptible to confounding by factors that change over 
time within individuals. Assessment of n-3 PUFAs intake is challenging. The reliability of 
self-reported food intake is uncertain, and in the Tromsø Study the reproducibility of self-
reported intake of fish is reported to be moderate (Spearman correlation coefficient = 0.41-
0.56) (40). In the present study, we accounted for differential contributions from fat and lean 
marine foods as well as from supplements, and only those who with complete dietary 
information on these items were included. The n-3 PUFAs variable used in the present study 
corresponded well with serum levels of n-3 PUFAs, as shown in our previous report (20). 
However, the included participants were somewhat healthier and younger compared with the 
excluded (20), which limits the generalizability or our results. There was a varying time-lag 
between the assessment of n-3 PUFAs intake and the VTE event that add to the uncertainty of 
the n-3 PUFAs intake at the time of the event. However, this uncertainty presumably 
constitutes non-differential misclassification, which might dilute OR differences across n-3 
PUFAs categories. Finally, even though confounding is controlled for within the case-
crossover design, our comparison of ORs across the n-3 PUFAs categories could potentially 
be confounded by age differences in n-3 PUFAs intake. Yet, the beneficial impact of high n-3 
PUFAs intake on surgery as a VTE trigger was still present in sensitivity analyses where we 
used two different approaches to control for age as a potential confounder. 
In conclusion, a high intake of n-3 PUFAs appeared to mitigate the effect of major 
surgery as a trigger for VTE, and PE in particular. Whether n-3 PUFAs may exert a 
preventive effect in patients undergoing surgery is an intriguing question that may be properly 
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Figure 1 The case-crossover design. For each case of venous thromboembolism, surgery was 
recorded in the 90-day hazard period prior to the event and in four preceding 90-day control 




Figure 2 Odds ratios (OR) with 95% confidence intervals (CI) for surgery as a VTE trigger 





Tables and Figures 
 
Table 1 Characteristics of participants at the time of venous thromboembolism (VTE) 
diagnosis according to tertiles of n-3 polyunsaturated long-chained fatty acids (n-3 PUFA) 
intake (n=445). 
 










Tertile range, grams/week - <8.1 8.1-28.9 >28.9 
Age, years (± SD) 66.8 (±13.5) 62.6 (±14.3) 66.4 (±13.6) 72.0 (±10.9) 
Male sex, n (%) 219 (49.2) 70 (47.3) 79 (51.0) 70 (49.3) 
DVT, n (%) 257 (57.7) 80 (54.1) 98 (66.2) 79 (55.6) 
PE, n (%) 188 (42.2) 68 (45.9) 57 (36.8) 63 (44.4) 
Surgery-related VTE     
  During hospitalization (n, %) 22 (26) 10 (12) 10 (12) 2 (2) 
  After hospitalization (n, %) 62 (74) 27 (32) 20 (24) 15 (18) 
DVT, deep vein thrombosis; n-3 PUFAs, polyunsaturated long-chained fatty acids; PE, pulmonary 









Table 2 Distribution of surgery in the hazard and control periods according to tertiles of n-3 
polyunsaturated long-chained fatty acids (n-3 PUFA) intake. 
 
Tertile 1 (n=148) Tertile 2 (n=155) Tertile 3 (n=142) 
 
Hazard Control Hazard Control Hazard Control 
All VTE, n (%*)  37 (25) 15 (3) 30 (19) 21 (3) 17 (12) 17 (3) 
PE, n (%) 19 (28) 6 (2) 8 (14) 6 (3) 7 (11) 10 (4) 
DVT, n (%) 18 (23) 9 (3) 22 (22) 15 (4) 10 (13) 7 (2) 
DVT, Deep vein thrombosis; n-3 PUFAs, polyunsaturated long-chained fatty acids; PE, 
Pulmonary embolism; VTE, venous thromboembolism.  





Table 3 Regression coefficients (β) with standard error (SE) and corresponding odds ratios 
(ORs) with 95% confidence intervals (CIs) for surgery as a trigger of incident venous 
thromboembolism (VTE) according to intake of n-3 polyunsaturated long-chained fatty acids 
(n-3 PUFAs).  
 OR (95% CI) 
 All (n=445) Tertile 1 (n=148) Tertile 2 (n=155) Tertile 3 (n=142) 
   All VTE 7.6 (5.2-11.1) 11.8 (6.1-22.6) 8.1 (4.2-15.7) 4.1 (2.1-8.2) 
   PE 6.8 (3.9-12.0) 14.7 (5.5-39.6) 7.0 (2.1-23.5) 2.8 (1.1-7.4) 





   All VTE 2.0 (0.19) 2.5 (0.33) 2.1 (0.34) 1.4 (0.35) 
   PE 1.9 (0.29) 2.7 (0.50) 1.9 (0.62) 1.0 (0.49) 
   DVT 2.1 (0.26) 2.3 (0.45) 2.2 (0.40) 1.8 (0.52) 
  Tertile 1 vs. Tertile 2 Tertile 1 vs. Tertile 3 Tertile 2 vs. Tertile 3 





   All VTE n/a 0.37 0.79 0.43 1.05 2.17 0.03 0.67 1.39 0.16 
   PE n/a 0.75 0.94 0.35 1.66 2.36 0.02 0.91 1.15 0.25 
   DVT n/a 0.12 0.19 0.85 0.42 0.62 0.53 0.31 0.47 0.64 
DVT, deep vein thrombosis; CI, confidence interval; n-3 PUFAs, polyunsaturated long-











Supplementary Table 1 Characteristics of participants at the time of venous 
thromboembolism (VTE) diagnosis, and ORs for surgery in the hazard period according to 
tertiles based on residuals from a linear regression of n-3 PUFAs on age. 










Tertile range, residuals - < -9.8 -9.8-8.4 >8.4 
Age, years (± SD) 66.8 (±13.5) 67.8 (±13.3) 63.9 (±14.9) 68.6 (±11.8) 
Male sex, n (%) 219 (49.2) 71 (47.6) 74 (50.0) 74 (50.0) 
DVT, n (%) 257 (57.7) 77 (51.7) 98 (66.2) 82 (55.4) 
PE, n (%) 188 (42.2) 72 (48.3) 50 (33.8) 66 (44.6) 
 
 
ORs for surgery in the hazard period: 
   All VTE 7.6 (5.2-11.1) 8.7 (4.9-15.4) 11.9 (5.4-26.3) 4.4 (2.2-8.6) 
   PE 6.8 (3.9-12.0) 11.9 (5.1-28.0) 3.6 (0.9-14.5) 4.0 (1.5-10.7) 
   DVT 8.3 (5.0-13.8) 6.4 (2.9-14.0) 20.2 (6.9-58.9) 4.7 (1.9-12.1) 
DVT, deep vein thrombosis; n-3 PUFAs, polyunsaturated long-chained fatty acids; PE, pulmonary 
embolism; VTE, venous thromboembolism.   
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Supplementary Table 2 Distribution of surgery in the hazard and control periods according 
to residuals of n-3 polyunsaturated long-chained fatty acids (n-3 PUFA) intake. 
 
Tertile 1 (n=149) Tertile 2 (n=148) Tertile 3 (n=148) 
 
Hazard Control Hazard Control Hazard Control 
All VTE, n (%*)  39 (26) 21 (4) 27 (18) 15 (3) 18 (12) 17 (3) 
PE, n (%) 22 (31) 9 (3) 4 (8) 5 (3) 8 (16) 8 (3) 
DVT, n (%) 17 (21) 12 (4) 23 (24) 10 (3) 10 (13) 9 (3) 
DVT, Deep vein thrombosis; n-3 PUFAs, polyunsaturated long-chained fatty acids; PE, 
Pulmonary embolism; VTE, venous thromboembolism.  
















c Verken god eller dårlig
c Dårlig 
c Meget dårlig
2 Hvordan synes du at helsen din er sammenlignet 






3 Har du eller har du hatt? Ja Nei
Alder første 
gang
Hjerteinfarkt ............................................................... c c
Angina pectoris (hjertekrampe) ....................... c c
Hjerneslag/hjerneblødning ........................... c c
Hjerteflimmer (atrieflimmer) .............................. c c
Høyt blodtrykk ......................................................... c c
Beinskjørhet (osteoporose) .................................. c c
Astma ............................................................................... c c
Kronisk bronkitt/emfysem/KOLS ........... c c
Diabetes ......................................................................... c c
Psykiske plager (som du har søkt hjelp for) ....... c c
Lavt stoffskifte .......................................................... c c
Nyresykdom, unntatt urinveisinfeksjon... c c
Migrene .......................................................................... c c
4 Har du langvarige eller stadig tilbakevendende 
smerter som har vart i 3 måneder eller mer?
c Ja c Nei
5 Hvor ofte har du vært plaget av søvnløshet de siste 
12 måneder? 
c Aldri, eller noen få ganger
c 1-3 ganger i måneden
c Omtrent 1 gang i uken
c Mer enn 1 gang i uken
6 Under finner du en liste over ulike problemer.  
Har du opplevd noe av dette den siste uken  









Plutselig frykt uten grunn ....... c c c c
Føler deg redd eller  
engstelig ................................................ c c c c
Matthet eller svimmelhet ...... c c c c
Føler deg anspent eller 
oppjaget ................................................ c c c c
Lett for å klandre deg selv .... c c c c
Søvnproblemer ................................ c c c c
Nedtrykt, tungsindig .................. c c c c
Følelse av å være unyttig, 
lite verd .................................................. c c c c
Følelse av at alt er et slit ......... c c c c
Følelse av håpløshet  
mht. framtida ................................... c c c c
7 Har du i løpet av de siste 12 måneder vært hos:  
Hvis JA; Hvor mange ganger?
Ja Nei Ant ggr
Fastlege/allmennlege ......................................... c c
Psykiater/psykolog ............................................... c c
Legespesialist utenfor sykehus 
(utenom fastlege/allmennlege/psykiater) ........... c c
Fysioterapeut ............................................................. c c
Kiropraktor ................................................................... c c
Annen behandler
(homøopat, akupunktør, fotsoneterapeut, natur-
medisiner, håndspålegger, healer, synsk el.l) ..... c c
Tannlege/tannpleier ............................................ c c
Skjemaet skal leses optisk. Vennligst bruk blå eller sort 
penn. Du kan ikke bruke komma, bruk blokkbokstaver.
2007 – 2008 Konfidensielt
9 Har du gjennomgått noen form for operasjon i løpet 
av de siste 3 årene?
c Ja c Nei
8 Har du i løpet av de siste 12 måneder vært på sykehus? 
Ja Nei Ant ggr
Innlagt på sykehus ................................................ c c
Konsultasjon ved sykehus uten innleggelse;
Ved psykiatrisk poliklinikk .................. c c
Ved annen sykehuspoliklinikk ........ c c
BRUK AV HELSETJENESTER
HELSE OG SYKDOMMER
19 Hva er din hovedaktivitet? (Sett ett kryss)
c Yrkesaktiv heltid c Hjemmeværende
c Yrkesaktiv deltid c Pensjonist/trygdet
c Arbeidsledig c Student/militærtjeneste
10 Bruker du, eller har du brukt, noen av følgende 






Medisin mot høyt blodtrykk ... c c c
Kolesterolsenkende medisin .... c c c
Medisin mot hjertesykdom .... c c c
Vanndrivende medisin ................ c c c
Medisin mot beinskjørhet 
(osteoporose) ............................................ c c c
Insulin ........................................................ c c c
Diabetesmedisin (tabletter) ........ c c c
Stoffskiftemedisinene  
Thyroxin/levaxin ............................. c c c
11 Hvor ofte har du i løpet av de siste 4 ukene brukt 











på resept ............... c c c c
Smertestillende 
reseptfrie ............... c c c c
Sovemidler .......... c c c c
Beroligende  
medisiner .............. c c c c
Medisin mot 
depresjon .............. c c c c
12 skriv ned alle medisiner – både de med og uten 
resept – som du har brukt regelmessig i siste 4 ukers 
periode. (Ikke regn med vitaminer, mineraler, urter, 
naturmedisin, andre kosttilskudd etc.)
Ved fRAMMØte vil du bli spurt om du har brukt 
antibiotika eller smertestillende medisiner de siste  
24 timene. Om du har det, vil vi be om at du oppgir 
preparat, styrke, dose og tidspunkt
13 Hvem bor du sammen med? (Sett kryss for hvert 
spørsmål og angi antall) 
Ja Nei Antall
Ektefelle/samboer ............................................. c c
Andre personer over 18 år ........................ c c
Personer under 18 år ...................................... c c
14 Kryss av for de slektninger som har eller har hatt
Foreldre Barn Søsken
Hjerteinfarkt .............................................. c c c
Hjerteinfarkt før fylte 60 år ......... c c c
Angina pectoris (hjertekrampe) ...... c c c
Hjerneslag/hjerneblødning .......... c c c
Beinskjørhet (osteoporose)  ................ c c c
Magesår/tolvfingertarmsår .......... c c c
Astma .............................................................. c c c
Diabetes ........................................................ c c c
Demens .......................................................... c c c
Psykiske plager ........................................ c c c
Rusproblemer ........................................... c c c
15 Har du nok venner som kan gi deg hjelp  
når du trenger det?
c Ja c Nei
16 Har du nok venner som du kan snakke fortrolig med?
c Ja c Nei
17 Hvor ofte tar du vanligvis del i foreningsvirksomhet 
som for eksempel syklubb, idrettslag, politiske lag, 
religiøse eller andre foreninger?
c Aldri, eller noen få ganger i året
c 1-2 ganger i måneden
c Omtrent 1 gang i uken
c Mer enn en gang i uken
ARBEID, TRYGD OG INNTEKT
18 Hva er din høyeste fullførte utdanning?  
(Sett ett kryss)
c Grunnskole, framhaldsskole eller folkehøyskole
c Yrkesfaglig videregående, yrkesskole eller realskole 
c Allmennfaglig videregående skole eller gymnas
c Høyskole eller universitet, mindre enn 4 år
c Høyskole eller universitet, 4 år eller mer
FAMILIE OG VENNERBRUK AV MEDISINER
Får du ikke plass til alle medisiner, bruk eget ark.
25 Hvor ofte driver du mosjon? (Med mosjon mener vi 
at du f.eks går en tur, går på ski, svømmer eller driver  
trening/idrett)
c Aldri
c Sjeldnere enn en gang i uken
c En gang i uken
c 2-3 ganger i uken
c omtrent hver dag
36 Hvor mange år til sammen har du røykt daglig?
Antall år
35 Hvor gammel var du da du begynte å røyke daglig?
Antall år
22 Arbeider du utendørs minst 25 % av tiden, eller i 
lokaler med lav temperatur, som for eksempel  
lager-/industrihaller?
c Ja c Nei
23 Hvis du er i lønnet eller ulønnet arbeid, hvordan vil 
du beskrive arbeidet ditt?
c For det meste stillesittende arbeid
(f.eks. skrivebordsarbeid, montering)
c Arbeid som krever at du går mye
(f.eks ekspeditørarbeid, lett industriarbeid, undervisning)
c Arbeid der du går og løfter mye
(f.eks postbud, pleier, bygningsarbeider)
c Tungt kroppsarbeid
24 Angi bevegelse og kroppslig anstrengelse i din  
fritid. Hvis aktiviteten varierer meget f eks mellom 
sommer og vinter, så ta et gjennomsnitt. spørsmålet 
gjelder bare det siste året. (Sett kryss i den ruta som 
passer best)
c Leser, ser på fjernsyn eller annen stillesittende  
beskjeftigelse
c Spaserer, sykler eller beveger deg på annen måte 
minst 4 timer i uken (her skal du også regne med gang 
eller sykling til arbeidsstedet, søndagsturer med mer)
c Driver mosjonsidrett, tyngre hagearbeid, snømåking 
e.l. (merk at aktiviteten skal vare minst 4 timer i uka)
c Trener hardt eller driver konkurranseidrett  
regelmessig og flere ganger i uka
26  Hvor hardt mosjonerer du da i gjennomsnitt?
c Tar det rolig uten å bli andpusten eller svett.
c Tar det så hardt at jeg blir andpusten og svett
c Tar meg nesten helt ut
29 Hvor mange enheter alkohol (en øl, et glass vin, eller 
en drink) tar du vanligvis når du drikker?
c 1-2 c 5-6 c 10 eller flere
c 3-4 c 7-9
32 Har du røykt/røyker du daglig?
c Ja, nå c Ja, tidligere c Aldri
27 Hvor lenge holder du på hver gang i gjennomsnitt ?
c Mindre enn 15 minutter c 30 minutter – 1 time
c 15-29 minutter c Mer enn 1 time
30 Hvor ofte drikker du 6 eller flere enheter alkohol ved 
en anledning?
c aldri
c sjeldnere enn månedlig
c månedlig
c ukentlig
c daglig eller nesten daglig
28 Hvor ofte drikker du alkohol? 
c Aldri
c Månedlig eller sjeldnere
c 2-4 ganger hver måned
c 2-3 ganger pr. uke
c 4 eller flere ganger pr.uke
21 Hvor høy var husholdningens samlede bruttoinntekt 
siste år? Ta med alle inntekter fra arbeid, trygder, 
sosialhjelp og lignende.
c Under 125 000 kr c 401 000-550 000 kr
c 125 000-200 000 kr c 551 000-700 000 kr
c 201 000-300 000 kr c 701 000 -850 000 kr 
c 301 000-400 000 kr c Over 850 000 kr
34 Hvis du røyker daglig nå eller har røykt tidligere: 
Hvor mange sigaretter røyker eller røykte du vanlig-
vis daglig?
Antall sigaretter
33 Hvis du har røykt daglig tidligere, hvor lenge er det 
siden du sluttet?
Antall år 
31 Røyker du av og til, men ikke daglig?
c Ja c Nei
20 Mottar du noen av følgende ytelser?
c Alderstrygd, førtidspensjon (AFP) eller etterlattepensjon




c Dagpenger under arbeidsledighet
c Overgangstønad
c Sosialhjelp/-stønad 
37 Bruker du, eller har du brukt, snus eller skrå?
c Nei, aldri c Ja, av og til
c Ja, men jeg har sluttet c Ja, daglig
FYSISK AKTIVITET
ALKOHOL OG TOBAKK
48 Hvis du har født, fyll ut for hvert barn: fødselsår og 
vekt samt hvor mange måneder du ammet.  
(Angi så godt som du kan)









39 Hvor mange enheter frukt og grønnsaker spiser du i 
gjennomsnitt per dag? (Med enhet menes f.eks. en 
frukt, glass juice, potet, porsjon grønnsaker)
Antall enheter
38 spiser du vanligvis frokost hver dag?
c Ja c Nei
40 Hvor mange ganger i uken spiser du varm middag? 
Antall
42 Hvor mye drikker du vanligvis av følgende?  















yoghurt .......................... c c c c c
Fruktjuice ...................... c c c c c
Brus/leskedrikker 
med sukker ................. c c c c c
44 Hvor ofte spiser du vanligvis fiskelever? 
(For eksempel i mølje)
c Sjelden/aldri c 1-3 g i året c 4-6 g i året































45 Bruker du følgende kosttilskudd?
Daglig Iblant Nei
Tran, trankapsler ..................................................... c c c
Omega 3 kapsler (fiskeolje,selolje) ............ c c c
Kalktabletter ............................................................ c c c
47 Hvor mange barn har du født?
Antall
49 Har du i forbindelse med svangerskap hatt for høyt  
blodtrykk?
c Ja c Nei
52 Hvis Ja, i hvilket svangerskap?
c Første c Senere
53 Ble noen av disse barna født mer enn en måned for 
tidlig (før termin) pga. svangerskapsforgiftning?
c Ja c Nei
55 Hvor gammel var du da du fikk menstruasjon  
første gang?
Antall år
51 Har du i forbindelse med svangerskap hatt protein  
(eggehvite) i urinen?
c Ja c Nei
50 Hvis Ja, i hvilket svangerskap? 
c Første c Senere
54 Hvis Ja, hvilke(t) barn
Barn 1 Barn 2 Barn 3 Barn 4 Barn 5 Barn 6
c c c c c c
43 Hvor mange kopper kaffe og te drikker du daglig? 






56 Bruker du for tiden reseptpliktige legemidler som 
påvirker menstruasjonen?
P-pille, hormonspiral eller lignende .......c Ja c Nei
Hormonpreparat for overgangs-
alderen .............................................................................c Ja c Nei
46 er du gravid nå?
c Ja c Nei c Usikker
Ved fRAMMØte vil du få utfyllende spørsmål om 
menstruasjon og eventuell bruk av hormoner. Skriv 
gjerne ned på et papir navn på hormonpreparater 
du har brukt, og ta det med deg. Du vil også bli 
spurt om din menstruasjon har opphørt og even-
tuelt når og hvorfor.
41 Hvor ofte spiser du vanligvis disse matvarene?
(Sett ett kryss pr linje)










Poteter ........................................ c c c c c
Pasta/ris ..................................... c c c c c
Kjøtt (ikke kvernet) ................ c c c c c
Kvernet kjøtt  
(pølser, hamburger o.l) ........... c c c c c
Grønnsaker, frukt, bær .. c c c c c
Mager fisk ............................... c c c c c
Feit fisk ....................................... c c c c c
(f.eks.laks, ørret, makrell, sild, kveite,uer)
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